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Syndrome
Abstract
Hutchinson-Gilford Progeria syndrome (HGPS) is a rare premature aging disease in which children
present with a rapid onset of clinical characteristics of aging. Ultimately, HGPS children die in their teen
years due to severe cardiovascular disease leading to heart attack and stroke. Despite discovering the
mutation resulting in HGPS, a single nucleotide point mutation in the Lamin A gene, how this mutated
form of Lamin A, termed progerin, results in such severe cardiovascular pathology is not well understood.
Although HGPS children do not have altered blood lipid profiles, they present with increased arterial
stiffness, a cholesterol-independent risk factor for cardiovascular disease that is also increased in the
normal aging population. Toward the end of their lifespan, the arteries of HGPS patients display a
dramatic loss of smooth muscle cells (SMCs) and a highly collagenous, fibrotic environment. However,
the initial driving factors of arterial stiffening and the decline in smooth muscle cell function are not well
characterized. In this work, I use the LMNAG609G/G609G mouse model (hereafter referred to as HGPS
mice), which harbors the equivalent mutation to that seen in the human disease, to study causal factors
initiating arterial stiffening and SMC decline in young mice. I found that the onset of arterial stiffening in
HGPS mice highly correlates with an increase in the collagen cross linking enzyme Lysyl Oxidase (LOX),
and pharmacologic inhibition of LOX in vivo corrected arterial stiffening and heart defects, such as
diastolic dysfunction, present in HGPS mice. Interestingly, I found that normally aged mouse arteries also
present with arterial stiffening and increased LOX abundance, although distinct from that seen in HGPS.
Furthermore, I found that SMC function declines well before the loss of SMCs from HGPS mouse arteries,
as young HGPS mice presented with decreased arterial contractility at an early age. I correlated this
decrease in arterial contractility with a reduction in smooth muscle myosin heavy chain (SM-MHC), and
restoration of SM-MHC corrected the decreased force generation exhibited by isolated HGPS SMCs.
Consistent with observations in HGPS mice, aged mouse arteries also presented with decreased
contractility and SM-MHC, although whether the mechanisms are similar or distinct from that of HGPS
requires further study. Overall, these studies demonstrate that arterial stiffening and decline in SMC
function occur at a very early age in HGPS and replicate many of the phenotypes seen in normal aged
arteries. Insight from this study provides new understanding of the early driving factors of arterial
stiffening and decline in SMC function and sheds light on potential therapeutic approaches to reduce the
burden of cardiovascular disease in HGPS.
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ABSTRACT
MECHANISMS OF EARLY ARTERIAL STIFFENING AND REDUCED SMOOTH MUSCLE
CONTRACTILITY IN THE PREMATURE AGING DISEASE HUTCHINSON-GILFORD
PROGERIA SYNDROME
Ryan von Kleeck
Richard Assoian

Hutchinson-Gilford Progeria syndrome (HGPS) is a rare premature aging disease
in which children present with a rapid onset of clinical characteristics of aging. Ultimately,
HGPS children die in their teen years due to severe cardiovascular disease leading to
heart attack and stroke. Despite discovering the mutation resulting in HGPS, a single
nucleotide point mutation in the Lamin A gene, how this mutated form of Lamin A,
termed progerin, results in such severe cardiovascular pathology is not well understood.
Although HGPS children do not have altered blood lipid profiles, they present with
increased arterial stiffness, a cholesterol-independent risk factor for cardiovascular
disease that is also increased in the normal aging population. Toward the end of their
lifespan, the arteries of HGPS patients display a dramatic loss of smooth muscle cells
(SMCs) and a highly collagenous, fibrotic environment. However, the initial driving
factors of arterial stiffening and the decline in smooth muscle cell function are not well
characterized.
In this work, I use the LMNAG609G/G609G mouse model (hereafter referred to as
HGPS mice), which harbors the equivalent mutation to that seen in the human disease,
to study causal factors initiating arterial stiffening and SMC decline in young mice. I
ii

found that the onset of arterial stiffening in HGPS mice highly correlates with an increase
in the collagen cross linking enzyme Lysyl Oxidase (LOX), and pharmacologic inhibition
of LOX in vivo corrected arterial stiffening and heart defects, such as diastolic
dysfunction, present in HGPS mice. Interestingly, I found that normally aged mouse
arteries also present with arterial stiffening and increased LOX abundance, although
distinct from that seen in HGPS.
Furthermore, I found that SMC function declines well before the loss of SMCs
from HGPS mouse arteries, as young HGPS mice presented with decreased arterial
contractility at an early age. I correlated this decrease in arterial contractility with a
reduction in smooth muscle myosin heavy chain (SM-MHC), and restoration of SM-MHC
corrected the decreased force generation exhibited by isolated HGPS SMCs. Consistent
with observations in HGPS mice, aged mouse arteries also presented with decreased
contractility and SM-MHC, although whether the mechanisms are similar or distinct from
that of HGPS requires further study.
Overall, these studies demonstrate that arterial stiffening and decline in SMC
function occur at a very early age in HGPS and replicate many of the phenotypes seen
in normal aged arteries. Insight from this study provides new understanding of the early
driving factors of arterial stiffening and decline in SMC function and sheds light on
potential therapeutic approaches to reduce the burden of cardiovascular disease in
HGPS.
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Chapter 1: Introduction
1.1 Hutchinson-Gilford Progeria Syndrome
(HGPS): mutation, consequences, and therapies
1.1a History and identification of HGPS

Hutchinson-Gilford Progeria Syndrome (HGPS) was a disease first discovered by
Dr. Jonathan Hutchinson in 1886 and later reported by Dr. Hastings Gilford in 1897 in
England (Hutchinson 1886). It was first diagnosed when Dr. Hutchinson noticed a boy
who had loss of hair and atrophic condition of the skin and appendages. Dr. Hutchinson
noted the boy as having a generally aged appearance with a short stature and “pinched
facial features” (Kashyap et al. 2014; Hutchinson 1886; McKusick 2005).

This rare

disease soon became commonly referred to as a disease of premature aging, with the
name Progeria derived from Greek meaning “prematurely old.” Intriguingly, although
these patients displayed severe growth defects, cognitive function remained intact
(Saxena & Kumar 2020). Interest and widespread knowledge of the disease became
prevalent after the birth of Sam Berns, the son of two medical doctors, who was
diagnosed with Progeria. Sam soon became a public figure and icon of Progeria, giving
TedX talks and participating in an HBO documentary about the disease to spread
awareness. Sam’s parents, Dr. Scott Berns and Dr. Leslie Gordon, devoted their work to
understanding the disease, later establishing the Progeria Research Foundation. This
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disease is now called Hutchinson-Guilford Progeria Syndrome (HGPS) to distinguish it
from other forms of premature aging.
HGPS is classified as an ultra-rare genetic disease, affecting around 1 in 4 to 8
million births (Sinha et al. 2014). There is no predisposition to HGPS and it has been
shown to affect all genders and ethnicities (Sinha et al. 2014). In 2003, the genetic basis
of HGPS was discovered to be a single nucleotide point mutation in the LMNA gene
(Lamin A) (Goldman et al. 2004; Eriksson et al. 2003; De Sandre-Giovannoli et al. 2003).
The median age for diagnosis of children with HGPS is around 3 years of age
(Hennekam 2006), and currently genetic testing (c.1824C>T in the LMNA gene) is used
to confirm diagnosis (Gordon et al. 2003; Saxena & Kumar 2020). Children diagnosed
generally present with alopecia, prominent scalp veins, and low bone density.
Histopathology is generally conducted on the skin and reveals abnormal nuclear
morphology (Gordon et al. 2003; Saxena & Kumar 2020).
The mutation causing nearly all cases of HGPS had been identified as a de novo
single nucleotide 1824C>T substitution in exon 11 of the LMNA gene (chromosome
1q21.2-q21.3) (De Sandre-Giovannoli et al. 2003; Eriksson et al. 2003; Goldman et al.
2004). Although this single nucleotide substitution does not result in a change in amino
acid (LMNAG608G), it creates a cryptic splice site toward the end of exon 11 of LMNA.
This abnormal splicing event leads to the deletion of 150 nucleotides, and subsequent
deletion of 50 amino acids, from exon 11 near the C-terminal end of pre-Lamin A
(Saxena & Kumar 2020). These 50 amino acids are critical for the recognition by
ZMPSTE24 endoprotease, which normally cleaves 14 amino acids and a farnesyl and
carboxymethyl group off the C-terminus of pre-Lamin A to generate mature Lamin A
protein. This mutated form of Lamin A in HGPS, termed progerin, retains the C-terminal
2

farnesyl and carboxymethylated CAAX motif that would normally be cleaved off during
natural processing by ZMPSTE24 (Fig. 1.01) (Hamczyk et al. 2018). The retention of
this farnesyl group causes progerin to accumulate on the nucleoplasmic side of the inner
nuclear membrane and progerin is unable to form a proper nuclear lamina network
(Saxena & Kumar 2020). The aberrant splicing of LMNA seen in HGPS also occurs at
very small levels in natural aging in skin fibroblasts and in the arterial wall leading to
accumulation of progerin with age in healthy individuals (Scaffidi & Misteli 2006; Olive et
al. 2010).

This has brought a lot of attention toward Progeria, as it may share

commonalities and a mechanistic relation with normal aging, though the very low amount
of progerin in normal aging confounds this simple idea.
Much work has been done in evaluating whether the toxicity of progerin
originates from the loss of 50 amino acids or from the retention of the farnesyl and
carboxyl moieties. Evidence for the hypothesis that the major driver of progerin toxicity
comes from its farnesylation can be seen from other atypical progeria syndromes such
as restrictive dermopathy, where patients present with specific mutations to ZMPSTE24
– the protease important for the cleavage of the farnesyl group from LMNA (MazereeuwHautier et al. 2007; Yang et al. 2005; Navarro et al. 2005; Navarro et al. 2004). These
patients present with even more severe progeria-like symptoms, dying in the first week
of life.

Indeed, ZMPSTE24-deficient mice also present with many common

characteristics of HGPS (Fong et al. 2004). In addition, mouse models such as the
LMNA-nHG transgenic mouse have been generated that replicate the loss of 150
nucleotides from exon 11 of LMNA typically seen in HGPS but have modified the CAAX
farnesylation motif into SAAX or CAX (Yang et al. 2008; Yang et al. 2011). This mouse
model produces unfarnesylated progerin protein (that still has the 50 amino acid
3

deletion) and shows a less severe HGPS phenotype, highlighting the toxicity of the
farnesyl group.
One of the major functions of the nuclear lamina is to serve as a scaffold to
structurally support the nucleus.

The improper lamina network formed by progerin

accumulation has been shown to cause a stiffer and thicker nuclear lamina, which
leaves the nucleus brittle and more susceptible to mechanical damage (Verstraeten et
al. 2008). This altered lamina network is also associated with the characteristic nuclear
blebbing phenotype seen in HGPS (Dahl et al. 2006; Verstraeten et al. 2008; Goldman
et al. 2004). In addition to structural support, it has become appreciated that the nuclear
lamina plays an important role in chromatin organization and signaling pathways. The
nuclear lamina binds heterochromatin, and loss of peripheral heterochromatin (Gesson
et al. 2016) and dramatic chromatin remodeling have been reported in HGPS nuclei
(Shumaker et al. 2006; Pegoraro et al. 2009). Nuclei with progerin accumulation also
display altered nuclear pore complex organization and changes in nuclear import and
export (Kelley et al. 2011; García‐Aguirre et al. 2019) in addition to increased DNA
damage as visualized through γHAX staining (Gonzalo et al. 2016; Liu et al. 2005).

1.1b Systemic consequences of Progerin expression

One of the major phenomena of HGPS is the severe growth retardation and loss
of hair in HGPS children. Clinical symptoms begin manifesting themselves around 1-2
years of age, as it is hypothesized that is when many cell types begin terminal
differentiation and commence increased expression of Lamin A (Merideth et al. 2008;
Saxena & Kumar 2020). Cognitive abilities of HGPS patients remain rather unaffected,
4

likely due to the low expression levels of Lamin A in the brain due to the presence of
microRNA-9 in neural cells (Nissan et al. 2012).
Additional abnormalities present in HGPS children include loss of subcutaneous
fat, reduced hearing, altered dentition, increased platelet number, absence of puberty,
extra-skeletal calcification, stiff joints, angina, and hip dislocation (Domingo et al. 2009;
Kieran et al. 2007; Gordon et al. 2019; Guardiani et al. 2011; Monnerat et al. 2019;
Merideth et al. 2008; Rork et al. 2014; Ullrich & Gordon 2015). However, the major
complication leading to death at a mean age of 14.5 years is the onset of cardiovascular
disease leading to heart attack or stroke. Children present with severe atherosclerosis of
coronary and cerebrovascular arteries (Merideth et al. 2008). Moreover, these progeria
children do not present with common risk factors for cardiovascular disease such as
hyperlipidemia or diabetes. HGPS patients present with low high-density lipoprotein
levels, but normal low-density lipoprotein and cholesterol levels (Szamosi et al. 1984;
Gordon et al. 2005). These findings suggest that progerin plays a pathogenic role in
promoting cardiovascular disease independent of dyslipidemia.
As mentioned, the main cause of death in HGPS children is complications arising
from severe atherosclerosis (Merideth et al. 2008; Saxena & Kumar 2020). Arterial
stenosis can affect HGPS children of all ages and has been used as an early indicator of
plaque formation and noninvasive imaging has been used to detect carotid plaques at
late stages in HGPS children (Gerhard-Herman et al. 2011; Merideth et al. 2008). In
addition, severe vascular smooth muscle cell (SMC) loss is also observed in HGPS
arteries, with late-stage patients presenting with little to no SMCs present and a highly
fibrotic arterial environment (Gerhard-Herman et al. 2011; Olive et al. 2010). Vascular
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calcification has also been observed in HGPS arteries along with adventitial thickening
and fibrosis (Villa-Bellosta et al. 2013; Ullrich & Gordon 2015).
Heart abnormalities are also present in HGPS patients (Prakash et al. 2018). In a
clinical study evaluating heart function through echocardiography, HGPS patients
presented with increased left ventricular hypertrophy and left ventricular diastolic
dysfunction. Calcification of the mitral and aortic valves was also observed and lead to
stenosis and regurgitation, especially as children became older (Prakash et al. 2018).
Additionally, HGPS children present with arterial vessel stiffening (Olive et al.
2010; Gerhard-Herman et al. 2011). Intriguingly, arterial stiffening is also seen in the
normal aging population (Mitchell et al. 2010).

Clinical studies evaluating arterial

stiffness through pulse-wave velocity measurements have shown that the vascular
stiffening in HGPS children is similar to adults of 60 years or older (Gerhard-Herman et
al. 2011). The arterial stiffening in these children has attracted a lot of attention from the
research community because arterial stiffening remains one of the most prominent
cholesterol-independent risk factors for cardiovascular disease (Mitchell et al. 2010), and
understanding the rapid stiffening process in HGPS may uncover molecular mechanisms
responsible for arterial stiffening in normal aging. Many of the cardiovascular
abnormalities in HGPS are also present in the normal aging population. Table 1,
modified from a review by from Hamczyk (2018), evaluates the common cardiovascular
characteristics between normal aging and HGPS (Hamczyk, del Campo, et al. 2018).
1.1c Current cell and animal models to study HGPS

Cell models
6

As HGPS is such a rare disease, many animal and cell models have been created to
study the disease and develop therapies. Currently, over 200 cell lines are available
from the Progeria Research Foundation tissue bank (Gordon 2019). The majority of cell
studies use HGPS patient fibroblasts and induced pluripotent stem cells (iPSCs) in order
to study cell behavior in vitro. These cells recapitulate many of the clinical observations
seen in HGPS patients including nuclear blebbing, increased cellular senescence,
altered nuclear trafficking and export, altered epigenetic markers, increased DNA
double-stranded breaks, and altered signaling pathways (Saxena & Kumar 2020).
Potential therapies that have been used on cell models include farnesyl transferase
inhibitors, to block the toxic farnesylation of progerin; all-trans-retinoic acid, to reduced
LMNA transcription; and mTOR inhibitors, to promote autophagy and clearance of
progerin protein (Pellegrini et al. 2015; Capell et al. 2005; Capell et al. 2008; Cao et al.
2011; Cenni et al. 2011; DuBose et al. 2018; Gabriel et al. 2016). However, one
disadvantage to cell models is that they lack critical information needed to carry over to
the clinic such as the pharmacodynamics of a drug and additional toxicity to other
organs and body systems. They also lack the ability to study progerin’s effect on an
entire organ system. Thus, many animal models have been generated to study HGPS
and evaluate potential therapeutic options.
ZMPSTE24-null mouse model
The first preclinical mouse model for HGPS was a ZMPSTE24-null mouse generated in
2002 (Pendás et al. 2002; Bergo et al. 2002). This model knocked out the protease
essential for cleaving the C-terminal end of Lamin-A, thus leading to the accumulation of
farnesylated pre-Lamin A. Although it shared many similar phenotypes with HGPS
children such as slow growth, lipodystrophy, low body weight, cardiac dysfunction, and
7

premature death (Mayoral et al. 2018), it lacks the equivalent mutation seen in human
HGPS patients, as progerin harbors an additional 50 amino acid deletion in comparison
to pre-Lamin A.
LmnaHG mouse model
The LmnaHG mouse model was generated, which has intron 10 and 11 as well as the
last 150 nucleotides of exon 11 deleted (Yang et al. 2005).

This mouse produces

progerin protein, but not through the creation of a cryptic splice site as seen in the
human disease. The deletion of introns 10 and 11 also abolish Lamin C synthesis, which
is normally present in HGPS. However, this model also phenocopies many of the
symptoms of HGPS (Yang et al. 2005; Mayoral et al. 2018; Yang et al. 2006).
BAC G608G mouse model
An additional mouse model termed the BAC G608G mouse was developed by Varga et
al. in 2006 and contains the mutant LMNAG608G (as found in HGPS patients) as a
transgene in a human bacterial artificial chromosome (Varga et al. 2006). These mice
especially model the arterial defects seen in the human disease, showing progressive
loss of medial SMCs, arterial calcification, adventitial thickening, and increased
extracellular matrix (ECM) deposition. However, these mice did not recapitulate many
clinical symptoms of progeria aside from defects in the cardiovascular system.
LMNA G609G mouse model and characterization
In 2011, Osorio et al. developed a transgenic mouse model harboring the equivalent
mutation to the human HGPS syndrome in the mouse genome (c.1827C>T; p.G609G),
termed the LMNAG609G model (Osorio et al. 2011). These mice mirrored many of the
features of the human disease, including depletion of SMCs and cardiovascular and
heart defects (Osorio et al. 2011). It was found that the homozygous LMNAG609G/G609G
8

mice (hereafter referred to as HGPS mice), presented with swift onset of the progeroid
symptoms and displayed premature death with a median survival of around 100 days.
The HGPS mice displayed progressive weight loss, with a plateau in weight starting as
early as 5 weeks of age and slowly declining until death (Osorio et al. 2011). The
heterozygous LMNA+/G609G mice displayed a delayed onset of progeroid symptoms, but
still displayed premature death at approximately 240 days (Osorio et al. 2011). Because
it effectively models the same point mutation and reproduces the exact molecular
situation that occurs at the LMNA locus seen in the human syndrome, the LMNAG609G
mouse model has become a widely used animal model in the field of HGPS.
Many groups in addition to Osorio et al. have characterized the LMNAG609G
mouse model. Like the human syndrome, the mice showed loss of the subcutaneous fat
layer, an increase in senescence associated β-galactosidase staining, and thinning and
loss of fur toward the end of their lifespan (Zaghini et al. 2020). The LMNAG609G mice
displayed reduced bone density and alterations in the bone structure of their skull. The
mutant mice displayed a loss of SMCs, specifically in the aortic arch. Although cause of
death is unclear in LMNAG609G mice, Zaghini et al. (2020) propose that it is likely a result
of cardiovascular abnormalities in addition to malnutrition (Zaghini et al. 2020).
Osmanagic-Myers (2018) found extensive myocardial and perivascular fibrosis
when characterizing cardiovascular defects in mice selectively expressing the
LMNAG609G mutation in endothelial cells

driven by the endothelium-specific Cdh5

promoter (Osmanagic-Myers et al. 2018). Although these mice did not present with
SMC loss, which is a hallmark of the human syndrome, they did present with left
ventricular hypertrophy and significant diastolic dysfunction. This study suggested that
the potent effect progerin has on the SMC population is due to intrinsic expression of
9

progerin in the SMC population and not caused by a dysfunctional endothelium.
However, endothelial-specific progerin expression was enough to induce cardiac fibrosis
with enhanced levels of Col3a1 transcript present in the heart (Osmanagic-Myers et al.
2018). The enhanced col3a1 expression was likely due to endothelial cells signaling
other cell types to increase collagen production, as the endothelial cells themselves did
not have increased col3a1 expression. However, since endothelial specific progerin
expression still led to left ventricular hypertrophy and diastolic dysfunction, endothelial
dysfunction may be responsible for a portion of the cardiac abnormalities in HGPS. This
study linked the profibrotic response of progerin-expressing endothelial cells to a defect
in nitric oxide signaling due to reduced nitric oxide synthase 3 (NOS3) levels, as nitric
oxide (NO) generally acts in a paracrine manner to cause an antifibrotic effect on
surrounding tissues (Osmanagic-Myers et al. 2018).
Work from the laboratory of Dr. Vicente Andres has further characterized the
effect of progerin expression on cardiovascular abnormalities in HGPS mice. Hamczyk
et al. (2018) used LMNAG609G mice crossed with ApoE-null mice to evaluate the
formation of atherosclerotic lesions due to progerin expression.

They found that

LMNAG609G/Apoe-null mice which were fed a high fat diet developed more severe
atherosclerotic lesions in comparison Apoe-null mice. Furthermore, they discovered that
these findings were replicated even when restricting progerin expression solely to the
SMCs, indicating that SMC progerin expression is critical for the generation of severe
atherosclerotic lesions seen in HGPS (Hamczyk, Villa-Bellosta, et al. 2018).
In addition, work from del Campo et al. (2019) and Murtada et al. (2020) revealed
that older LMNAG609G mice displayed increased aortic stiffness between 13-15 weeks of
age (toward the end of their lifespan). Mice expressing progerin selectively in endothelial
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cells did not present with increased aortic stiffness (del Campo et al. 2019). However,
restricting progerin expression to SMCs was able to reproduce this increase in aortic
stiffness, suggesting that arterial stiffening in HGPS is a consequence of altered
vascular SMC function. Furthermore, treatment of aortas with collagenase prevented
stiffening of G609G aortas, whereas treatment with elastase or mycalolide B had no
effect on vessel stiffness, indicating that altered collagen is likely the cause of increased
arterial stiffness rather than elastin abnormalities or cytoskeletal integrity (del Campo et
al. 2019). This idea was substantiated by the observed increased levels of collagens III,
IV, V and XII present through arterial staining. In addition, recent work by del Campo et
al. (2020) showed that SMC-specific progerin expression also results in decreased
arterial contraction and relaxation in response to vasoconstrictors and vasodilators,
whereas endothelial specific progerin expression had no effect on vessel contractility
(del Campo et al. 2020). It is important to note that these studies have evaluated HGPS
mice at a very late stage in their lifespan, when there has been significant reported loss
of SMCs (Murtada et al. 2020; Osorio et al. 2011). Thus, findings of increased arterial
stiffness and decreased arterial contractility at this late timepoint may be confounded by
the loss of SMCs from HGPS mice. In conclusion, although it is likely a combinatorial
effect of progerin expression in the endothelium as well as the smooth muscle cell layer
that presents HGPS children with such a high risk of cardiovascular disease, the SMC
population is critical in causing increased arterial stiffening and reduced contractility in
HGPS.
1.1d Current therapeutic options to treat HGPS
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Currently, the major approved treatment for HGPS consists of the administration
of farnesyl transferase inhibitors (FTIs). FTIs that were originally used for the treatment
of cancer have proven effective in HGPS patients and animal models (Toth et al. 2005;
Capell et al. 2005; Capell et al. 2008; Yang et al. 2006; Yang et al. 2005; Glynn & Glover
2005; Pacheco et al. 2014).

FTIs work through binding to the farnesytransferase

enzyme at the CAAX-binding domain, preventing the enzyme from recognizing the
CAAX motif and inhibiting farnesylation of the protein. It is believed that the defarnesylated form of progerin is then targeted for degradation (Columbaro et al. 2005). In
a clinical study following children treated with FTI Lonafarnib (Gordon et al. 2018), it was
found that Lonafarnib significantly lowered mortality during a 2.2-year study. Initial trials
with Lonafarnib also showed reduced arterial stiffening as measured by pulse wave
velocity and carotid artery wall echo density. One of the limitations of FTI therapy is that
in place of farnesylation, prelamin A can still undergo prenylation with the addition of
geranylgeranyl groups. In this case, combination treatment with statins is effective
because statins reduce geranylgeranylation (Varela et al. 2008).
Additional therapies currently undergoing clinical trials include mTOR inhibitors,
including the rapamycin analog everolimus. These mTOR inhibitors increase autophagic
clearance of progerin (Cao et al. 2011; DuBose et al. 2018; Gabriel et al. 2016).
Combinatorial therapies of lonafarnib and everoliumus correct altered genome
organization and DNA damage in an HGPS fibroblast model (Bikkul et al. 2018) and are
currently undergoing clinical trials.
Lastly, attempts at genome editing using CRISPR-cas9 have also been
promising in reducing the effects of progerin in mouse models (Beyret et al. 2019;
Santiago-Fernández et al. 2019). Adenoviral delivery of a CRISPR-cas9 vector targeting
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progerin was shown to reduce both progerin and Lamin A levels and prolong lifespan of
LMNAG609G HGPS mice. However, some of the current downsides to this treatment are
potential off-target effects that may cause mutations at undesired sites in the genome as
well as the efficacy and distribution of the CRISPR-cas9 vector throughout the body.
Currently, technology is not sufficient for a large portion of cells within a tissue to receive
and incorporate the viral genome. An exciting new technology of base editing has also
been applied to HGPS mouse models to correct the C>T mutation at the Lamin A locus.
A single injection containing the base-editing technology packaged in an adenoassociated virus corrected the pathogenic mutation by 20-60% in various tissues, greatly
extended lifespan, and corrected the vascular pathology in an HGPS mouse model
(Koblan et al. 2021).

1.2 Arterial stiffening and mechanical properties
of the ECM

1.2a Changes in artery structure in aging and disease

The arterial wall is composed of three major layers (Fig. 1.02). The lumen of the
vessel is primarily composed of endothelial cells. These endothelial cells sit anchored on
a basement membrane which is majorly composed of laminin and collagen proteins
synthesized from the endothelial cells, but over 20 additional basement-matrix proteins
have been identified in arteries (Xu & Shi 2014). An inner elastic lamina composed of
elastin fibers separates the endothelial layer from the smooth muscle cell layer. This
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layer of SMCs, or media layer, is highly rich in collagen and elastin fibers. In addition, an
abundance of microfibrils, proteoglycans, and glycoproteins are also synthesized by the
SMCs residing in this layer. The outer layer of the artery, or adventitia layer, is separated
from the media by an external elastic lamina (Wagenseil & Mecham 2009; Xu & Shi
2014). This exterior layer of connective tissue is primarily synthesized by resident
(adventitial) fibroblasts and consists mainly of fibrillar collagens, proteoglycans, and
fibronectin among many other ECM proteins. It is important to note that the ECM in the
vessel wall is constantly undergoing change and remodeling in response to stimuli such
as pressure and flow, and these changes can affect the mechanics of arteries and
signaling to cells over time (Wagenseil & Mecham 2009; Xu & Shi 2014).
Mechanisms of arterial stiffening have been well-studied in the normal aging
population. The composition of the ECM plays a critical role in arterial stiffness (Cox &
Erler 2011). The stiffness of the major arteries relies on a balance of elastin and collagen
fibers (Humphrey et al. 2014; Wagenseil & Mecham 2012) to maintain a proper
response to blood pressure. Elastin allows for recoil at lower load and dampens cyclic
loading from the beating heart while fibrillar collagens contribute to the strain-stiffening
property of arteries at high load (Kohn et al. 2015). Arteries express three main fibrillar
collagens, with collagen-I>collagen-III>collagen-V in abundance (Hulmes 2008; Prockop
& Kivirikko 1995). Increased collagen deposition as well as elastin fragmentation has
been observed in the arteries of HGPS children at autopsy (Olive et al. 2010; GerhardHerman et al. 2011; Merideth et al. 2008) and in aged arteries (Kohn et al. 2015; Tsamis
et al. 2013).
In addition to increases in fibrillar collagens, the mechanical properties of tissues
are further regulated by matrix remodeling enzymes (Freitas-Rodríguez et al. 2017;
14

Lampi & Reinhart-King 2018), and especially Lysyl Oxidase (LOX) and its family
members (LOXL1, LOXL2, LOXL3 and LOXL4) (Yamauchi & Sricholpech 2012; Nilsson
et al. 2016; Steppan et al. 2019). These enzymes covalently cross-link newly
synthesized collagen and elastin fibers to enhance their tensile strength (Tsamis et al.
2013; Baker et al. 2013; Herchenhan et al. 2015), and their overexpression is commonly
seen in stiffness-related pathologies (Desmoulière et al. 1997; Kagan 1994). However,
since elastin biosynthesis ends early in life (Tsamis et al. 2013; Wagenseil & Mecham
2012; Davidson et al. 1986; Mithieux & Weiss 2005; Kelleher et al. 2004), LOX-mediated
crosslinking is thought to target newly synthesized collagens in normal aging. While
increased collagens and matrix modifying enzymes such as LOX can promote pathology
through increasing arterial stiffness, it is important to note that decreases in these
proteins can also cause arterial pathologies. For example, degradation of elastin and
reduction in collagen cross-linking promote the formation of aortic aneurysms (Xu & Shi
2014). Thus, the arterial wall relies on a delicate balance of ECM proteins to maintain an
appropriate stiffness to properly handle the mechanical load from the heart, and changes
to arterial stiffness in either direction can have drastic consequences.
Ultimately, changes in stiffness of the arteries can cause downstream effects on
the heart and increased pressure on the arterial network. Increased arterial stiffening
can lead to increased afterload on the heart which has been linked to left ventricular
hypertrophy and ventricular stiffening, conditions commonly observed in HGPS (Mottram
et al. 2005; Kim et al. 2017; Prakash et al. 2018). As the left ventricle wall remodels to
become thicker, its capacity for blood decreases in comparison to a healthy ventricle.
This results in a decreased stroke volume and less blood supplied to the body, ultimately
leading to heart failure. In addition, prior evidence from our lab supports the idea that
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increased arterial stiffness may promote atherosclerosis by increasing macrophage
binding to endothelial cells, as macrophages preferentially adhere to stiffer surfaces
(Kothapalli et al. 2012). Because arterial stiffness is correlated with many of the
additional negative cardiovascular outcomes seen in HGPS, it offers a very promising
point of study and therapeutic intervention.
1.2b Collagens, crosslinking, and lysyl oxidase

Collagens are the most abundant proteins in mammals, comprising around 30%
of total protein mass (Ricard-Blum 2011). The most abundant class of collagens
expressed in the body are the type-1 fibrillar collagens. However, there are currently 28
members of the collagen family, and each collagen type can have multiple alpha chains
(i.e. Col1a1, Col1a2) (Ricard-Blum 2011). At their core, all collagens possess the
common structural feature of a triple helix domain, a combination of three alpha chains.
These triple helix domains are generally composed of Gly-X-Y repeats and depending
on the type of collagen can be rather flexible if there are imperfections or short
interruptions in these repeats (Bella et al. 2006; Khoshnoodi et al. 2008; Ricard-Blum
2011). Fibril forming collagens, such as Collagens-I, III, and V have one large triple helix
domain, and play a structural role, where they contribute to tissue shape and mechanical
properties (Ricard-Blum 2011). Fibril-associated collagens with interrupted triple-helices
(FACIT) such as collagens IX, XII, and XIV have multiple triple helices (Shaw & Olsen
1991). In addition, non-fibrillar network-forming collagens such as collagen-IV can form
stable basement membranes for cells and serve as anchors for the binding of other
collagen molecules (Ricard-Blum 2011).
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Fibrillar collagens are synthesized as a procollagen peptide and secreted into the
extracellular space (Gelse et al. 2003). Then, the N- and C- terminal propeptides are
cleaved by BMP-1/Tolloid like proteinases, leaving the collagen molecule with N- and Cterminal telopeptides. The fibrillar collagen molecules then self-assemble into fibrils and
can be stabilized through covalent crosslinks between lysine residues in the telopeptide
regions between collagen molecules (Yamauchi & Sricholpech 2012).

Covalent

crosslinks of collagens include oxidative deamination of lysines by the Lysyl Oxidase
enzyme family, disulfide bonds, and the Nε(γ-glutamyl)lysine isopeptide catalyzed by the
transglutaminase-2 enzyme (Ricard-Blum 2011).
Collagens can be degraded by several types of proteases among which is the
matrix metalloproteinase family of enzymes (MMPs). MMPs are zinc-dependent
endopeptidases that normally are responsible for physiological tissue repair processes
but also play a role in tumorigenesis and metastasis. The fibrillar collagens are generally
cleaved by MMP-1 and MMP-8 at specific MMP cleavage sites (Ricard-Blum 2011; Klein
& Bischoff 2011).
One of the major enzymes responsible for the lysine crosslinking of the
telopeptides of collagens are of the Lysyl Oxidase (LOX) family of enzymes, consisting
of 5 family members including LOX, and four LOX-Like proteins, LOXL 1-4 (Mäki 2009;
Eyre & Wu 2005; Trackman 2016). Collagen-1 contains two possible lysines available
for crosslinking in the C-terminal telopeptide and three in the N-terminal. LOX works by
performing an oxidative deamination reaction to convert the amino group in the lysine
residue into a more reactive aldehyde moiety. This lysine-aldehyde can then condense
with lysine or hydroxylysine residues from telopeptides of other collagen molecules
(Yamauchi & Sricholpech 2012; Lucero & Kagan 2006). This covalent modification
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between collagen molecules stabilizes the collagen and increased cross-linking is
observed in many stiffness-related pathologies (Fig. 1.03).
LOX works extracellularly on newly synthesized collagens and itself is secreted
as a pro-LOX protein. Like pro-collagens, pro-LOX must also be cleaved by BMP1/Tolloid-like proteinases, thus providing a mechanism by which BMP1 catalytically
activates LOX in addition to preparing its collagen substrate (Yamauchi & Sricholpech
2012). LOX also requires a copper ion and cofactor LTQ (Lysine tyrosylquinone) to
oxidize its lysine substrate. Beta-aminopropionitrile (BAPN) is a well-known inhibitor of
LOX isoforms, acting in an irreversible manner through the formation of a dead-end
complex with essential cofactor LTQ (Yamauchi & Sricholpech 2012). BAPN can inhibit
all LOX isoforms (Nilsson et al. 2016). Although BAPN is a highly effective inhibitor in
vitro, the compound can be oxidized by additional amine oxidases, such as serum amine
oxidases, and lead to accumulation of toxic products in vivo (Trackman 2016).
In the majority of tissues, LOX is the most abundantly expressed of the family
isoforms and is required for completion of proper collagen and elastin biosynthesis
(Trackman 2016). LOX knockout mice die perinatally due to vascular defects (SharmaBhandari et al. 2015; Atsawasuwan et al. 2005; Mäki et al. 2002). In addition, the LOX
isoform is commonly upregulated in fibrotic diseases, and its crosslinking of collagens is
thought to provide resistance of the extracellular matrix to degradation (Mäki et al. 2002).
LOXL-1 is primarily linked to elastin maturation, as LOXL1-knockout mice show skin,
uterine, and lung abnormalities and LOXL-1 closely associates with elastic fibers in vivo
(Liu et al. 2004; Lee et al. 2008). Studies of LOXL-2 have focused on the protein’s
upregulation in many cancers (Torres et al. 2015; Moon et al. 2013; Trackman 2016).
Additional roles (aside from crosslinking) for LOXL2 in signal transduction have also
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been studied, and a direct interaction of LOXL2 with nuclear proteins, such as HSP90,
has been demonstrated (Mccready et al. 2014). Currently, aside from its upregulation in
fibrosis like other LOX isoforms, not much is known about LOXL3 (Trackman 2016).
LOXL4 is highly expressed in the vascular tissues and has also been linked to fibrotic
pathologies (Trackman 2016).
1.2c Elastin synthesis and maturation

Elastin is the major component of the ECM that provides elasticity to the tissue
and is predominantly found in the large arteries, tendons, skin, and lungs (Mithieux &
Weiss 2005). In contrast to the high Young’s modulus of collagen (1x106 kPa), elastin
has a relatively low Young’s modulus of 300-600 kPa and can extend from 100-220% of
its unstretched length (Gosline 1976; Fung 1993). Bundles of elastin form elastic fibers,
in which elastin comprises the core of the fiber (approximately 90% of the fiber); smaller
microfibrils surround the sheathe of elastin. Elastin comprises around 30-57% of the
aorta and in large arteries is organized into concentric rings around the lumen of the
vessel, with a layer of smooth muscle cells between each elastic lamina (Vrhovski &
Weiss 1998; Li et al. 1998). These elastic fibers undergo billions of cycles of extension
and recoil without mechanical failure (Keeley et al. 2002). Elastin has a very long halflife, estimated to be around 70 years in humans (Petersen et al. 2002; Mithieux & Weiss
2005), and as such there is very little turnover in healthy tissues. Elastogenesis takes
place during the late fetal and early neonatal period, with smooth muscle cells being the
primary cell-type depositing elastin in the large arteries (Uitto et al. 1991). Before the
deposition of elastin, microfibrils are first deposited and thought to act as a scaffold for
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orientation of the elastic fibrils (Kielty et al. 2002; Davis & Mecham 1993). These
microfibrils are composed of several molecules that help aid in hydration, growth factor
association, and regulation of cellular activities, including proteoglycans such as fibrillin1 and -2. When initially synthesized, elastin is formed by the cross-linking of lysines on
tropoelastin monomers (Mithieux & Weiss 2005). This cross-linking is performed similar
to collagen cross-linking and is also done by the lysyl oxidase family of enzymes (Kagan
& Sullivan 1982; Liu et al. 2004; Noblesse et al. 2004). Cross-linking of lysine residues is
the only known post-translational modification of elastin. Because of the extensive
crosslinking by LOX family members, elastin degradation is very slow (Mithieux & Weiss
2005). However, elastin fiber breakdown is increased, particularly during aging, due to
elastases (Faury 2001). Elastin degradation products can then produce responses such
as increased ECM synthesis, cell migration, and cell proliferation (Mithieux & Weiss
2005).

1.3 Arterial contractility and smooth muscle cell
biology

1.3a Regulators of smooth muscle contractility

Vascular smooth muscle cells (SMCs) line the medial layer of arteries, and one
of their major functions is to regulate blood flow to target organs by modulating arterial
tone and peripheral resistance (Webb 2003; Hathaway et al. 1991). Vascular tone is
regulated through tonic contraction and dilation of the larger arteries. Similar to other
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muscle cells, the major contractile components in SMCs consists of actin and myosin.
However, in contrast to skeletal muscle, smooth muscle cells undergo tonic, or
prolonged contraction (Webb 2003; Hathaway et al. 1991). Thus, they possess cell-type
specific forms of actin and myosin.
A smooth muscle specific form of myosin heavy chain (encoded by the myh11
gene, SM MHC protein) and smooth muscle alpha-actin (acta2 gene, SMA protein) exist
in SMCs and have been designated critical components for cellular contraction (Lehman
& Morgan 2012; Babu et al. 2000; Martin et al. 2007). The smooth muscle-specific
myosin isoforms have greater force generating capacity than striated muscle myosins
and allow for the prolonged tonic contraction of SMCs (Babu et al. 2000). Smooth
muscle myosins are composed of two heavy chains, two essential light chains, and two
regulatory light chains and associate with the contractile SMA filaments which anchor to
dense bodies and adhesion plaques on the cell membrane (Lehman & Morgan 2012).
Additionally, SMCs contain other cell-specific contractile proteins such as transgelin
(gene Tagln), an actin cross-linking protein, and calponin (gene Cnn1), which can
regulate ATPase activity of myosin in smooth muscle (Webb 2003; Hathaway et al.
1991). Inability to properly regulate vascular tone through contraction and dilation may
lead to impaired blood flow to target tissues.
The contraction of SMCs is largely calcium-dependent (Fig. 1.04) (Morgan 1990;
Webb 2003; Somlyo et al. 2004; Hathaway et al. 1991). Influx of calcium into the
cytoplasm by either calcium channels on the cell membrane or release of intracellular
calcium stores can allow calcium to bind to calmodulin and activate myosin light chain
kinase (MLCK). Phosphorylation of the regulatory light chain of smooth muscle myosin
by MLCK allows for cycling of cross bridges between actin and myosin to initiate
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contraction. This phosphorylation of myosin light chain allows for enhanced inorganic
phosphate release to increase the rate of the actomyosin ATPase cycle. Additionally,
alpha adrenergic agonists such as norepinephrine and phenylephrine can cause release
of calcium through signaling cascades involving the activation of heterotrimeric Gproteins and activation of the second messengers IP3 (inositol triphosphate) and DAG
(Diacylglycerol). Binding of IP3 to the sarcoplasmic reticulum promotes calcium release,
and DAG signaling activates protein kinase C (PKC) to phosphorylate ion channels and
promote intracellular calcium transport (Webb 2003; Hathaway et al. 1991; Ahmed &
Warren 2018; Zhu et al. 2019; Ringvold & Khalil 2017).
Acting antagonistic to MLCK, myosin light chain phosphatase (MLCP) can
dephosphorylate the regulatory light chain of smooth muscle myosin to lessen the rate of
the actomyosin ATPase cycle. RhoA and Rho-associated protein kinase (ROCK)
signaling can phosphorylate MLCP in order to inhibit its function and promote
contractility. The Rho pathway is thought to be activated upon receptor binding of
phenylephrine or other alpha adrenergic agonists by release of Rho-GEFs from the cell
membrane (Webb 2003; Hathaway et al. 1991; Szasz & Webb 2017). To promote
relaxation of smooth muscle, calcium is removed from the cytoplasm by Calciummagnesium-ATPase pumps on the sarcoplasmic reticulum or the cell membrane in
addition to sodium calcium exchange pumps. Additionally, activation of MLCP also
promotes relaxation (Webb 2003; Hathaway et al. 1991).
1.3b Smooth muscle myosins and smooth muscle actin
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SMCs possess 4 unique isoforms of the myosin heavy chain subunit (SM-MHC)
which originate from alternative splicing of the Myh11 gene. These four isoforms result
from the addition of an insert in either the head region or on the COOH terminus of the
protein (Fig. 1.05) (Eddinger & Meer 2007). Smooth muscle also has two smooth muscle
myosin light chain-17 (SM-MLC17) isoforms and two regulatory SM-MLC20 isoforms
(Lenzs et al. 1989; Lash et al. 1990; Eddinger & Meer 2007). In addition to smooth
muscle specific myosins, SMCs also contain non-muscle myosin heavy chain (NM-MHC)
isoforms IIA, IIB, and IIC, and in contrast to SM-MHC, these NM-MHC isoforms do not
possess a head or tail insert (Eddinger & Meer 2007). There is currently no data
supporting combination of NM- MHC and SM-MHC to form active myosins. However,
there is data suggesting non-muscle myosin light chain subunits may combine with SMMHC subunits, although this may be tissue specific (Eddinger & Meer 2007).
Although containing both NM-MHC and SM-MHC, as SMCs begin to
differentiate, the abundance of NM-MHC decreases over time from around 50% of total
myosin in neonates to around 10% of total myosin in mature adults as observed in
swine, rat, and mouse, and SM-MHC increases to become the predominant myosin
present (Eddinger & Murphy 1991; Eddinger & Wolf 1993; Frid et al. 1994; Gaylinn et al.
1989). This suggests that SM-MHC has a critical role in the function of SMCs and
arterial physiology that differs from the role of non-muscle myosins. Indeed, in contrast
to other muscles, smooth muscle can shorten by 80% of its original length (Eddinger &
Meer 2007). This is in part due to the smooth muscle specific isoforms of myosin
present, and that smooth muscle thick filaments possess four myosins per 14.5nm in
contrast to three myosins in tissue like striated muscle (Tonino et al. 2002). Furthermore,
smooth muscle thick filaments are thought to be more labile than other muscle filaments,
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so assembly and disassembly of actomyosin filaments may also contribute to the unique
contractility of SMCs (Eddinger & Meer 2007). The NM-MHC isoforms present in SMCs
have been proposed to be involved in housekeeping processes instead of contractility,
as SMCs can still experience large tonic forces when there is little or no NM-MHC
(Eddinger & Meer 2007).
In addition to myosins, SMCs also have four isoforms of actin (Fatigati & Murphy
1984; Kim et al. 2008). The alpha isoform of SMA dominates in supporting the
contractile ability of SMCs in comparison to the gamma isoform (Lehman & Morgan
2012). Additionally, SMCs have two non-muscle beta and gamma actin isoforms which
play a maintenance role in cell structure (Drew et al. 1991; Fatigati & Murphy 1984; Kim
et al. 2008). Some studies support that the actin isoforms segregate into separate
filaments in the cell, with the alpha smooth muscle actin filaments running along the
length of the cell and the gamma isoform localized at the cortex (Gallant et al. 2011;
Lehman & Morgan 2012). Both of these actin filaments anchor to dense bodies, which
are strong focal adhesions that form on the cell membrane and provide anchoring
structures to allow for contraction of the actomyosin skeleton. What may set the actin
cytoskeleton of smooth muscle apart from skeletal muscle is that the exchange of
smooth muscle actin is much more rapid, and increased polymerization of actin has
been shown to correlate with an increase in the magnitude of contractile force generated
(Lehman & Morgan 2012; Mehta & Gunst 1999; Jones et al. 1999; Gunst & Zhang
2008). Overall, the unique isoforms smooth muscle cells possess of actin and myosin
allow for their distinct physiological function of tonic contraction and regulation of
vascular tone.
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1.3c Smooth muscle biology and phenotypic switching

SMCs exist along a range of phenotypes from “contractile” to “synthetic.” In
relation to regulating blood pressure, vascular tone, and blood distribution, it is important
that SMCs possess a contractile ability (Owens et al. 2004; Davis-Dusenbery et al.
2011). However, in response to specific conditions such as vascular injury, it is important
that the SMCs are capable of migrating, proliferating and synthesizing large amounts of
extracellular matrix to repair the wound, all of which are characteristic of the synthetic
state. The ability of SMCs to transition from a contractile state to matrix-remodeling state
is called phenotypic switching (Hao et al. 2003; Owens et al. 2004; Rensen et al. 2007).
Major markers of the contractile cell phenotype include, but are not limited to, SM-MHC,
SMA, myocardin (see below), and calponin - all proteins involved in the contractility of
SMCs. Synthetic molecular markers include increased collagen I and osteopontin
expression, and increased synthesis of MMP isoforms, in addition to other markers
(Rensen et al. 2007; Owens et al. 2004; Beamish et al. 2010; Long et al. 2008; Miano
2003; Rzucidlo et al. 2007). It is important to note that SMCs do not exist in either a
solely contractile or synthetic state but exist instead along a spectrum ranging from
either end.
Phenotypic switching can occur due to chemical or mechanical cues. For
instance, platelet-derived growth factor (PDGF) induces a more synthetic phenotype (Li
et al. 1997; Hao et al. 2002; Kotani et al. 2003) while transforming growth factor beta
(TGF-β) signaling induces a contractile phenotype (Hautmann et al. 1997; Hao et al.
2002). Mechanical stimuli can also play a role in SMC differentiation, as stretch (caused
by variations in arterial pressure) and flow (caused by blood passing through arteries)
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can also alter phenotype. Shear stress caused by flow promotes a more synthetic
phenotype, showing reduced SMA and SM-MHC expression (Hao et al. 2002; Rensen et
al. 2007). Stretch increases the abundance of both contractile proteins and matrix
proteins (O’Callaghan & Williams 2000; Reusch et al. 1996; Birukov et al. 1998; Lehoux
& Tedgui 1998; Reusch et al. 1997). Fibronectin and collagen abundance are increased
upon mechanical strain of SMCs, and it is thought that constant strain on the SMCs can
lead to build-up of matrix proteins to cause stiffening of the arteries (O’Callaghan &
Williams 2000).
At a genetic level, SMC phenotype is regulated by several transcription factors
and transcriptional co-activators that control the expression of contractile genes (Fig.
1.06) (Davis-Dusenbery et al. 2011).

Cis-acting elements termed CArG boxes

(CC(AT)6GG) are upstream of many SMC contractile genes, which allows for the
binding of serum response factor (SRF) and activation of transcription (Kim et al. 1997;
Li et al. 1996; Mack & Owens 1999; Manabe & Owens 2001). SRF affinity for the CArG
motif is dramatically enhanced by the binding of myocardins or MRTFs (myocardinrelated transcription factors) and negatively regulated by KLF4 (Du et al. 2003; Chen et
al. 2002; Wang et al. 2003; Hinson et al. 2007; Davis-Dusenbery et al. 2011).
Furthermore, microRNAs such as mir-143/145 also play a role in regulating SMC
differentiation by targeting and degrading KLF4 transcript to promote the contractile
phenotype (Boettger et al. 2009; Zhang 2009; Hutcheson et al. 2013). Overall, a wide
variety of stimuli and signals can influence the gene profile of SMCs to allow for varying
phenotypic state, and overabundance or loss of particular signals can be devastating for
SMC and arterial function.
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1.4 Mechanotransduction from the ECM
In addition to contributing to the mechanical properties of tissues, the ECM, in
combination with cell force generation, can also modulate inter and intra-cellular
signaling pathways (Figure 1.07). Cells adhere to the ECM through transmembrane
receptors. The most common cellular attachments to the ECM are transmembrane
proteins called integrins. These integrins are associated with matrix components outside
of the cell and linker proteins inside the cell that connect integrins to the cytoskeleton.
Thus, integrins are transmembrane adhesions that form a mechanism to transduce
mechanical signals from outside the cell into biochemical signals inside the cell
(Humphrey et al. 2014; Ciobanasu et al. 2013; Ingber 2008). The clustering of integrins
and collection of signaling molecules at these clustering sites has been termed a focal
adhesion, and it has been demonstrated that cells on stiffer substrates generate larger
and more stable focal adhesions, as the integrin adhesions strengthen under force.
Inside the cell, linker proteins which consist of Talin, Vinculin, and Paxillin among many
others, connect the integrin to the actomyosin cytoskeleton. The coupling of the
actomyosin skeleton to the rigid ECM allows the cell to generate tension and unfold
signaling and docking proteins, such as Talin and Vinculin, to allow for biochemical
signaling events to take place (Humphrey et al. 2014; Martino et al. 2018; Geiger et al.
2009; Burridge & Guilluy 2016).
The increased generation of cellular tension on stiff substrates can enforce the
stabilization of the actin cytoskeleton, leading to increased polymerization of actin
filaments to form large bundles called stress fibers. For example, intracellular tension
has been shown to activate Rho signaling and downstream Rho associated kinase
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(ROCK) and LIM Kinase to phosphorylate cofilin and stabilize actin filaments (Martino et
al. 2018; Fukata et al. 2001; Hayakawa et al. 2011). This polymerization of actin can
further influence downstream biochemical signaling. For instance, the transcriptional
coactivator MKL-1 (or MRTF-A; myocardin-related transcription factor) is generally
sequestered in the cytoplasm by monomeric G-actin. As actin fibers form due to
increased polymerization, the abundance of G-actin decreases and MKL becomes freed
of its binding from G-actin and can translocate to the nucleus to transcribe many
contractility-related genes (Martino et al. 2018; Ho et al. 2013).
Similar to the connections that exist between the ECM and the cytoplasmic actin
skeleton, force can also be transduced from the actin cytoskeleton to the nucleus
through the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex. The LINC
complex connects to the actin cytoskeleton and intermediate filaments through Nesprin
proteins which cross the outer nuclear membrane. Nesprins connect to SUN proteins in
the nuclear envelope, and SUN proteins connect to the nuclear lamina meshwork on the
inner nuclear membrane (Dahl et al. 2008; Dahl & Kalinowski 2011; Crisp et al. 2006;
Martino et al. 2018).
Another example of force transduction signaling has been demonstrated through
transcriptional regulators YAP/TAZ (Yes-associated protein 1, and WW-domaincontaining transcription regulator 1, respectively). Dupont et al. (2011) showed that
YAP/TAZ are mechanically activated transcriptional regulators that are predominantly
cytosolic on softer substrates, but translocate to the nucleus on stiff substrates (Dupont
et al. 2011). Novel studies by Elosegui-Artola et al. (2017) have shown that force on
LINC connections can act to open nuclear pores and promote entry of transcription
factors such as YAP/TAZ into the nucleus (Elosegui-Artola et al. 2017). In addition, it has
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been hypothesized that force generation on the LINC complex can act to regulate
epigenetics (van Steensel & Belmont 2017; Lelièvre 2009).
In HGPS, progerin expression and the consequently altered nuclear lamina has
been shown to influence mechanotransduction. Dahl and colleagues (2006) have shown
that the nuclear lamina of HGPS cells has reduced nuclear deformability and a reduced
ability to rearrange under mechanical stress (Dahl et al. 2006). Supporting this study,
Verstraeten et al. (2008) showed that HGPS nuclei are much stiffer and HGPS cells are
more susceptible to mechanical stress than cells with a healthy nuclear lamina
(Verstraeten et al. 2008). Others have shown dysregulated interactions between
progerin and SUN proteins, further suggesting progerin expression can cause altered
mechanotransduction to the nucleus (Chen et al. 2014). As Lamin A plays such a critical
role in structural integrity of the nucleus and mechanotransduction, it is no surprise
progerin can alter both of these integral functions.

1.4 Rationale and objectives

Arterial stiffening and reduced arterial contractility have been reported in HGPS
children and animal models, but the initial drivers and molecular mechanisms remain
unknown. Previously, arterial stiffening and reduced contractility have been reported in
HGPS mouse models at late-stage time-points, near the end of the animal’s lifespan
(Murtada et al. 2020; del Campo et al. 2020). However, the interpretation of these results
in terms of vascular biology is confounded by the low numbers of arterial SMCs at this
late stage. The work in this thesis seeks to understand the initial molecular regulators of
arterial stiffening and reduced contractility. By using the LMNAG609G mouse model and
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evaluating cardiovascular abnormalities at a young age before the onset of severe
HGPS pathology, we can understand some of the molecular drivers leading to altered
cardiovascular function.
In Chapter 2, I show that arterial stiffening and diastolic dysfunction begins at a
very early time-point in HGPS mice and correlates with an increase in LOX abundance.
In vivo administration of LOX inhibitor BAPN corrected arterial stiffening and diastolic
dysfunction. Genome-wide profiling revealed reduced miR-145 as a mechanism for the
increased LOX abundance, and restoration of miR-145 in primary cultured HGPS SMCs
reduced LOX transcript to WT levels. We also compare the arterial stiffening of young
HGPS mice to normally aged WT mice and show unique differences in axial versus
circumferential stiffening. Interestingly, although we report increased LOX abundance in
normally aged arteries, we did not find reduced miR-145 levels. This indicates that the
arterial stiffening in normal aging versus premature aging may occur through differential
mechanisms.
In Chapter 3, I explore the mechanism of reduced arterial contractility in HGPS. I
show that HGPS carotid arteries have reduced vasoconstriction in response to
potassium chloride. In surveying key SMC contractility markers, I discovered HGPS
SMCs display reduced SM-MHC levels. This reduction in SM-MHC is causal for
decreased force generation in isolated HGPS SMCs as restoration of SM-MHC
significantly increased traction force. Lastly, I show that normally aged arteries of both
mice and humans display decreased SM-MHC levels, indicating that a reduction in SMMHC and arterial contractility may be a common phenomenon of normal and premature
aging.
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In Chapter 4, I will present early findings to understand the direct effects of
progerin expression on LOX and SM-MHC. I show that acute progerin expression in WT
SMCs does not recapitulate the high LOX or reduced miR-145 observed in HGPS but
does result in the selective decrease in SM-MHC. Additionally, I show decreased nuclear
localization of myocardin-related transcription factor-A (MRTF-A), a key regulator of
SMC contractile gene expression, in HGPS SMCs. Furthermore, I show that knockdown
of MRTF-A in WT SMCs partially mimics the contractile gene profile of HGPS SMCs.
In Chapter 5, I summarize the findings of this work and discuss hypotheses
relating to how and why HGPS SMCs may be altering the arterial ECM, and I consider
ideas of how progerin may be directly causing decreased force generation in SMCs. I
also discuss potential implications of my work in the context of therapies for HGPS and
normal aging and explore the commonalities and differences I have observed between
premature and natural aging.
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1.5 Figures
A

B

Figure 1.01. Post-translational processing of Lamin A and Progerin. (A) In healthy
cells, the Prelamin A precursor protein is produced from proper splicing of the LMNA
gene and subsequently processed with post-translational modifications. In a final step,
ZMPSTE24 cleaves the farnesylated and carboxymethylated C-terminus of Prelamin A
to produce mature Lamin A protein. In cases of ZMPSTE24 deficiency, a farnesylated
and carboxymethylated Prelamin A protein produces a progeroid phenotype. (B) In
classic HGPS, the c.1824C>T mutation in LMNA results in aberrant splicing between
exons 11-12 and the loss of 50 amino acids from the resultant protein. These 50 amino
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acids are critical for the recognition of progerin by ZMPSTE24, and the farnesyl and
carboxymethyl moieties remain attached to the C-terminus, leading to nuclear defects.
Figure made in BioRender (biorender.com).
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Figure 1.02. Large elastic artery structure. The large elastic arteries such as the aorta
have three distinct layers. The inward most layer facing the lumen of the vessel is
comprised of endothelial cells, which are essential in responding to changes in blood
flow and additional soluble factors present in the blood. The endothelial layer is
separated from the media layer by the inner elastic lamina. The media layer is
comprised of smooth muscle cells which are essential for regulating vascular tone.
Layers of smooth muscle are separated by concentric rings of elastin fibers. The media
layer is separated from the outer adventitia layer by an external elastic lamina. The
adventitia layer is a highly collagenous connective tissue synthesized by fibroblasts.
Figure made in BioRender (biorender.com).
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Figure 1.03. Lysyl Oxidase (LOX)-mediated crosslinking of collagen. (A)
Crosslinking locations of the 5 lysine or hydroxylysine residues on the telo-peptide
region of type-I collagen (denoted by blue circles). LOX mediates collagen crosslinking
through conversion of Lysine to a more reactive Lysine-aldehyde and requires Cu2+ and
cofactor LTQ. (B) Inter-peptide crosslinking sites between triple helices on type-I
collagen. Figure prepared in Biorender (biorender.com).
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Figure 1.04. Mechanisms of smooth muscle cell contraction. Agonist binding (such
as phenylephrine) to G-protein coupled receptors can induce the production of two
second messengers through activation of phospholipase C. Diacylglycerol (DG) triggers
contraction through activation of protein kinase C (PKC), which can phosphorylate
calcium ion channels and additional proteins that regulate myosin cross-bridge cycling.
Inositol 1,4,5-trisphosphate (IP3), binds to the sarcoplasmic reticulum to trigger calcium
release. Alternatively, increased KCl can cause membrane depolarization and activation
of voltage-gated calcium channels on the cell membrane. Calcium binding to calmodulin
activates myosin light chain kinase (MLCK) to promote a contracted state through the
phosphorylation of myosin light chain. Additionally, receptor binding can activate RhoA
and downstream Rho-kinase to phosphorylate and inactivate myosin phosphatase and
promote contraction. Figure modified from Webb (2003).
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Figure 1.05. Smooth muscle myosin heavy chain (SM-MHC) isoforms. Alternative
splicing of the Myh11 gene generates four distinct isoforms of SM-MHC. The SM1
isoform contains an additional insert in the –COOH terminus of the protein not present in
the SM2 isoform. The SMA isoform lacks an insert near the N-terminus in comparison to
the SMB isoform. Figure made in BioRender (biorender.com).
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Figure 1.06. Regulation of SMC phenotypic switching and contractility. (A) SMCs
exist along a phenotypic spectrum ranging from synthetic, proliferating and ECMproducing cells, to contractile cells expressing an abundance of contractile machinery.
Various stimuli such as platelet derived growth factor (PDGF), shear stress, or stretch
have been reported to promote a more synthetic phenotype. Transforming growth factor
beta (TGFβ) and stretch have been reported to promote a contractile phenotype. (B)
Regulation of contractile gene transcription relies on CArG box motifs on DNA upstream
of contractile genes that bind serum response factor (SRF). Binding of myocardin or
myocardin like transcription factors (MRTFs) enhance the transcriptional activity of SRF.
In contrast, KLF4 can negatively regulate contractile gene expression.

38

Figure 1.07. Mechanotransduction from the ECM to the nucleus. Extracellular
mechanical signals are transmitted to the nucleus through connections of the cyto- and
nucleo-skeleton. Integrins bind to various extracellular matrix components and form focal
adhesions, recruiting proteins such as talin, vinculin (VCL), and paxillin (PXN) to their
intracellular domain and link the integrin to the actomyosin cytoskeleton. Stabilization of
the actomyosin skeleton is enforced by the activation of RhoA and downstream LIM
Kinase (LIMK) to phosphorylate cofilin. Force generated from the contraction of
actomyosin filaments is transmitted to the nucleus through the Linker of Nucleoskeleton
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and Cytoskeleton (LINC) complex. Nesprin proteins anchor to cytoskeletal filaments in
the cytoplasm and SUN proteins in the inner nuclear space. In turn, SUN proteins
anchor to the nuclear lamin network. Mechanosensitive gene transcription is activated
by the nuclear localization of mechanosensitive transcription factors or transcriptional
regulators and through changes in chromatin structure. Figure made in BioRender
(biorender.com).
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1.6 Tables
Table 1. Common cardiovascular complications present in physiological aging
and in the premature aging disease Hutchinson-Gilford Progeria Syndrome. Table
adapted from Hamczyk et al. (2018)

Cardiovascular Complications

Physiological Premature
aging
aging

Heart failure

Yes

Yes

Left ventricular diastolic
dysfunction

Yes

Yes

Ventricular hypertrophy

Yes

Yes

Cardiac fibrosis

Yes

Yes

Heart valve dysfunction

Yes

Yes

Increased sympathetic activity

Yes

Yes

Decreased baroreflex sensitivity

Yes

Yes

Intima-media thickening

Yes

Yes

Vascular stiffening

Yes

Yes

Vascular fibrosis

Yes

Yes

Endothelial dysfunction

Yes

No

Atherosclerosis

Yes

Yes

Vascular calcification

Yes

Yes

Hypertension

Yes

Yes

Elevated platelet count

No

Yes

Prolonged prothrombin time

No

Yes
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2.1 Abstract
Arterial stiffening and cardiac dysfunction are hallmarks of premature aging in
Hutchinson-Gilford Progeria Syndrome (HGPS), but the molecular regulators remain
unknown. Here, we show that the LaminAG609G mouse model of HGPS recapitulates the
premature arterial stiffening and early diastolic dysfunction seen in human HGPS. Lysyl
oxidase (LOX) is upregulated in the arteries of these mice, and treatment with the LOX
inhibitor, β-aminopropionitrile, improves arterial mechanics and cardiac function.
Genome-wide and mechanistic analysis revealed reduced expression of the LOXregulator, miR-145, in HGPS arteries, and forced expression of miR-145 restores normal
LOX gene expression in HGPS smooth muscle cells. LOX abundance is also increased
in the carotid arteries of aged wild-type mice, but its spatial expression differs from
HGPS and its upregulation is independent of changes in miR-145 abundance. Our
results show that miR145 is selectively misregulated in HGPS and that the consequent
upregulation of LOX is causal for premature arterial stiffening and cardiac dysfunction.
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2.2 Introduction
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disease of
premature aging. HGPS is caused by an autosomal dominant mutation in LMNA, the
gene encoding Lamin A (Gonzalo et al. 2016; Capell et al. 2007). The mutation is "silent"
(LaminAG608G) but leads to a defect in biosynthetic processing of the Lamin A precursor
and results in a truncated, farnesylated version of Lamin A called Progerin, that is
defective in its localization within the nucleus (Gonzalo et al. 2016; Capell et al. 2007).
Children with HGPS typically die in their teenage years as a consequence of
cardiovascular disease (atherosclerosis, myocardial infarction, heart failure, and/or
stroke) (Gonzalo et al. 2016; Capell et al. 2007). These cardiovascular consequences
occur in the absence of high cholesterol or triglycerides (Gordon et al. 2005), suggesting
that cholesterol-independent risk factors must be at play.
Intriguingly, the arteries of HGPS patients are abnormally stiff (Gerhard-Herman
et al. 2011), and arterial stiffness is a cholesterol-independent risk factor for
cardiovascular disease (Mitchell et al. 2010). Increased arterial stiffness is also a
hallmark of normal aging and increases substantially after the age of 50 in healthy males
and females (Mitchell et al. 2007). However, the arterial stiffness in HGPS children
resembles that of ~60 year-old individuals (Gerhard-Herman et al. 2011), indicating a
striking acceleration of arterial stiffening. Pathologically stiff arteries increase load on the
heart (Safar 2010; Laurent & Boutouyrie 2015), which can then have systemic
consequences and correlates with cardiac abnormalities such as left ventricular
hypertrophy and diastolic dysfunction (Mottram et al. 2005; Kim et al. 2017). Consistent
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with these relationships, left ventricular hypertrophy and, particularly, diastolic
dysfunction are also observed in HGPS children (Prakash et al. 2018).
The composition of the extracellular matrix (ECM) plays a critical role in arterial
stiffness (Cox & Erler 2011). The stiffness of the major arteries relies on a balance of
elastin and collagen fibers (Humphrey et al. 2014), which maintains a proper response to
blood pressure. Elastin allows for recoil at lower load and dampens cyclic loading from
the beating heart while fibrillar collagens contribute to the strain-stiffening property of
arteries at high load (Kohn et al. 2015). Arteries express three main fibrillar collagens,
with collagen-I>collagen-III>collagen-V in abundance (Hulmes 2008; Prockop & Kivirikko
1995). Increased collagen deposition as well as elastin fragmentation has been
observed in the arteries of HGPS children at autopsy (Olive et al. 2010; Merideth et al.
2008) and in aged arteries (Kohn et al. 2015; Tsamis et al. 2013).
In addition to increases in fibrillar collagens, the mechanical properties of tissues
are regulated by matrix remodeling enzymes (Freitas-Rodríguez et al. 2017; Lampi &
Reinhart-King 2018), especially Lysyl Oxidase (LOX) and its family members (LOXL1,
LOXL2, LOXL3 and LOXL4) (Yamauchi & Sricholpech 2012; Nilsson et al. 2016;
Steppan et al. 2019). These enzymes covalently cross-link newly synthesized collagen
and elastin fibers to enhance their stability and tensile strength (Tsamis et al. 2013;
Baker et al. 2013; Herchenhan et al. 2015), and LOX overexpression is commonly seen
in stiffness-related pathologies (Desmoulière et al. 1997; Kagan 1994). However, since
elastin biosynthesis ends early in life (Tsamis et al. 2013; Wagenseil & Mecham 2012;
Davidson et al. 1986; Mithieux & Weiss 2005; Kelleher et al. 2004), LOX-mediated
crosslinking is thought to target newly synthesized collagens in normal aging and
promote arterial stiffening.
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Since HGPS is a very rare genetic disease (Gerhard-Herman et al. 2011; Olive et
al. 2010) the number of HGPS patients is very small and the detailed analysis of early
and potentially causal events in the pathogenesis of HGPS must rely heavily on animal
models. Osorio et al. (Osorio et al. 2011) developed a knock-in mouse (hereafter called
HGPS mouse) that models the human disease by expressing murine Progerin
(LmnaG609G/G609G) at the endogenous Lmna locus. These mice display many traits of the
human disease including premature death. Arterial stiffening, left ventricular diastolic
dysfunction, and an increase in the expression of several collagens, including collagenIII, IV, and V is also apparent in these mice near the end of their lifespan (del Campo et
al. 2019; Murtada et al. 2020). Whether these changes are primary or secondary effects
of progerin expression is not known.
In this chapter, I have examined arterial mechanics, cardiac function, and
molecular mechanism in young HGPS mice (2-months of age, before the onset of
morbidity) in an effort to identify early and potentially causal events in disease
progression. We report that arterial stiffening in HGPS is strikingly premature and
associated with diastolic dysfunction. Arterial LOX is strongly upregulated in these young
mice, and systemic LOX inhibition improves arterial mechanics and cardiac function.
Genome-wide profiling and cell-based mechanistic analysis indicates that a pathologic
misregulation of miR-145 in HGPS is a critical and selective determinant of elevated
LOX expression.
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2.3 Results
Premature arterial stiffening in HGPS mice. I began my studies of arterial stiffening in
HGPS by comparing mechanics and ECM remodeling in the arteries of WT mice versus
the Progerin-expressing HGPS mouse. I focused on the carotid artery, a prominent site
of atherosclerotic lesion formation, as its occlusion is thought to be responsible for
induction of stroke in HGPS children (Gerhard-Herman et al. 2011). Freshly isolated
carotid arteries were stretched below, at, and above their in vivo lengths at constant
pressure to provide insight into axial arterial stress (Fig. 2.01A1, left). The artery was
also stretched to its in vivo length (referred to as the In Vivo Stretch; IVS), and then
pressurized incrementally to provide insight into circumferential vessel mechanics (Fig.
2.01A2, right). Changes in outer diameter, wall thickness, and inner radius were used to
generate axial and circumferential stress-stretch relationships, in which axial and
circumferential stiffness is represented as the stress the artery experiences for a defined
increase in stretch. These stress-stretch data were also used to derive the axial and
circumferential tangent modulus (vs. stretch), an additional way to estimate arterial
stiffness.
Brankovic et al. (2019) recently used these analyses to examine the mechanical
and geometric properties of carotid arteries of C57BL/6 mice aged from 2-24 months;
the results showed decreases in IVS as well as increased axial and circumferential
arterial stiffness with age, beginning at 12-months and becoming even more evident by
24 months (Brankovic et al. 2019). Therefore, young (2-month) HGPS mice and 24month WT mice were compared to understand how arterial mechanics are affected early
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in HGPS and how they compare to the changes that occur in normal aging. Additionally,
use of the Progerin-expressing HGPS mouse allowed me to analyze sex differences in
arterial biomechanics that have not been attainable given the small numbers of HGPS
girls and boys.
Changes in outer diameter, inner radius, and wall thickness with pressure (Fig.
2.02A-F) were measured and used to establish stress-stretch relationships in carotid
arteries from 2-month WT and HPGS mice.

The circumferential stress-stretch (Fig.

2.01B and D) and tangent modulus (Fig. 2.03B and D) curves of young HGPS and aged
WT mice were left-shifted for both sexes indicating increased circumferential stiffness.
Axially, the IVS was reduced in HGPS male and female mice, but the magnitude was
less than that seen in old WT mice of either sex (Table 1). The axial stress-stretch (Fig.
2.01C and E) and tangent modulus (Fig. 2.03A and C) curves suggested that axial
stiffening can occur early in HGPS but may be less prominent than circumferential
stiffening, particularly in the males. Collectively, these data indicate that arterial stiffening
in HGPS mice is premature as it is in the human syndrome, but the early effect is
anisotropic, especially in males, an insight that has not been obtainable by pulse-wave
velocity studies of HGPS children (Gerhard-Herman et al. 2011).
Osorio et al. (2011) have reported that heterozygous HGPS mice begin to display
a delayed decline in weight at around 8-months of age with an average survival of
approximately 240 days. Changes in carotid artery outer diameter, inner radius, and wall
thickness with pressure were analyzed in 2- and 9- month male heterozygous HGPS
(LMNA+/G609G) mice (Fig. 2.04A-C). Interestingly, 2-month male heterozygous HGPS
mice displayed similar circumferential stress-stretch relationships as 2-month male WT
mice but the circumferential stiffening effect was observed by 9-months of age (compare
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Figs. 2.01 and 2.04D). However, heterozygous HGPS mice also displayed a significant
decrease in IVS (Table 2) and increase in axial arterial stiffness at 9 months (Fig.
2.04E), effects that were not seen in the 2-month male homozygous mice (Table 1 and
Fig. 2.01). This suggests that a single copy of progerin also produces increased arterial
stiffening and that the effect is delayed relative to the homozygous male mice. However,
it is important to note at this 9-month timepoint it is difficult to tease out the contribution
of arterial stiffening from aging versus progerin expression. Further comparisons of
arterial mechanics in WT mice at 9-months may be an interesting matter for future study,
Although reduced smooth muscle cell (SMC) number has been reported in the
ascending aorta of HGPS children at autopsy (Hamczyk & Andrés 2019), histological
analysis of 2-month WT and HGPS carotid arteries showed similar cellularity (Fig.
2.05A) and numbers of SMC nuclei in the medial layer of young mouse carotids (Fig.
2.05B). We observed a small increase in the abundance of the senescence marker
p16INK4A in the carotid medial layer of 2-month HGPS mice (Fig. 2.05C-D), but other
markers of late HGPS vascular lesions including increases in calcium content (Merideth
et al. 2008; Olive et al. 2010), apoptotic cells, and changes in elastin integrity were not
seen in the HGPS carotid arteries at this early time-point (Figs. 2.05E-F and 2.06A-C).
Collectively, these results indicate that arterial stiffening is a very early event in the
progression of HGPS and that our experimental conditions have the potential to identify
initiating events before the onset of gross HGPS arterial pathology.

Canonical upregulation of fibrillar collagens is lacking in early HGPS. Tissue remodeling
and stiffening often involves increased amounts of fibrillar collagens and/or elastin
fragmentation. Collagen-I is the major strain-stiffening component of the arterial ECM,
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but an immunostaining analysis of carotid sections was unable to detect statistically
significant increases in collagen-I in either the medial or adventitial layers of 2-month
male HGPS carotid arteries as compared to age- and sex-matched WT controls (Figs.
2.07A-B and 2.08A-B). Of the minor fibrillar collagens, these young HGPS carotid
arteries showed a statistically significant but small increase in medial collagen-III and no
change in the abundance of collagen-V (Figs. 2.07A-B and 2.08). Second harmonic
generation (SHG) imaging was performed collecting both forward and backward scatter
in order to capture collagen structure at multiple distances within the sample and detect
fibers at different optical alignments (Williams et al. 2005). SHG showed that fibrillar
collagen was much more abundant in the adventitia than the media for all samples. I
saw no dramatic changes in SHG signals in the media layer of 2-month WT and HGPS
carotid arteries. (Fig. 2.09). Thus, the SHG results indicated that collagen structure was
similar in the carotid arteries of 2-month male WT and HGPS mice. Higher resolution
analysis by Transmission Electron Microscopy (TEM; Fig. 2.10A) did allow for a more
detailed analysis of collagen between the two genotypes (Fig. 2.10B-C).

Similar to

observations in humans (Greenberg 1986), TEM revealed that collagen in the medial
layer of both WT and HGPS mouse carotid arteries was restricted to the elastin folds
(Fig. 2.10A). While the area of collagen within these folds was significantly greater in
HGPS, the magnitude of the effect was small (Fig. 2.10B-C).

Upregulation of Lysyl Oxidase is an early event in HGPS and causal for premature
arterial stiffening. In contrast to the results with collagens, immunostaining readily
detected a pronounced increase in abundance of LOX in the medial layer of carotid
arteries from 2-month HGPS mice as compared to age-matched WT mice (Fig. 2.07C76

D). To determine the onset of this LOX upregulation in HGPS, we examined LOX
abundance in 1-month mice. Although medial LOX levels were slightly increased in 1month HGPS mice, the effect was not significant and much less pronounced than at 2
months (Fig. 2.07C-D). Adventitial LOX abundance was not affected by age or genotype
(Fig 2.07C-D).
To determine if the minimal increase in abundance of LOX in 1-month HGPS
mice correlated with changes in arterial stiffening, pressure-outer diameter, inner radius,
and wall thickness measurements (Fig. 2.11A-C) were used to generate circumferential
and axial stress-stretch (Fig. 2.11D-E) and tangent modulus (Fig. 2.11F-G) curves for
these very young WT and HGPS mice. The pronounced genotype differences in the
circumferential stress-stretch relationship (compare Fig. 2.01 and 2.11E) and tangent
modulus curves (Fig. 2.11G) were much attenuated at 1 month. Axial arterial mechanics
in 1-month HGPS carotid arteries, as judged by the IVS (Table 3) and stress-stretch and
tangent modulus curves (Fig. 2.11D and F), were similar to the WT controls. Thus, the
molecular analysis (Fig. 2.07C-D) and functional testing (Fig. 2.01 and 2.11) are in
agreement and indicate that the time-dependent increase in medial LOX abundance in
HGPS mice begins between 1-2 months of age and is coincident with the onset of acute
arterial stiffening.
HGPS mice were treated with the highly selective LOX enzymatic inhibitor, βaminopropionitrile (BAPN) (Finney et al. 2014; Tang et al. 1983; Jung et al. 2003; Kim et
al. 2003; Lee & Kim 2006; Rodriguez et al. 2010) to determine the role of lysyl oxidase
activity in the early arterial stiffening of HGPS. BAPN was administered between 1 and
2-months of age, when the levels of medial LOX are increasing (Fig. 2.07C-D). The
BAPN concentration and injection regime used was previously shown to be effective in
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altering fibrillar collagen structure and reducing arterial stiffness in vivo (Kothapalli et al.
2012). Furthermore, SHG imaging revealed a reduction in SHG signal in the adventitial
layer of BAPN-treated HGPS carotid arteries, confirming that our dosing regimen was
sufficient to reduce fibrillar collagen structure (Fig. 2.12). However, the area of collagen
within the medial elastin folds of carotid arteries was similar with or without BAPN
treatment as was the expression of arterial LOX (Fig. 2.13A-D).
Biaxial inflation-extension tests examined the effect of LOX inhibition on arterial
mechanics of the HGPS carotid arteries. Pressure-outer diameter, inner radius and wall
thickness measurements (Fig. 2.14A-C) were used to generate circumferential and axial
stress-stretch curves (Fig. 2.15A-B), and these (together with the corresponding tangent
modulus graphs; Fig. 2.14D-E) showed that BAPN reduced circumferential stiffness of
the HGPS carotid arteries without comparable effect on the WT controls (Figs. 2.15A-B
and 2.14D). In fact, the circumferential stretch of BAPN-treated HGPS mice showed no
statistical difference from those of WT mice treated with PBS (Fig. 2.15A and 2.14D).
The IVS was not affected by BAPN (Table 4), but curiously, the axial stress-stretch
curves showed small but opposing effects in HGPS and WT mice (Fig. 2.15B and
2.14E). Collectively, the elevated expression of LOX coincident with premature
circumferential arterial stiffening and the correction of this defect by BAPN indicates that
early LOX induction plays an important causal role in the premature circumferential
arterial stiffening of HPGS.
In addition to arterial stiffness, HGPS patients display cardiac abnormalities,
particularly diastolic dysfunction, which may increase the risk for death (Prakash et al.
2018; Halley et al. 2011). As diastolic dysfunction has been positively correlated with
arterial stiffness (Mottram et al. 2005; Kim et al. 2017), we asked if the BAPN-mediated
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reduction in circumferential arterial stiffness of HGPS mice was also associated with
improved diastolic function. HGPS mice were treated with vehicle or BAPN using
conditions shown in Figs. 2.15A-B. Echocardiography was performed to measure E
(mitral peak velocity of early filling) and E' (early diastolic mitral annular velocity) (Fig.
2.16A-B). We then determined (E/E') as a measure of diastolic dysfunction. E/E' was
improved in the BAPN-treated HGPS mice and similar to that of age-and sex-matched
WT mice (Fig. 2.15C). Although less common, left ventricular hypertrophy has been
detected in HGPS children, mostly as they age (Prakash et al. 2018). Consistent with
these studies, the left ventricular mass index (LVMI), a marker of LV hypertrophy,
trended lower in the BAPN-treated HGPS mice. (Fig. 2.15D) Systolic, diastolic, and
pulse pressures were not affected by BAPN (Fig. 2.16C-E).
To determine if BAPN treatment improved HGPS mouse lifespan, BAPN was
administered to WT and HGPS mixed-sex mice starting at 1-month of age and continued
until the mice became moribund. We observed no changes in survival of HGPS mice
treated with BAPN (Fig. 2.17A). This could be a result of BAPN’s toxic metabolite
effects, as chronic administration of BAPN has well-demonstrated toxicity (Bachhuber et
al. 1955; Levene 1985). However, BAPN administration did not significantly reduce WT
or HGPS mouse weights in comparison to vehicle-treated mice (Fig. 2.17B).
Alternatively, reducing arterial stiffness through BAPN administration may not improve
lifespan because C57BL/6 mice are highly resistant to dying from cardiovascular disease
(Oppi et al. 2019; von Scheidt et al. 2017). Future studies may want to explore the
potential success for combination therapies (e.g. farnesyl transferase inhibitors with use
of less toxic LOX inhibitors.

79

To determine if the morphologic and molecular characteristics of the HGPS
carotid extended to other large arteries, the analyses shown in Figs. 2.05 and 2.07 were
repeated in 2-month WT and HGPS aortas. Indeed, results in the aortas were similar to
those seen in the carotid arteries with regard to overall morphology, SMC number, p16
expression, calcification, and apoptosis (Fig. 2.18A-F). I also found that these 2-month
WT and HGPS mice had similar expression levels of collagen-I, -III and -V protein (Fig.
2.19A-B) and mRNAs (Fig. 2.19C-D) in the aortic media and adventitia, results that
again resembled those seen in the carotid. The only exceptions were the modest
increases in p16 and collagen-III, which were statistically significant in the HGPS carotid
media but not in the aortic media (Fig. 2.18C and 2.19B, respectively). Importantly, the
notably increased medial abundance of LOX in the HGPS carotid artery was also seen
in the HGPS aorta (Fig. 2.20A-B and C-D). Additionally, the relatively larger aortic mass
allowed us to demonstrate that the increased abundance of arterial LOX protein in
HGPS was accompanied by increased LOX enzymatic activity (Fig. 2.20E).

Reduced expression of miR-145 underlies the misregulation of arterial LOX in HGPS
SMCS. We used isolated aortas and primary aortic smooth muscle cells from agematched WT and HGPS mice to explore the molecular mechanism responsible for
upregulation of arterial LOX. We first found that the increased abundance of LOX protein
we observed in the arterial media of 2-month HGPS mice was accompanied by an
increase in medial LOX mRNA (Fig. 2.20F-G). As in the carotid, this upregulation was
minimally detected in younger (1-month) HPGS mice (Fig. 2.21A.) We then extended
the mRNA analysis to all of the LOX family members: LOXL4 mRNA was increased
significantly in 2-month HGPS aortic media and adventitia (Fig. 2.20F-G), but a
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comparison of delta-Ct values revealed that arterial expression of LOXL4 is very low
relative to the LOX isoform (Fig. 2.21B).

Continued mechanistic analysis therefore

focused on regulation of the LOX isoform in vascular smooth muscle cells.
To identify molecular mechanism(s) upstream of LOX gene expression in HGPS,
we performed a genome-wide analysis of descending aortas from 2-month WT and
HGPS mice in addition to 24-month WT mice. A principal component analysis showed
clustering amongst the replicates and separation between the experimental conditions
(Fig. 2.22A). Using a 1.5x fold change and an adjusted p-value of <0.001 as cut-offs, we
identified nearly 4,000 differentially expressed genes (DEGs) between 2-month WT and
HGPS aortas, and a gene ontology analysis identified "extracellular matrix" among the
most differentially expressed gene categories (Fig. 2.22B). We then used Ingenuity
Pathway Analysis (IPA) to identify 852 regulators predicted to be either activated or
inhibited based on the entire set of DEGs (Fig. 2.23A and Table 5). Within this list of
852, we focused on the 139 categorized as transcription regulators (which includes both
transcription factors and epigenetic modifiers) and 10 categorized as microRNAs (miRs)
(Fig. 2.23A-B).
The set of 139 activated or inhibited transcription regulators identified from
genome-wide analysis was compared to the IPA list of 29 transcription regulators
reported to be upstream of LOX (Fig. 2.23B; left). This analysis identified 8 candidate
transcription regulators of LOX (Fig. 2.23B and Table 6) that were either activated or
inhibited in HGPS. However, none of these were strong candidates for LOX mRNA
regulation either because their predicted activation/inhibition state did not match with the
upregulation of LOX mRNA in HGPS or because their reported transcriptional effects
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were inconsistent with the selective upregulation of the LOX isoform we detected in
HGPS (Fig. 2.20F-G and Table 6).
We then examined the 10 upstream microRNA (miR) regulators identified by IPA
(Fig. 2.23B; right). All of these miRs were predicted to have an inhibited activation state
(Table 5), but an analysis of LOX-targeting miRs with TargetScan indicated that only one
of them, miR-145, had a highly conserved target sequence in the 3' UTR of LOX (Fig.
2.23C). The miR-145 target sequence is also absent from the LOX family members that
are not strongly upregulated in HGPS.

RT-qPCR extended the IPA prediction of a

reduced miR-145 signature and showed that miR-145 levels are downregulated in the
medial layer of 2-month HGPS aortas (Fig. 2.23D) but not in the adventitial layer (Fig.
2.23E), which (as with the protein; refer to Fig. 2.20A-B) expressed lower levels of LOX.
This downregulation of medial miR-145 may be specific to the HGPS vasculature as it
was not detected in two other SMC-containing tissues, intestine and bladder (Fig. 2.21CD). The levels of miR-145 were also similar in the aortas of 1-month WT and HGPS
mice (Fig. 2.21A), consistent with the absence of strongly upregulated LOX gene
expression (Fig. 2.21) or arterial stiffening (Fig. 2.11) at this early 1-month time-point.
We were able to extend our results to isolated aortic SMCs. Primary SMCs from
HGPS mice also displayed reduced miR-145 transcript levels (Fig. 2.24A). Moreover,
ectopic expression of miR-145 in primary WT and HGPS aortic SMCs reduced the level
of LOX mRNA, and the elevated expression of LOX mRNA seen in HGPS SMCs
became similar to that of the WT controls (Fig. 2.24B). While these results do not
exclude a possible role for aberrant transcriptional control of LOX in HGPS, they strongly
support miR-145 downregulation as an important and causal regulator of arterial LOX
abundance in HGPS.
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As HGPS is associated with reduced expression of WT Lamin A as well as
expression of progerin (see Introduction), we depleted Lamin A from WT SMCs with
siRNAs and asked if reduced Lamin A abundance would be sufficient to generate the
miR-145/LOX relationship seen in HGPS. Distinct Lamin A siRNAs effectively reduced
Lamin A protein levels (Fig. 2.24C) but did not significantly alter the expression levels of
LOX protein (Fig. 2.24C), LOX mRNA (Fig. 2.24D), or miR-145 (Fig. 2.24D). We
conclude that a Progerin-mediated gain-of-function in HGPS mice is responsible for the
downregulation of miR-145 and the consequent increase of LOX gene expression in
HGPS.
Finally, we used TargetScan to identify several other putative miR-145 targets
within the DEGs of 2-month WT and HGPS aortas (Fig. 2.25A). We selected 3 of those
genes based on fold changes that were greater or equal to that of LOX and then
examined changes in their mRNA levels in isolated SMCs with and without ectopic miR145 expression. None showed the strong regulation by miR-145 seen with LOX. (Fig.
2.25B). Thus, arterial LOX mRNA appears to be a particularly strong miR-145 target in
HGPS.

Distinct regulation of the ECM, Lysyl Oxidase and miR-145 in HGPS and normal aging.
As many parallels have been drawn between HGPS and normal aging, we evaluated
levels of the fibrillar collagens, LOX, and miR-145 in aged (24-month) WT mice (Fig.
2.26). The carotid arteries of the aged WT mice showed only small changes in medial
collagen III and collagen-V (Fig. 2.26A-B). However, aged WT mice showed a
statistically significant increase in adventitial collagen-I (Fig. 2.26A-B); this was not seen
in HGPS (refer to Fig. 2.07). LOX protein increased with time in both the carotid medial
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and adventitial layers during normal aging (Fig. 2.26C-D), whereas it was mostly limited
to the carotid media in HGPS (refer to Fig. 2.07C-D).

Unexpectedly, our RNASeq

analysis indicated that LOX mRNA abundance was minimally altered in the aortas of 2versus 24-month WT mice (Fig. 2.22C), and RT-qCPR showed that this change was not
significant (Fig 2.26E). Similarly, arterial miR-145 levels were not decreased in aged WT
mice (Fig. 2.26F). These data indicate that arterial LOX upregulation in normal aging is
mechanistically distinct from that seen in HGPS. Thus, the downregulation of miR-145
and consequent steady-state increase in LOX mRNA and protein we describe in HGPS
are disease-specific effects.

2.4 Discussion
We show here that the carotid arteries of HGPS mice stiffen prematurely and that
this stiffening is preferentially circumferential, particularly in males. Although the
expression of several arterial collagens is elevated in old HGPS mice (del Campo et al.
2019), our results show that the initiation of arterial stiffening in HGPS is much more
closely associated with increased medial LOX expression. Importantly, pharmacologic
intervention with the pan-LOX inhibitor, BAPN, improved arterial mechanics of HPGS
mice, thereby establishing LOX upregulation as an underlying and causal mechanism in
the early arterial stiffening of HGPS.
While we did not see pronounced increases in arterial fibrillar collagens early in
HGPS, TEM revealed a slight increase in collagen area within the medial elastin folds of
HGPS arteries. As adventitial collagen abundance was similar in WT and HGPS mice,
the medial collagen in these folds may be the target of the elevated medial LOX in
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HGPS. Indeed, previous studies have reported that the medial layer contributes more
toward circumferential stiffening while the adventitial layer contributes more to axial
mechanics (Kohn et al. 2015). Since the expression of collagen genes can increase with
ECM stiffness (Kothapalli et al. 2012), the LOX-mediated increase in arterial stiffness
described in our studies here with very young HGPS mice may also contribute to the
eventual induction of other SMC collagens as seen when HGPS mice are aged (del
Campo et al. 2019).
In addition to reducing arterial stiffness, BAPN administration also improved
diastolic function in HGPS mice. Diastolic dysfunction is a prominent cardiac abnormality
in both HGPS children (Prakash et al. 2018) and HGPS animal models (OsmanagicMyers et al. 2018; Dorado et al. 2019; Murtada et al. 2020). Although the basis of
diastolic dysfunction is multi-faceted, it has been correlated with increased arterial
stiffness (Mottram et al. 2005; Kim et al. 2017). Thus, the reduction in arterial stiffness by
BAPN may be causal for the observed improvement in diastolic function. However, it is
not yet clear if our systemic administration of BAPN is affecting diastolic dysfunction
indirectly through its effects on arterial stiffness, or directly through effects on LOX
activity in the heart. A comparative analysis of BAPN effects on arterial versus cardiac
(cardiomyocyte and cardiac fibroblast) LOX abundance and enzymatic activity, as well
as the consequences of BAPN treatment for the arterial and cardiac ECMs, will be
required to address this issue.
Genome-wide analysis predicted that the elevated expression of LOX in HGPS is
linked causally to an abnormal downregulation of miR-145 in vascular SMCs. Others
have shown that miR-145 is one of the most highly expressed microRNAs in rodent
carotid arteries, where it is largely restricted to the SMCs (Cheng et al. 2009; Zhang
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2009). miR-145 is thought to play a critical role in vascular smooth muscle function and a
protective role preventing fibrotic ECM synthesis (Zhao et al. 2015). In addition, Faccini
and colleagues (Faccini et al. 2017) identified reduced circulating levels of miR-145 as a
diagnostic biomarker for coronary artery disease. Our results extend those findings to
HGPS, which shows reduced aortic miR-145 abundance relative to age-matched WT
arteries and isolated smooth muscle cells.
In addition to the bioinformatic prediction, a connection between miR-145 and
LOX mRNA abundance has been described experimentally. We have previously
reported that overexpression of miR-145 reduced LOX mRNA levels in WT SMCs
(Kothapalli et al. 2012). Additionally, the same study showed that a miR-145 antagomir
counteracted the suppression of LOX mRNA seen in WT SMCs having elevated miR145. The work described here extends these studies by demonstrating that enforced
expression of miR-145 restores near-normal LOX mRNA levels to HGPS SMCs.
Collectively, these results strongly suggest a causal connection between the decreased
expression of miR-145 and the increased expression of LOX in HGPS. A reporter assay
showing that miR-145 can regulate mRNA abundance through the LOX 3'UTR would
further support this connection.
Reduced expression of WT Lamin A failed to regulate miR-145 or LOX mRNA,
indicating that misregulation of miR-145 and LOX in HGPS reflects a gain-of-function
from progerin expression. However, how progerin may be eliciting these effects is cause
for further study. As it has recently been appreciated that Lamin A and the nuclear
lamina play an important role in mediating transfer of information from the cytoplasm to
the nucleus, the altered nuclear structure due the presence of progerin in HGPS may
hinder or promote transfer of this information across the nuclear boundary, leading to
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deregulated gene expression (Kelley et al. 2011; Wilson 2018). Additionally, progerin
may have a more direct effect on miR-145 expression, as recent studies have shown
that HGPS nuclei have a dramatically altered epigenetic signature which can lead to
improper gene silencing or activation (Arancio et al. 2014; Köhler et al. 2020). Altered
LOX and miR-145 expression in HGPS could also be a secondary effect of long-term
progerin expression, perhaps with progerin-expressing SMCs secreting altered
chemokines to promote vascular remodeling in HGPS.
As progerin has been detected in aged tissues, cells, and atherosclerotic lesions
(Scaffidi & Misteli 2006; Olive et al. 2010; McClintock et al. 2007), there has been
significant interest in the idea that progerin-like splicing may contribute to phenotypes of
natural aging in addition to driving early aging in HGPS. Indeed, both 2-month HGPS
and 24-month WT carotid arteries display increased expression of medial LOX and
increased circumferential stiffness. However, the axial mechanics of 2-month male
HGPS carotid arteries are mostly intact, while 24-month male WT carotids display clear
axial stiffening. This distinction implies that in addition to the common effect of increased
LOX abundance, there must also be inherent differences between the early arterial
stiffening in HGPS and the late arterial stiffening of normal aging. Interestingly, this
distinction in the directionality of arterial stiffening is lost as HGPS progresses; HGPS
mice much nearer to the end of their life display axial stiffening (Murtada et al. 2020).
Others have recently reported increased LOX and LOXL2 in old (20-22 month)
versus young (3-4 month) aortas of WT mice (Steppan et al. 2019). This work
complements our findings of increased LOX expression in HGPS carotid arteries, and
the joint findings support the idea that increased LOX activity with age is likely to be a
general feature of large artery stiffening. However, in our work, LOX, rather than LOXL2,
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is the major upregulated arterial LOX family member. We also identified upregulated
levels of LOXL4 mRNA in HGPS. As BAPN is an inhibitor of all LOX isoforms, we cannot
exclude a potential role for LOXL4 in arterial stiffening. However, LOXL4 expression
levels were much lower than the LOX isoform.
Our immunofluorescence analysis shows that LOX is induced in both the arterial
medial and adventitial layers with natural aging whereas its induction is largely restricted
to the media in HGPS. Finally, unlike HGPS, the levels of miR-145 are not strongly
reduced in aged WT mice. The preferential expression of miR-145 by arterial SMCs
(Cheng et al. 2009; Zhang 2009) could explain why we see a selective effect on medial
rather than adventitial LOX in HGPS. Thus, while an increase in overall LOX activity is a
common feature of arterial stiffening in both natural aging and HGPS, the uncoupling of
LOX expression from miR-145, the distinct spatial expression patterns of arterial LOX,
and the differences in directional arterial stiffening distinguish natural aging and HGPS.
Although we show that LOX levels are not increased in other SMC-containing tissues in
HGPS mice (i.e., bladder and intestine), it would be of interest to evaluate LOX and miR145 expression levels in non-SMC containing tissues such as the skin, which also
displays abnormalities in HGPS (Gonzalo et al. 2016).
Administration of sodium nitrate to HGPS mice (del Campo et al. 2019) and
administration of Lonafarnib, a farnesyltransferase inhibitor, to HGPS children reduce
arterial stiffness (Gordon et al. 2012; Gordon et al. 2018). Furthermore, the reduction in
arterial stiffness by lonafarnib was associated with an increased lifespan of HGPS
children (Gordon et al. 2018). These studies did not distinguish between effects on axial
versus circumferential mechanics, nor are the mechanisms by which nitrate and
lonafarnib reduce arterial stiffness fully clear. Nevertheless, these studies and this report
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collectively indicate that decreasing arterial stiffness could lessen the burden of
cardiovascular disease in HGPS. Our results further

indicate that targeting

circumferential arterial mechanics, potentially though LOX inhibition, may be an
important consideration in the development of mechanically inspired therapeutics for
HGPS.
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2.5 Methods
Mice and artery isolation. WT C57BL/6 mice were purchased from Jackson Labs and
aged to 24-months. LMNAG609G/+ mice on the C57/BL6 background were generously
provided Dr. Carlos Lopez-Otin (Universidad de Oviedo, Oviedo, Spain). Mice were
genotyped by ear clipping and DNA was isolated using Puregene Core Kit A (Qiagen
1042601) according to manufacturer's instructions. DNA was amplified using the
following primers (at a final concentration of 0.5µm): Forward:
AAGGGGCTGGGAGGACAGAG; and Reverse: AGCATGCCATAGGGTGGAAGGA
using the following PCR protocol: 95°C for 60s, [95°C for 30s, 64°C for 30s, 72°C for
30s]x35, 72°C for 120s to generate bands of 100bp for WT and 240bp for LMNAG609G.
Mice were fed a chow diet ad libitum. For experiments including HGPS arteries or cells,
WT littermate controls were obtained from LMNAG609G/+ matings. At the appropriate
age, the mice were sacrificed by CO2 asphyxiation, the left carotid artery was
immediately removed, stripped of most fat, and used for pressure myography as outlined
below. The remaining arteries were perfused in situ with PBS. The right carotid artery
was then removed, cleaned in PBS and fixed in either Prefer for paraffin-embedding or
TEM fixative (see below). The descending aorta was isolated from the end of the aortic
arch to the diaphragm, cleaned as above, and used either for the preparation of RNA
(for RT-qPCR and genome-wide analysis) or protein for immunoblotting (see below and
Methods). Animal protocols were approved by the University of Pennsylvania
Institutional Animal Care and Use Committee. All experiments were performed on male
mice unless otherwise specified in the legends.
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Biaxial extension-inflation tests using a pressure myograph. Arterial mechanics were
determined on a DMT 114P pressure myography with force transducer largely as
described (Brankovic et al. 2019). Freshly isolated carotid arteries from WT and HGPS
mice (with a mean age of 31 ± 1 days for 1-month mice, 64 ± 6 days for 2-month mice,
and 726 ± 9 days for 24-month mice) were secured to 380 µm (outer diameter) cannulas
using silk sutures; blood was cleared, and any remaining fat was removed. Once
mounted,

the

arteries

were

visualized

by

light

microscopy,

and

the

unloaded/unpressurized arterial wall thickness and inner radius was measured at the
axial length where the artery transitioned from being bent to straight. Arteries were
brought to a stretch of 1.7 and pressurized to 100 mm Hg for 15 min with HBSS. The
arteries were then preconditioned by cyclic pressurization three times from 0–140 mmHg
in 1-min increments. Unloaded (unstretched and unpressurized) vessel wall thickness
and outer diameter were measured in multiple sections after preconditioning and
averaged for post-test data analysis.
In vivo stretch (IVS) was determined using force-length tests as described
(Brankovic et al. 2019; Ferruzzi et al. 2013). Briefly, the carotid arteries were axially
stretched in 10% increments at three constant pressures (90, 120, and 140 mmHg).
Equilibrium force was recorded for each stretch and pressure, and the intersection of the
three force-stretch curves was defined as the IVS. Loaded inner radius and wall
thickness were determined from pressure-outer diameter tests with samples at their IVS
and pressurized in 10-mm Hg (30-sec) steps from 0–140 mm Hg before returning the
artery to 0 mm Hg (Brankovic et al. 2019). This test was performed three times, and the
mean of three stress-stretch curves was taken. We confirmed the validity of our IVS
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determinations by measuring axial force through the circumferential tests, and we
excluded samples where axial force varied from the mean by >25% with pressure.
Stress-stretch relationships were also analyzed by deriving the tangent modulus. See
Methods for further details of data analysis.

Transmission Electron Microscopy (TEM) analysis of collagen structure. Carotid arteries
for TEM were fixed overnight at 4oC in 0.1M sodium cacodylate buffer, pH7.4 containing
2.5% glutaraldehyde and 2.0% paraformaldehyde. After subsequent buffer washes, the
samples were post-fixed in 2.0% osmium tetroxide for 1 hour at room temperature and
rinsed in water prior to en bloc staining with 2% uranyl acetate. Briefly, after dehydration
through a graded ethanol series, the tissue was infiltrated and embedded in EMbed-812
(Electron Microscopy Sciences, Fort Washington, PA). Thin cross sections were stained
with uranyl acetate and lead citrate and examined with a JEOL 1010 electron
microscope fitted with a Hamamatsu digital camera and AMT Advantage image capture
software. Images of artery cross sections were taken at increasing magnification;
collagen abundance was evaluated as described in Methods.

In vivo treatment with BAPN. Mixed sex WT and HGPS mice (a mean age of 35 ± 2 days
old) were injected peritoneally with BAPN (Sigma A3134; 333 mg/kg) or an equal volume
of vehicle (PBS). BAPN was dissolved in PBS and injected in a volume of 0.2 ml per day
until the mice reached 2-months of age (a mean of 24 ± 2 days of injections). No
dramatic alterations in mouse behavior, no changes in appearance, and no weight loss
were observed during the injection period. At approximately 2-months of age (a mean of
60 ± 2 days old), the mice were sacrificed, carotid arteries were isolated, and unloaded
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wall thickness and inner radii were determined. The samples were then analyzed by
pressure myography as described above. For the echocardiography and invasive
hemodynamics experiments, male mice were analyzed between 64-75 days of age
immediately after a 30-day treatment with BAPN (333 mg/kg as described; (Kothapalli et
al. 2012)). Echo and hemodynamics performed by the UPenn Cardiovascular
Phenotyping Core. See Methods for additional echocardiography methods.

In vivo BAPN survival study. Mice were IP injected daily starting from 30 days of age
with 200ul of solution 50mg/ml Beta-aminopropionitrile (Sigma Aldrich A3134) in PBS.
Solution was sterile filtered and injected into

mice using 26Gx8/3

syringe

(0.45mmx10mm; BD syringe 309625). Vehicle-treated mice were given 200ul of sterile
filtered PBS by IP injection. Food and water were replenished weekly, and cages
changed bi-weekly. Mice were weighed once a week with progeria mice showing a
decline in weight as the study progressed. Injections were continued until progeria mice
began to display signs of morbidity, which was uncontrolled shivering and lethargic
activity. No dramatic changes in WT mice were observed either with vehicle or BAPN
injections. After all progeria mice in the study had died, injections of BAPN and vehicle
were continued in WT mice for two additional weeks before euthanasia. After sacrificing
mice, all portions of the aorta were collected, heart, and carotids.

Genome-wide sequencing and analysis:

Descending aortas containing the intimal,

medial and adventitial layers were isolated from six 2-month male WT, six 24-month WT
mice, and six HGPS mice, and RNA was extracted using the RNeasy Plus Micro kit
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(Qiagen 74034). The high-throughput library was prepared using the truSeq stranded
total RNA (ribo-Zero) kit (Illumina 20037135). Paired end sequencing was performed on
a HiSeq4000 Sequencing System (Illumina) and generated 14-30 million reads/sample.
Raw sequence files were mapped to the genome with using salmon
(https://combine-lab.github.io/salmon/) against the mouse transcripts described in
genecode

(version

M23,

built

on

the

mouse

genome

GRCm38.p6, https://www.gencodegenes.org). Transcript counts were summarized to
the

gene

level

using

tximport

(https://bioconductor.org/packages/release/bioc/html/tximport.html), and normalized and
tested

for

differential

expression

using

DESeq2

(https://bioconductor.org/packages/release/bioc/html/DESeq2.html). Sequence files can
be found under GEO ascension number GSE165409. The normalized values for the 300
genes with the highest variance across all samples were imported into Partek Genomics
Suite (v7, Partek, Inc., St. Louis, MO) for principal component analysis.
DEGs having a 1.5x fold change and adjusted p-values of <0.001 were subjected
to

gene

ontology

analysis

(GO

cellular

component)

using

DAVID

(https://david.ncifcrf.gov/home.jsp) and a core analysis with Ingenuity Pathway Analysis
(IPA). Default settings were used for all other core analysis parameters.

The core

analysis included the prioritization of upstream regulators based on enrichment of a
regulator’s target gene set in the set of DEGs. For each regulator, IPA tested the
directionality of each of the genes in the overlap to infer an activation or inactivation of
the regulator (Z-score). We defined putative upstream regulators of DEGs as those
having Z-scores >1.75 (activated) or <-1.75 (inhibited). This set of upstream regulators
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was then filtered to identify those classified by IPA as either transcription regulators
(including transcription factors and epigenetic regulators) or microRNAs (miRs).
The list of transcription regulators categorized by IPA as either being in an
activated or inhibited state (positive or negative Z-scores, respectively) was compared to
the transcriptional regulators of LOX present in the IPA database. The overlapping gene
set was individually examined to determine if its proposed activation or inhibition state
correctly corresponded to the experimental upregulation of LOX we observed in HGPS.
We also checked for the specificity of upstream regulator effect on the LOX gene. These
comparisons allowed us to assess the appropriateness of the IPA-proposed transcription
regulator relationship. The list of 10 miRs identified by IPA were all categorized as being
in an inhibited activation state in HGPS (negative Z-scores). The entire miR list was
therefore compared to the list of miRs targeting mouse LOX as determined by
TargetScan (www.targetscan.org).

Statistical Analysis. Statistical analysis was performed using Prism software (GraphPad).
For the pressure myography experiments, differences in inner radius, wall thickness,
axial stress and circumferential stretch at pressure-matched points were compared by
age, genotype, or response to BAPN across the entire curves and analyzed by two-way
ANOVA relative to the relevant 2-month WT control. For other mouse experiments and
for all studies with isolated cells, ANOVAs were used for multiple comparisons, and twotailed Mann-Whitney tests were used to compare two datasets. Statistical significance
for all graphs is demarcated by *(p<0.05), **(p<0.01), ***(p<0.001). Box plots show
Tukey whiskers.
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Carotid artery and aorta immunostaining and histologic analysis. Isolated arteries were
fixed after excision in Prefer (Anatech #414), embedded in paraffin, and 5-µm cross
sections were stained. Paraffin-embedded sections (5 µm) of freshly isolated carotid
arteries or descending aortas were deparaffinized and hydrated before antigen
unmasking (Vector Labs, H3300). Carotid or aortic cross sections were washed in PBS
three times before blocking with 2% BSA in PBS for 15 min, incubated overnight at 4oC
with antibodies directed to p16INK4A (Proteintech, 10883-1-AP; 1:50 dilution), collagen-I
(Southern Biotech, 1310-01; 1:400 dilution), collagen-III (Proteintech, 22734-1-AP; 1:400
dilution), collagen-V (Abcam, ab7046; 1:250 dilution), and LOX (Santa-Cruz, sc32409
selective for the LOX isoform; 1:50 dilution). Replicate sections were incubated in
parallel with isotype-matched control antibodies. All samples were washed three time
with PBS before incubation with a 1:100 dilution of Alexa 594-conjugated isotypematched secondary antibody (Lifetech donkey anti-goat A11058 or Invitrogen Goat antirabbit A11012) for two hours at room temperature. Sections were then washed three
times in PBS followed by addition of Dapi (1:1000 dilution in PBS). Slides were briefly
washed in PBS and then water before mounting with SlowFade Gold (Thermo, S36936).
Results were visualized with a Nikon Eclipse 80i microscope with a QI-Click Qimaging
camera. Carotid arteries were imaged at 20x magnification.
Images were quantified using ImageJ. The media of each section was traced
using the polygon drawing tool, and its raw integrated intensity was divided by the area
of the outlined media to obtain relative fluorescence intensity. The procedure was then
repeated for the adventitial layer. Relative fluorescence intensity values were then
plotted relative to the mean fluorescence intensity value of the corresponding WT
control. Fluorescent intensity values were passed through a Grubbs’ test. Background
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intensity, as determined from the isotype-matched control antibodies, was negligible
(see Fig. 2.10). Results are presented as box plots with Tukey whiskers.
Staining with Hematoxylin (Fisher, SH30-500D) and Eosin (Fisher, SE22-500D)
was

performed

using

standard

procedures.

Apoptosis

was

determined

by

immunostaining for cleaved caspase-3 (Cell Signaling Technologies SignalStain
Apoptosis IHC Detection kit, #12692S) according to manufactures instructions with
tumor xenograft sections as positive controls. To determine calcium deposition,
deparaffinized and hydrated sections were incubated with a 5% solution of Alizarin Red
S (Sigma, A5533) pH 4.2 for 30 minutes, with calcified bone tissue as positive control.
Arterial elastin layers were visualized by autofluorescence using a cyan filter on a Nikon
Eclipse 80i Fluorescence microscope.

Carotid artery second harmonic generation imaging. Paraffin-embedded carotid artery
cross-sections were de-paraffinized in xylene (20 minutes) and hydrated in decreasing
concentrations of ethanol (100%, 95%, 75%, 50%), following by a 5 min wash in
deionized water. Slides were stored in water until ready for imaging. SHG imaging was
performed on a Leica SP8 multiphoton microscope, using an immersion lens, keeping
the carotid cross-sections hydrated in water. Forward and backward SHG signals were
collected to capture collagens at multiple distances within the sample and detect fibers
at different optical alignments.

Quantification of collagen within elastin folds. TEM images of vehicle (PBS)-treated or
untreated WT and HGPS carotid arteries were taken at 7500 x magnification to visualize
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the elastin folds (Fig 2.10; A1). The folds were defined as areas where the elastin
invaginates, creating a roughly parabolic shape (Fig. 2.10; A2). Using the polygon
Selection Tool in ImageJ, an area was defined by continuously tracing along the two
sides of the parabolic shape; that region was then enclosed by connecting the two
apexes with a straight line (Fig. 2.10; A3). This area was added to the ROI Manager
to calculate total area of the elastin fold. To calculate the area within the fold containing
collagen, the Paintbrush Tool was used to manually black-out areas containing collagen
fibers (Fig. 2.10; A4). The painted area was isolated with the Threshold Tool (Fig.
2.10; A5) and added to the ROI manager (Fig. 2.10; A6). The ratio of collagen/total
areas was defined as percent collagen in the elastin fold.

RT-qPCR of mRNAs and miRs. Descending aortas from 2-month WT and HGPS mice
were isolated and stripped of adventitia. The adventitial and remaining medial/intimal
(referred to as medial tissue in the text) tissues were stored separately in RNAlater
(Qiagen) at -80oC for subsequent analysis. To strip adventitia from the aorta, a cleaned
isolated aorta was incubated in 1 mg/ml Type 2 collagenase (Worthington Biochem,
LS004174) in Hanks Balanced Salt Solution (Lifetech, 14170-112) for 10 minutes at
37oC. The adventitial layer was carefully peeled off before storing the aorta
(intimal/medial and adventitial layers separately) in RNAlater. Total RNA was isolated
with the RNeasy Fibrous Tissue Mini Kit (Qiagen) according to manufacturer's
instructions and using 0.3 ml buffer RLT per aorta. Reverse transcription reactions
contained 200-500 ng of total RNA. RNA was extracted from cultures of primary SMCs
with TRIzol reagent (Thermofisher 15596026) according to manufacturer’s instruction.
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microRNA was reverse transcribed from total RNA using the TaqMan microRNA reverse
transcription kit (ABI 4366596).

Ten to fifteen percent of the cDNA was subjected to

qPCR with the following primer-probe sets from Applied Biosystems: Col1a1
(Mm00801666_g1), Col3a1 (Mm00802300_m1), Col5a1 (Mm00489299_m1); LOX
(Mm00495386_m1), LOXL1 (Mm01145738_m1), LOXL2 (Mm00804740), LOXL3
(Mm01184865_m1), LOXL4 (Mm00446385), has-miR-145 (TM: 002278), SnoRNA202
(TM:001232). The primer-probe set for 18S rRNA has been described (Klein et al. 2007).
qPCR samples were analyzed in duplicates. Levels of each tested transcript were
normalized to 18S rRNA (for mRNA) or SnoRNA202 (for miRNA), and changes in RNA
abundance were calculated using the ddCT method.

Immunoblotting. Intact descending aortas (consisting of the adventitia, media and intima)
that had been stored in RNAlater (Thermo-Fisher) were chopped into small pieces and
sonicated in lysis buffer (50mM Tris-HCl pH8, 250mM NaCl, 2mM EDTA, 1%NP40)
containing protease inhibitors (Cell Signaling Technologies 5872S). Lysates were
centrifuged for 5 min (4oC, 15,000 rpm), and the supernatants were diluted into SDS
sample buffer (final concentration of 2% SDS, 10% glycerol, 50mM Tris pH 6.8, 0.01%
Bromphenol blue, 1% β-mercaptoethanol) and analyzed by immunoblotting after SDSPAGE. Approximately 20-30 μg protein was fractionated per sample on an 8%
polyacrylamide gel. Lamin A (protein tech 10298), and Focal Adhesion Kinase (BD
Transduction Labs 610088), and Lysyl Oxidase (abcam ab31238) antibodies were used
at a 1:300 dilution.
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Lysyl Oxidase Activity Assay. Intact descending aortas were isolated, flash frozen in
liquid nitrogen and stored at -80oC prior to the analysis of LOX activity. Thawed aortas
were chopped into small pieces and sonicated in 0.2ml PBS three times for 15-20
seconds each and stored immediately on ice. Lysates were centrifuged at 14,000 x g for
5 min, and 50 μl of each supernatant was analyzed using the Abcam Lysyl oxidase
activity assay kit (ab112139) according to manufacturer’s instructions. Samples were run
in technical duplicates. Relative fluorescent intensity values were normalized to the total
protein concentration of each lysate as determined using BioRad protein concentration
reagent (Biorad 5000006).

Myograph data analysis. Measurements of intraluminal pressure, force, and outer
diameter were converted into stress-stretch curves using equations 1–4 where l and
L=loaded and unloaded vessel lengths, respectively (µm), ai and Ai=loaded and
unloaded inner radii, respectively (µm), ao and Ao=loaded and unloaded outer radii,
respectively (µm), h and H = loaded and unloaded vessel wall thickness, respectively
(µm), P= intraluminal pressure (mm Hg), and fT=axial force (nN). Vessel wall thickness
was calculated in the post-test analysis as described (Brankovic et al. 2019) with the
standard assumption that the sample was incompressible.

Equation 1: Axial stretch

Equation 2: Axial stress

Equation 3: Circumferential stretch
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Equation 4: Circumferential stress

Axial stress-stretch curves show means ± SD. Circumferential stress-stretch curves as
well as inner radius and wall thickness results were determined from triplicate
determinations per sample and are therefore presented as means ± SE.

To estimate tissue stiffness, axial and unloaded circumferential stresses and
stretches for each tested vessel were fit to an exponential function (y=abx) using Matlab
(R2020a, Curve Fitting Tool). The derivative of each vessels exponential fit was then
used to plot the tangent modulus as a function of stretch for each individual vessel.
Tangent modulus values were passed through the Grubbs’ test and one mouse was
eliminated as an outlier. These results were then averaged and plotted as the tangent
modulus graphs. The adjusted R2 values identified in MatLab for each fit were assessed
to be greater than 0.95 in order to be included in the mean tangent modulus curves.

Echocardiography. Ultrasound examination of the left ventricle was performed using a
Fujifilm VisualSonics Ultrasound System (VisualSonics Inc, Toronto, ON, Canada) and
using MS400 (18-38 MHZ) transducer. Mice were lightly anesthetized with an i.p.
injection of 0.005 ml/g of 2% Avertin (2,2,2-Tribromoethanol, Sigma-Aldrich, St. Louis,
MO). Hair was removed from the anterior chest using chemical hair remover (Nair), and
the animals were placed on a warming pad in a left lateral decubitus position to maintain
normothermia (37°C), monitored by a rectal thermometer. Ultrasound gel was applied to
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the chest. Care was taken to maintain adequate contact while avoiding excessive
pressure on the chest. Left ventricular (LV) systolic function: Two-dimensional long-axis,
short-axis M-Mode images were obtained. LV diastolic function: Transmitral inflow
pattern and tissue Doppler were obtained in modified 4 chamber apical view. After
completion of the imaging studies, mice were allowed to recover from anesthesia and
returned to their cages. M Mode Images were analyzed for LV structure and function
related parameters and Pulse wave and tissue Doppler images were analyzed for
diastolic function related parameters using Vevo Lab software (Visual Sonics Inc,
Toronto, ON, Canada).

Aortic Catheterization. Closed-chest cardiac catheterization was performed under
isoflurane (1.5-4%) by ligating the right carotid artery and advancing a 1F Millar catheter
(SPR-1000) into the ascending aorta, where it was secured. Measurements were taken
using Millar MPVS Ultra and ADInstruments LabChart for approximately 5 minutes after
catheter insertion. The temperature of the animal was maintained between 36.5-37.5
degrees Celsius.

Cell culture, viral infection and RNAi. Primary mouse SMCs were isolated from the
descending aortas of 2-month old WT and HGPS male mice and prepared by explant
culture as described (Cuff et al. 2001). SMCs were cultured in growth medium [1:1
Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F-12 supplemented with 2mM Lglutamine and 20mM HEPES, pH7.4] with 20% FBS. Cells were passaged at near
confluence with trypsin/EDTA and used between passages 2-4. Near confluent,
asynchronous SMCs were infected with adenoviruses encoding LacZ (control) or miR102

145 (AdmiRa-has-miR-145-5p; ABM #mh0185) at a MOI of 600 in growth medium and
incubated overnight. The cells were incubated for 72 hours in fresh growth medium
before sample collection. Infection efficiency of the miR-145 adenovirus was ~70% as
determined by expression of co-transcribed GFP. siRNA-mediated knock-down of Lamin
A in near-confluent WT SMCs was performed using Lipofectamine RNAiMAX
Transfection Reagent (Thermofisher #13778100) in OPTI-MEM with final siRNA
concentrations of 150 nM (Thermofisher siRNA ID #s69252, #s69253, #s69254). A nonspecific siRNA (Ambion 4390843) was used as control. After 4 hours of siRNA
transfection, cells were switched to fresh growth medium. Total RNA or protein was
collected 72 hours after transfection using TRIzol reagent (for RNA analysis) or
immunoblotting lysis buffer (see above), respectively.
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2.7 Figures
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Fig. 2.01. Mechanical properties of isolated carotid arteries display premature
circumferential stiffening in HGPS male and female mice. Carotid arteries from male
(panel B-C) and female (panel D-E) 2-month (n=7 per sex) and 24-month (n=5 per sex)
WT and 2-month HGPS (n=6 per sex) mice were analyzed by pressure myography. (A1)
Arteries are axially stretched at multiple pressures, and the intersection point of the
stretch-force curves defines the “in vivo stretch” (IVS). The graph displays a
representative axial stretch-force curve for a 2-month WT mouse carotid artery (red
arrow shows the IVS). (A2) Arteries are brought to their individual IVS and pressurized.
White arrows indicate circumferential deformation with pressure (IR=inner radius, h=wall
thickness). (B,D) Circumferential stretch-stress curves for male and female mice,
respectively. Each data point corresponds to the circumferential stress and stretch at
increments of 10mmHg starting from 0 to 140mmHg. (C,E) Axial stretch-stress curves,
determined at 90mmHg, for male and female mice, respectively. Results in panels B and
D show means ± SE and results in panel C and E show means ± SD. Statistical
significance in all panels was determined by two-way ANOVA in comparison to 2-month
WT mice. Myographic experiments were performed in collaboration with Sonja Brankovic
(University of Pennsylvania).
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Fig. 2.02. Biaxial inflation-extension tests and biomechanical properties of WT and
HGPS carotid arteries. Changes in outer diameter (A,D), inner radius (B,E) and wall
thickness (C,F) with pressure for the male (A-C) and female (D-F) mice in Figure 2.01.
Results show mean ± SE. Statistical significance was determined by 2-way ANOVA
relative to the 2-mo WT arteries.
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Fig. 2.03. Stiffness estimates by tangent modulus. Derived axial (A and C) and
circumferential (B and D) tangent modulus versus stretch plots of the carotid arteries
from male (A-B) and female (C-D) WT and HGPS mice shown in Figure 2.01.
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Fig. 2.04. Pressure myography characterization of male 2-mo (n=6) and 9-mo (n=5)
LMNA+/G609G (heterozygous; Het) mice. Changes in (A) outer diameter, (B) inner
radius, (C) wall thickness with pressure. Results in A-C show means ± SD. (D)
Circumferential stress-stretch curves. Results show mean ± SE. (E) Axial stress-stretch
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curves performed at 90mmHg. Results show mean ± SD. Statistical significance in A-E
was determined by two-way ANOVA. Myograph analysis was performed in collaboration
with Sonja Brankovic.
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Fig. 2.05. Carotid arteries from 2-month WT and HGPS mice display similar
histology. (A-B) Carotid artery cross sections from 2-month WT and HGPS mice were
stained with H&E (scale bar = 50 µm and inset bar = 25 µm), and the number of medial
smooth muscle cell (SMC) nuclei was quantified from H&E images (n=7-10 carotids per
genotype with 3 sections analyzed per mouse). (C-D) Carotid cross sections were
immunostained for the senescence marker, p16INK4A, and the level of medial
p16INK4A was normalized to the mean signal intensity of carotid sections from 2-month
WT mice; (n=6-10 per genotype). Scale bar = 50 µm. Statistical significance in B and D
was determined by Mann-Whitney tests. (E) Carotid cross sections were stained with
Alizarin Red (n=5 per genotype) and (F) immunostained for cleaved caspase-3 (n=5 per
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genotype). Scale bars in E and F = 50 µm. The arterial media (M) is outlined with
dashed lines.

Fig. 2.06. Positive controls for morphologic analyses and evaluation of elastic
laminae of in WT and HPGS carotid arteries. (A-B) The images presented in Fig. 2EF are reproduced here with corresponding positive controls, bone and tumor tissue,
respectively. (C) Representative elastin autofluorescence images of 2-mo WT and
HGPS carotid artery cross sections (n=7-9 per genotype). Scale bar = 50 µm.
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Fig. 2.07. HGPS carotid arteries display alterations in abundance of fibrillar
collagens and Lysyl Oxidase (LOX). (A) Representative images of carotid artery cross
sections from 2-month WT and HGPS mice immunostained for collagen-I (n=11-12), -III
(n=13-15), and -V (n=9-10); scale bar = 50 µm. (B) Collagen signal intensities from the
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immunostained sections were quantified, and results were normalized to the mean
signal intensity in the 2-month WT media. (C) Representative images of LOX
immunostaining of carotid artery sections from 1- and 2-month WT and HGPS mice
(n=7-9 mice per age and genotype). Scale bar = 50 µm. (D) LOX signal intensities from
the medial and adventitial layers were quantified, and the results were normalized to the
mean signal intensity of the 1-month WT medial layer. Statistical significance in B and D
was determined by Mann-Whitney tests. The arterial media (M) is outlined with dashed
lines.
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Fig. 2.08. Immunostaining controls for WT and HGPS carotid arteries.
Representative images of background signals for carotid artery cross sections incubated
with targeted versus isotype-matched (negative control) primary antibodies from (A) goat
(LOX and COL1) or (B) rabbit (COL3 and COL5).
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Fig. 2.09. Forward and backward second harmonic generation (SHG) imaging of
carotid artery cross sections. Carotid artery cross sections of 2-mo WT and HGPS
mice were imaged by second harmonic generation (n=4 mice per genotype).
Representative images are shown. Media layer is denoted by “M” and outlined in white
dashed lines. The adventitia layer is noted by “A.” Scale bar 10μm.
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Fig. 2.10. Quantification of collagen abundance in elastin folds. (A) Representative
transmission electron microscopy (TEM) images from a mouse carotid artery cross
section processed in ImageJ to quantify the area of collagen within an elastin fold. The
boxed region in image A1 is shown in images A2-A6. Scale bar = 2 µm. See Methods
for details. (B) Carotid arteries from 2-mo WT and HGPS mice were sectioned and
imaged by TEM. Representative images are shown at the indicated magnification.
Numbers in each image correspond to the boxed ROI in the preceding image. In image
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1, the lumen (L), media (M), and adventitia (A) of the artery are noted (scale bar = 6 µm).
Image 2 shows multiple elastin folds, and image 3 shows a 2-fold enlargement of an
individual fold used to quantify collagen area as described in Methods (scale bar = 2
µm). In image 4, individual collagen fibrils within the elastin fold are readily
distinguishable (scale bar = 200 nm). (C) Collagen area in elastin folds of WT and HGPS
carotid arteries was quantified as described in methods (n=6 mice per genotype, 60
elastin folds per genotype). Mouse numbers in C were accrued from vehicle-injected and
uninjected mice. Statistical significance was determined by Mann-Whitney test. TEM
performed by Kyle Bruun (University of Pennsylvania).
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Fig. 2.11. Mechanical properties of 1-month WT and HGPS carotid arteries. Carotid
arteries from mixed sex 1-mo WT (n=5) and HGPS (n=5) mice were analyzed by
pressure myography. (A-C) Changes in inner radius, wall thickness, and outer diameter
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with pressure. Results show mean ± SE. (D) Axial stress-stretch curves performed at
80mmHg. Results show mean ± SD. (E) Circumferential stress-stretch curves. Results
show mean ± SE. Statistical significance in A-E was determined by two-way ANOVA. (FG) Derived axial and circumferential tangent modulus versus stretch plots. Male 2-mo
HGPS tangent curves were reproduced from Figure 2.03 for reference (dashed red line).
Myographic experiments were performed in collaboration with Emilia Roberts (University
of Pennsylvania).
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Fig. 2.12. BAPN treatment reduces second harmonic generation (SHG) signal of
carotid artery adventitia. Mixed-sex HGPS mice were treated with daily IP injections of
PBS (vehicle) or BAPN for approximately 30 days starting at 1-month (see methods for
additional details). Carotid artery cross sections were then imaged by second harmonic
generation (n=4 mice per treatment group). Representative images are shown. The
external elastic lamina is outlined in white dashed lines. Scale bar 50μm.
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Fig. 2.13. Collagen and LOX abundance in PBS and BAPN-treated mice. (A)
Representative TEM images (50,000x magnification) of cross sections from 2-mo HGPS
carotid arteries that had been treated with vehicle (PBS) or BAPN as described in
Materials and Methods. Scale bar = 200 nm. (B) Quantification of collagen area within
the elastin folds as described in Methods and Fig. 2.10 (n=3-4 mice per treatment with
10 elastin folds analyzed per mouse). (C-D) Aorta lysates, prepared from 2-mo HGPS
mice treated with PBS or BAPN, were analyzed by western blotting and probed for LOX
and Focal Adhesion Kinase (FAK, loading control). (C) Representative western blot;
white spaces indicate removal of extraneous data. (D) Quantification of LOX signal
intensities, normalized to the loading control, in HGPS mice treated with PBS (n=4) or
BAPN (n=4). TEM experiments were performed in collaboration with Kyle Bruun.
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Fig. 2.14. Effect of BAPN on carotid artery geometry and tangent modulus in
mixed sex WT and HGPS mice. (A-C) Changes in outer diameter, inner radius, and
wall thickness with pressure for the PBS- and BAPN-treated HGPS and WT mice shown
in Figure 2.15. Results show mean ± SE. Statistical significance was determined by 2123

way ANOVA relative to the vehicle treated arteries. (D-E) Derived circumferential and
axial tangent modulus versus stretch plots. Myography experiments were performed in
collaboration with Emilia Roberts. Elizabeth Hawthorne assisted with BAPN injections.

124

Fig. 2.15. Elevated Lysyl Oxidase expression is linked to premature arterial
stiffening and diastolic dysfunction in HGPS mice. Mixed sex WT and HGPS mice
aged to 1-month were treated with β-aminopropionitrile, BAPN (WT n=5, HGPS n=6) or
PBS (WT n=6, HGPS n=7) for approximately 30 days followed by pressure myography
of isolated carotid arteries. (A-B) Circumferential and axial stretch-stress curves,
respectively, of WT and HGPS mice treated with PBS or BAPN. Results in panels A
display means ± SE, and results in panel B display means ± SD. Statistical significance
for

the

myographic

analysis

was

determined

by

two-way

ANOVA.

(C-D)

Echocardiography measurements of (C) the E/E’ ratio and (D) the left ventricular mass
index (LVMI, left ventricular mass to body weight ratio) of 64-75 day old HGPS mice
(n=4), 65-75 day old HGPS mice treated with BAPN (n=4), and 66-75 day WT mice
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(n=4). Mouse numbers in C-D were accrued from vehicle-injected and uninjected mice,
and statistical significance was determined by Mann- Whitney tests.
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Fig. 2.16. Effect of BAPN on diastolic function and aortic hemodynamics in HGPS
mice. Diastolic function and pressures of the mice used in Figs. 2.15C-D. (A-B) E and
E’ as determined by echocardiography. (C) Systolic pressure, (D) diastolic pressure, and
(E) pulse pressure. Statistical significance was determined by Mann-Whitney test.
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Fig. 2.17. Daily BAPN administration does not prolong HGPS mouse lifespan. 1month WT and HGPS mixed-sex mice were injected daily with PBS (WT n=5; HGPS
n=6) or BAPN (WT n=3; HGPS n=5) until moribund as described in methods. (A)
Kaplan-Meier curve displaying percent survival of mice treated with PBS or BAPN. No
statistical changes in survival of HGPS mice after BAPN administration was observed by
Gehan-Breslow-Wilcoxon test. (B) Weekly bodyweight measurements of WT and HGPS
mice starting at the time of initial injection of PBS or BAPN (~1-month of age) until
euthanasia. No significance in weight change was observed between PBS or BAPN
treatment in WT or HGPS mice as determined by 2-way ANOVA with Holm-Sidak posttests comparing weight each week.
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Fig. 2.18. Characterization of 2-mo WT and HGPS aortas. (A-B) WT and HGPS aortic
cross sections were characterized for overall morphology and SMC number by H&E
staining. The number of SMC nuclei was quantified (n=7 mice per genotype, 3 sections
per mouse). (C-D) 2-mo WT and HGPS aorta were immunostained with anti-p16 (n=7),
and signal intensity in the medial layer (dashed lines) was quantified and normalized to
2-mo WT. (E) Calcification was assessed by alizarin red staining (n=4), with bone tissue
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used as a positive control as in Fig. 2.06. Scale bar in panels A-E=100 mm. (F)
Apoptotic cells were assessed in WT and HGPS aortas by staining for cleaved caspase3 (scale bar=50 mm, n=4) with tumor tissue used as positive control as in Fig. 2.06.
Medial

layer

is

outlined

in

dashed
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lines

and

marked

with

“M”.

Fig. 2.19. Collagen immunostaining and transcript levels in 2-month WT and HGPS
aortas. (A) Representative images of collagens-I, -III, -V immunostaining in 2-mo WT
(n=7) and HGPS (n=7) aortic cross sections. Scale bar 100 mm. Medial layer is outlined
in dashed lines and marked with “M”. (B) Quantification of immunostaining with results
presented as fold change in fluorescent signal intensity for the medial and adventitial
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layers normalized to the mean intensity of the 2-mo WT media. Statistical significance
between genotypes was evaluated by Mann-Whitney test. (C-D) Col1a1, Col3a1, and
Col5a1 transcript levels in aortic (C) media layer (n=4 per genotype) or (D) adventitia
layer (n=4 per genotype).
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Fig. 2.20. HGPS aortas display increased Lysyl Oxidase (LOX) abundance and
activity. (A) Representative images of 2-month WT (n=8) and HGPS (n=7) aortic
sections immunostained for LOX; scale bar = 100 µm. The arterial media (M) is outlined
with dashed lines. (B) LOX signal intensities from the immunostained sections were
quantified, and results were normalized to the mean signal intensity of the 2-month WT
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medial layer. (C) Representative immunoblot of aortic lysate from 2-month WT and
HGPS mice, and (D) quantification of immunoblots (n=6-7 per genotype). (E) LOX
activity in 2-month WT and HGPS aortic tissue (n=5 per genotype). Statistical
significance in A-E was determined by Mann-Whitney tests between genotypes. (F)
mRNA expression levels of LOX family isoforms in adventitia-free 2-month WT and
HGPS aortas and (G) 2-month WT and HGPS aortic adventitial tissue were quantified by
RT-qPCR (n=4 independent experiments, with 2 aortas pooled per experiment).
Transcript levels were normalized to 2-month WT medial layer values. Statistical
significance was determined by two-way ANOVA followed by Holm-Sidak post-tests.
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Fig. 2.21. LOX and miR-145 transcript abundance. (A) LOX and miR-145 transcript
levels in 1-month male WT and HGPS mice (n=4 per genotype). Statistical significance
was determined by Mann-Whitney tests. (B) Relative abundance of the LOX family
members in the medial and adventitial layers of 2-month WT and HGPS aorta was
quantified by RT-qPCR. Results show delta-Ct values plotted as Tukey plots (n=4 mice
per genotype). Statistical significance was determined by Two-way ANOVA using LOX
as a reference; results of the individual Holm-Sidak post-tests are shown. (C-D) LOX
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and miR-145 transcript levels in intestine (n=4 per genotype) and bladder (n=4 per
genotype) of 2-mo male WT and HGPS mice.
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Fig. 2.22. Initial characterizations of the genome-wide analysis. (A) Principal
component analysis of RNASeq data performed in Partek Genomics Suite. (B) Gene
ontology (GO) cellular component analysis performed in DAVID as described in
Materials and Methods. GO Terms with greater than a -LOG10(P value) of 5 are shown.
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(C) Fold changes and adjusted p-values for LOX mRNA in the DEGs of aortas from 2mo HGPS and 24-mo WT mice as normalized to 2-mo WT mice.

138

Fig. 2.23. HGPS aortic tissues show reduced miR-145 transcript levels. RNAsequencing analysis was performed (see Materials and Methods) on cleaned aortas
from 2-month WT and HGPS mice (n=6 per genotype) to identify potential upstream
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regulators of LOX. (A) The number of activation or inhibition signatures in the HGPS vs.
WT aortas was inferred from an Ingenuity pathway (IPA) core analysis of differentially
expressed genes (DEGs), and the list of total activation/inhibition signatures (top) was
subdivided into transcription regulators and microRNAs. (B) Venn diagram identifying
the number of activation/inhibition signatures in HGPS categorized as either transcription
regulators (left, green) or microRNAs (right, blue) were compared to known
transcriptional or microRNA regulators of LOX identified from IPA (beige). The likelihood
of the 8 transcription regulators and 1 miR accounting for LOX upregulation in HGPS
was then considered individually using the criteria shown ("Filters"). (C) TargetScan
depiction of the conserved 3'UTR miR-145-5p target sequence in LOX.

(D) miR-145

transcript levels from the medial layer (n=6) and (E) adventitial layer (n=4) of 2-month
WT and HGPS mice. miR-145 transcript levels were normalized to WT-media values.
Statistical significance was determined by Mann-Whitney tests.
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Fig. 2.24. Ectopic expression of miR-145 reduces Lysyl Oxidase (LOX) mRNA in
primary HGPS vascular smooth muscle cells (SMCs) and Lmna knockdown does
not recapitulate the HGPS phenotype. (A) miR-145 transcript levels in isolated WT
and HGPS SMCs as determined by RT-qPCR (n=8 per genotype).

Statistical

significance was determined by a Mann-Whitney test. (B) LOX mRNA levels in WT and
HGPS SMCs infected with adenoviruses encoding LacZ (control) or miR-145 determined
by RT-qPCR and normalized to the WT LacZ control (n=5). Statistical significance was
determined by Mann-Whitney tests. (C) WT SMCs were transfected with a control siRNA
or two different siRNAs targeting LMNA; lysates were analyzed by western blotting and
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probed for Lamin A, LOX, and FAK (loading control) (n=3). HGPS SMCs were included
as reference. White spaces indicate removal of extraneous data. (D) LMNA mRNA was
knocked-down in WT SMCs using two distinct siRNAs, and transcript levels of Lmna,
Lox, and miR-145 were analyzed by RT-qPCR and normalized to the Ctrl siRNA
treatment (n=5). Statistical significance was determined by two-way ANOVA with HolmSidak post-tests. The light grey bars in the Tukey plots show HGPS references for miR145 and LOX and are reproduced from Figure 2.24A and B, respectively.
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Fig. 2.25. Additional differentially expressed miR-145 target genes in HGPS. (A)
The list of miR-145-5p predicted transcripts with conserved sites in the mouse genome,
as determined by TargetScan (www.targetscan.org), were compared to the differentially
expressed genes in the aortas of 2-mo HGPS vs. WT mice using a log2 fold change >
0.8 and an adjusted p-value of <0.0001 as cut-offs. (B) Primary aortic smooth muscle
cells from 2-mo WT and HGPS mice were infected with an adenovirus encoding LacZ
(control) or miR-145. After 72 hours, RNA was isolated and analyzed by RT-qPCR (n=4)
for three of the putative miR-145 target genes from panel A, which were selected based
on their similar or greater induction than LOX mRNA in HGPS aortas.
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Fig. 2.26. Differential mechanisms drive overexpression of Lysyl Oxidase (LOX) in
normal aging. C57BL/6 (WT) mice were aged from 2 to 24 months. (A) Representative
images of collagen-I, -III, -V immunostaining in carotid artery sections of 2- and 24144

month WT mice (n=4-7 mice per age group). (B) Collagen signal intensities in the medial
and adventitial layers of the immunostained carotid cross sections were quantified, and
results were normalized to the mean of the 2-month WT medial layer for each collagen.
Statistical significance was determined by Mann-Whitney tests between ages. (C)
Representative images of LOX immunostaining of carotid artery cross sections from 2month (n=8), 6-month (n=7), 12-month (n=4), and 24-month (n=9) WT mice. (D) LOX
signal intensities were quantified from the immunostained sections, and results were
normalized to the mean signal intensity of the 2-month WT medial layer. Statistical
significance was determined by one-way ANOVA relative to the 2-month mice followed
by Holm-Sidak post-tests. (E) LOX mRNA (n=5 per age) and (F) miR-145 expression
levels (n=6 per age) in 2- and 24-month WT aorta determined by RT-qPCR and
normalized to 2-month WT. Statistical significance was determined using Mann-Whitney
tests. In carotid cross section images, the arterial media (M) is outlined with dashed
lines; scale bar = 50 µm.
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2.8 Tables
Table 1. In Vivo Stretch (IVS) values for WT and HGPS mice. Significance was
determined by Mann-Whitney test in comparison to the IVS of 2-month WT mice. NS;
not significant.

n

p (relative to 2-mo
WT)

0.04

13

reference

1.72

0.05

5

***

M

1.79

0.10

9

NS

2 mo

F

1.88

0.07

7

reference

WT

24 mo

F

1.74

0.04

5

*

HGPS

2 mo

F

1.79

0.07

10

*

Genotype

Age

Sex

IVS (mean) IVS (SD)

WT

2 mo

M

1.85

WT

24 mo

M

HGPS

2 mo

WT
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Table 2. In Vivo Stretch (IVS) values for heterozygous 2-month and 9-month and
HGPS mice. Significance was determined by Mann-Whitney test.
Age

IVS
(mean)

IVS
(SD)

n

p

2-mo

1.94

0.07

6

reference

9-mo

1.77

0.04

5

**

147

Table 3. In Vivo Stretch (IVS) values for mixed sex, 1-month WT and HGPS mice.
Significance was determined by Mann-Whitney test. NS; not significant.
Genotype

IVS
(mean)

IVS
(SD)

n

p

WT

1.83

0.02

5

reference

HGPS

1.8

0.03

5

NS
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Table 4. In Vivo Stretch (IVS) values for mixed sex, 2-month WT and HGPS mice
treated with vehicle or BAPN. Significance was determined by Mann-Whitney test. NS;
not significant.
Genotype BAPN
WT
WT

✓

HGPS
HGPS

✓

IVS (mean)

IVS (SD)

n

p (relative to untreated mice)

1.85

0.05

6

reference

1.84

0.06

5

NS

1.73

0.07

7

reference

1.74

0.05

6

NS

149

Table 5. Candidate upstream regulators in HGPS as identified by IPA. The list of
852 upstream regulators that are activated or inhibited in the aortas of 2-month old male
HGPS mice relative to 2-month old male WT littermates using a Z-score cutoff of > +1.75
(activated) or < -1.75 (inhibited).
Activation
z-score

Upstream Regulator

Molecule Type

poly rI:rC-RNA

biologic drug

5.411

vancomycin

biologic drug

3.348

enterotoxin B

biologic drug

2.724

oblimersen

biologic drug

2.538

aldesleukin

biologic drug

2

isotretinoin

biologic drug

1.867

ceruletide

biologic drug

1.759

chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian

beta-estradiol
palmitic acid
hydrogen peroxide
tretinoin
inosine
fatty acid
cholesterol
D-fructose
homocysteine
aldosterone
ethanol
Ca2+
linoleic acid
2-arachidonoylglycerol
lysophosphatidylinositol
carbohydrate
acetyl-L-carnitine
cyclic AMP
sucrose
L-triiodothyronine

chemical - endogenous
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5.241
4.009
3.923
3.791
3.719
3.615
3.539
3.419
3.145
3.122
3.052
2.747
2.615
2.574
2.53
2.449
2.414
2.386
2.335
2.268

mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous
mammalian
chemical - endogenous nonmammal
chemical - endogenous nonmammal

dihydrotestosterone
diacylglycerol
oxysterol
advanced glycation end-products
ursodeoxycholic acid
fluoride
DL-fructose
heparin
prostaglandin E2
uric acid
hyaluronic acid
manganese
8,9-epoxyeicosatrienoic acid
lactic acid
beta-glycerophosphoric acid
acetone
norepinephrine
anandamide
epinephrine
platelet activating factor
chenodeoxycholic acid
oleic acid
L-methionine
sterol
lipid
levodopa
beta-carotene
estriol
choline
salmonella minnesota R595 lipopolysaccharides
E. coli serotype 0127B8 lipopolysaccharide
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2.263
2.236
2.236
2.219
2.209
2.2
2.183
2.131
2.082
2.041
2.015
1.982
1.982
1.98
1.964
1.951
1.947
1.929
1.91
1.785
1.756
1.755
-1.786
-1.84
-2
-2.083
-2.331
-2.53
-2.599
3.97
3.873

tunicamycin
E. coli B5 lipopolysaccharide
guanidinopropionic acid
5-O-mycolyl-beta-araf-(1->2)-5-O-mycolyl-alpha-araf-(1->1')glycer
lipoteichoic acid
hemozoin
E. coli lipopolysaccharide
peptidoglycan
brefeldin A
linalool
diallyl trisulfide
N-acetylmuramyl-L-alanyl-D-isoglutamine
baicalin
pregna-4,17-diene-3,16-dione
largazole

chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal
chemical - endogenous nonmammal

3.722
3.611
3.439
2.84
2.587
2.533
2.316
2.133
2.13
2
1.982
1.977
1.912
-1.982
-2

SP600125

chemical - kinase inhibitor

-1.84

Go6983

chemical - kinase inhibitor

-1.982

JAK inhibitor I

chemical - kinase inhibitor

-1.982

KN 93

chemical - kinase inhibitor

-1.982

H-7

chemical - kinase inhibitor

-1.982

wortmannin

chemical - kinase inhibitor

-2.374

tyrphostin AG 1478

chemical - kinase inhibitor

-2.465

bisindolylmaleimide I

chemical - kinase inhibitor

-2.536

calphostin C

chemical - kinase inhibitor

-2.647

AG490

chemical - kinase inhibitor

-2.709

Bay 11-7082

chemical - kinase inhibitor

-2.71

H89

chemical - kinase inhibitor

-2.725

Go 6976

chemical - kinase inhibitor

-2.736

Ro31-8220

chemical - kinase inhibitor

-3.077

PD98059

chemical - kinase inhibitor

-4.259

LY294002

chemical - kinase inhibitor

-4.51

U0126

chemical - kinase inhibitor

-4.629

SB203580

chemical - kinase inhibitor

-4.908

cardiotoxin

chemical - other

3.9

phorbol esters

chemical - other

1.918

2-amino-5-phosphonovaleric acid

chemical - other

1.763
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lactacystin

chemical - protease inhibitor

3.077

proteasome inhibitor PSI

chemical - protease inhibitor

1.754

TAPI-1

chemical - protease inhibitor

-2

tosylphenylalanyl chloromethyl ketone

chemical - protease inhibitor

-2.213

lipopolysaccharide

chemical drug

7.159

rosiglitazone

chemical drug

5.827

cisplatin

chemical drug

4.858

tetradecanoylphorbol acetate

chemical drug

4.817

CpG oligonucleotide

chemical drug

4.475

bleomycin

chemical drug

4.375

bezafibrate

chemical drug

4.357

acetaminophen

chemical drug

3.75

clofibrate

chemical drug

3.705

AGN194204

chemical drug

3.569

imiquimod

chemical drug

3.548

GW501516

chemical drug

3.465

indomethacin

chemical drug

3.411

gentamicin

chemical drug

3.394

fenofibrate

chemical drug

3.325

PLX5622

chemical drug

3.162

cytarabine

chemical drug

3.091

triamterene

chemical drug

3.08

paclitaxel

chemical drug

3.079

5-azacytidine

chemical drug

3.033

resiquimod

chemical drug

3.026

trovafloxacin

chemical drug

3

CL 316243

chemical drug

2.974

phenylbutazone

chemical drug

2.949

alitretinoin

chemical drug

2.911

gemfibrozil

chemical drug

2.853

allopurinol

chemical drug

2.846

troglitazone

chemical drug

2.817

pioglitazone

chemical drug

2.753

cephaloridine

chemical drug

2.735

deferoxamine

chemical drug

2.683

lomustine

chemical drug

2.673

gentamicin C

chemical drug

2.668

mibolerone

chemical drug

2.592

fluticasone propionate

chemical drug

2.566

ciprofibrate

chemical drug

2.549
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diethylstilbestrol

chemical drug

daidzein

chemical drug

2.53

isoproterenol

chemical drug

2.524

1-(carboxymethylthio)tetradecane

chemical drug

2.425

tosedostat

chemical drug

2.408

ribavirin

chemical drug

2.408

hydroxyurea

chemical drug

2.405

clopidogrel

chemical drug

2.4

doxifluridine

chemical drug

2.384

arsenic trioxide

chemical drug

2.319

methotrexate

chemical drug

2.311

NO 1886

chemical drug

2.236

idarubicin

chemical drug

2.236

methylprednisolone

chemical drug

2.233

raloxifene

chemical drug

2.232

GW7647

chemical drug

2.219

WR 1065

chemical drug

2.208

docetaxel

chemical drug

2.205

vitamin K3

chemical drug

2.176

deoxycorticosterone acetate

chemical drug

2.174

phenacetin

chemical drug

2.157

vinblastine

chemical drug

2.156

nelfinavir

chemical drug

2.121

cocaine

chemical drug

2.04

bardoxolone

chemical drug

2.025

glucocorticoid

chemical drug

2.008

genistein

chemical drug

2.001

meldonium

chemical drug

2

hyperforin

chemical drug

2

chloropromazine

chemical drug

1.982

ABT-737

chemical drug

1.982

calcium chloride

chemical drug

1.96

mitomycin C

chemical drug

1.949

camptothecin

chemical drug

1.944

streptozocin

chemical drug

1.943

amitriptyline

chemical drug

1.941

progestin

chemical drug

1.941

nitrofurantoin

chemical drug

1.846

phenobarbital

chemical drug

1.754

valsartan

chemical drug

-1.896
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2.53

fingolimod

chemical drug

-1.901

fulvestrant

chemical drug

-1.927

roscovitine

chemical drug

-1.937

midostaurin

chemical drug

-1.96

prednisolone

chemical drug

-1.963

edaravone

chemical drug

-1.982

ramipril

chemical drug

-1.982

chelerythrine

chemical drug

-2

nilotinib

chemical drug

-2

zinc

chemical drug

-2.01

thalidomide

chemical drug

-2.219

oleoyl-estrone

chemical drug

-2.224

everolimus

chemical drug

-2.364

alpha-tocopherol

chemical drug

-2.393

spironolactone

chemical drug

-2.42

halofuginone

chemical drug

-2.433

silibinin

chemical drug

-2.439

tanespimycin

chemical drug

-2.655

minocycline

chemical drug

-2.749

flutamide

chemical drug

-2.779

medroxyprogesterone acetate

chemical drug

-2.865

calcitriol

chemical drug

-2.916

alvocidib

chemical drug

-2.939

vitamin E

chemical drug

-2.94

ST1926

chemical drug

-3

N-acetyl-L-cysteine

chemical drug

-3.78

sirolimus

chemical drug

-4.472

metribolone

chemical reagent

6.102

trinitrobenzenesulfonic acid

chemical reagent

3.767

1,2-dithiol-3-thione

chemical reagent

3.282

2-bromoethylamine

chemical reagent

3.217

fenamic acid

chemical reagent

3.05

(5-(4-N-methyl-N(2-pyridyl)amino)ethoxy)benzyl thiazolidine-2,4dion

chemical reagent

Ni2+

chemical reagent

2.621

LG100268

chemical reagent

2.596

CpG ODN 1826

chemical reagent

2.584

CpG ODN 2395

chemical reagent

2.433

CpG ODN 2006

chemical reagent

2.417

ionomycin

chemical reagent

2.399

3M-002

chemical reagent

2.383
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2.621

calcimycin

chemical reagent

2.266

CpG ODN 2216

chemical reagent

2.219

azetidyl-2-carboxylic acid

chemical reagent

2.2

Pam3-Cys-Ser-Lys4

chemical reagent

2.175

TO-901317

chemical reagent

2.11

gamma-secretase inhibitor XX

chemical reagent

2

ST3-Hel2A-2

chemical reagent

2

5,8,11,14-eicosatetraynoic acid

chemical reagent

2

MALP-2s

chemical reagent

2

DPP-23

chemical reagent

1.982

15-E2-isoketal modified phosphatidylethanolamine

chemical reagent

1.98

SR1078

chemical reagent

1.972

N-acetylsphingosine

chemical reagent

1.793

puromycin aminonucleoside

chemical reagent

1.765

sodium orthovanadate

chemical reagent

1.761

NS-398

chemical reagent

-1.794

U73122

chemical reagent

-1.96

cycloheximide

chemical reagent

-1.995

JNJ-39933673

chemical reagent

-2

sea cucumber body wall meal

chemical reagent

-2

poloxamer

chemical reagent

-2.166

diphenyleneiodonium

chemical reagent

-2.216

pyrrolidine dithiocarbamate

chemical reagent

-2.251

pifithrin alpha

chemical reagent

-2.401

GW9662

chemical reagent

-3.03

torin1

chemical reagent

-4.841

mono-(2-ethylhexyl)phthalate

chemical toxicant

6.472

pirinixic acid

chemical toxicant

5.924

E. coli B4 lipopolysaccharide

chemical toxicant

4.744

forskolin

chemical toxicant

3.531

lipid A

chemical toxicant

3.44

thioacetamide

chemical toxicant

3.398

chrysotile asbestos

chemical toxicant

3.078

hexachlorobenzene

chemical toxicant

3.023

cigarette smoke

chemical toxicant

2.945

isobutylmethylxanthine

chemical toxicant

2.709

ethionine

chemical toxicant

2.53

cadmium

chemical toxicant

2.478

methylnitronitrosoguanidine

chemical toxicant

2.388

6-hydroxydopamine

chemical toxicant

2.364
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1,4-bis[2-(3,5-dichloropyridyloxy)]benzene

chemical toxicant

2.319

thapsigargin

chemical toxicant

2.274

pristane

chemical toxicant

2.219

methyl methanesulfonate

chemical toxicant

2.189

bucladesine

chemical toxicant

2.185

cadmium chloride

chemical toxicant

2.167

diethylmaleate

chemical toxicant

2.158

3-methylcholanthrene

chemical toxicant

2.116

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

chemical toxicant

2.028

monocrotaline

chemical toxicant

2.016

4-nitroquinoline-1-oxide

chemical toxicant

2

triadimefon

chemical toxicant

2

1-methyl-4-phenylpyridinium

chemical toxicant

1.945

reactive oxygen species

chemical toxicant

1.828

Salmonella enterica serotype abortus equi lipopolysaccharide

chemical toxicant

1.824

mercuric chloride

chemical toxicant

1.819

GW 4064

chemical toxicant

1.768

4-tert-octylphenol

chemical toxicant

1.753

Sn50 peptide

chemical toxicant

-1.891

rottlerin

chemical toxicant

-2.147

CD3

complex

4.886

PDGF BB

complex

4.568

LDL

complex

4.47

CG

complex

4.213

PI3K (complex)

complex

4.159

Ige

complex

4.018

NFkB (complex)

complex

4.004

T3-TR-RXR

complex

2.359

Lh

complex

2.304

Collagen type IV

complex

2.236

MAC

complex

2.2

Calcineurin protein(s)

complex

2.136

Pka

complex

2.014

IL23

complex

1.961

MTORC1

complex

1.819

BCR (complex)

complex

1.807

histone deacetylase

complex

-2

CSF2

cytokine

6.388

IFNG

cytokine

5.357

IL5

cytokine

5.216
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IL6

cytokine

4.702

SPP1

cytokine

4.637

CSF1

cytokine

4.412

IL1B

cytokine

4.349

TNF

cytokine

4.151

IL13

cytokine

4.011

IL17A

cytokine

3.85

IL4

cytokine

3.816

IFNA2

cytokine

3.794

IL15

cytokine

3.515

IL3

cytokine

3.466

IL1A

cytokine

3.294

TNFSF11

cytokine

3.234

CCL5

cytokine

3.215

IFNB1

cytokine

3.099

OSM

cytokine

3.048

IL21

cytokine

3.047

LIF

cytokine

2.953

IL2

cytokine

2.94

CD40LG

cytokine

2.897

IL33

cytokine

2.873

C5

cytokine

2.846

IL18

cytokine

2.65

IL17F

cytokine

2.425

IFNL1

cytokine

2.415

IL24

cytokine

2.243

IFNE

cytokine

2.219

IFNA1/IFNA13

cytokine

2.209

IL10

cytokine

2.133

TNFSF12

cytokine

2.099

FLT3LG

cytokine

2.057

IL7

cytokine

2.043

Ccl6

cytokine

2

IFNK

cytokine

2

FASLG

cytokine

1.982

CCL11

cytokine

1.97

IL9

cytokine

1.954

TSLP

cytokine

1.941

EPO

cytokine

1.929

IFNA4

cytokine

1.912
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PRL

cytokine

1.891

CCL2

cytokine

1.808

MIF

cytokine

1.755

IL1RN

cytokine

-1.997

TGM2

enzyme

4.181

CD38

enzyme

3.594

PNPLA2

enzyme

3.37

FASN

enzyme

2.924

HRAS

enzyme

2.813

PTGS2

enzyme

2.795

CYP2E1

enzyme

2.765

FN1

enzyme

2.509

KRAS

enzyme

2.505

TRAF6

enzyme

2.425

NSUN6

enzyme

2.309

FMO3

enzyme

2.236

ACSS2

enzyme

2.236

CGAS

enzyme

2.224

SAT1

enzyme

2.2

DGAT1

enzyme

2.186

PIN1

enzyme

2.135

CPT1C

enzyme

1.987

LDHB

enzyme

1.982

PRPF19

enzyme

1.982

PARP2

enzyme

1.98

PLCE1

enzyme

1.964

DDX58

enzyme

1.816

RACK1

enzyme

-1.953

ST8SIA1

enzyme

-1.97

TREX1

enzyme

-1.98

SURF1

enzyme

-1.982

EHHADH

enzyme

-2

PLA2G6

enzyme

-2

PNPT1

enzyme

-2.137

RNF31

enzyme

-2.143

SUV39H1

enzyme

-2.2

SCD

enzyme

-2.206

SIRT6

enzyme

-2.213

DNASE2

enzyme

-2.216

CBLB

enzyme

-2.219
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ENPP2

enzyme

-2.236

PCYT2

enzyme

-2.236

SSB

enzyme

-2.236

DICER1

enzyme

-2.241

CBS/CBSL

enzyme

-2.425

SPTLC2

enzyme

-2.425

B4GALNT1

enzyme

-2.433

ADA

enzyme

-2.589

CYB5R4

enzyme

-2.622

CAT

enzyme

-2.896

FBXW7

enzyme

-2.905

ALDH2

enzyme

-2.985

ACOX1

enzyme

-3.002

NRAS

enzyme

-3.52

PTGER2

G-protein coupled receptor

3.147

C5AR1

G-protein coupled receptor

2.963

CASR

G-protein coupled receptor

2.834

F2R

G-protein coupled receptor

2.785

FZD9

G-protein coupled receptor

2.619

FFAR3

G-protein coupled receptor

2.376

ADRB3

G-protein coupled receptor

2.191

VIPR1

G-protein coupled receptor

1.987

CCR5

G-protein coupled receptor

1.837

HCAR2

G-protein coupled receptor

-2

SMO

G-protein coupled receptor

-2.232

ACKR2

G-protein coupled receptor

-3.118

Ifnar

group

4.021

Mek

group

3.919

ERK

group

3.915

IFN Beta

group

3.786

P38 MAPK

group

3.643

Interferon alpha

group

3.609

Vegf

group

3.18

ERK1/2

group

3.1

Jnk

group

3.091

Ifn

group

3.052

E2f

group

2.933

cytokine

group

2.869

CD3 group

group

2.767

IL1

group

2.702

160

Srebp

group

2.646

caspase

group

2.607

MAP2K1/2

group

2.578

Nfat (family)

group

2.517

IFN type 1

group

2.406

Creb

group

2.229

Insulin

group

2.227

IL12 (family)

group

2.189

JAK1/2

group

2.121

Tlr

group

2.029

Gsk3

group

2

elastase

group

1.98

Fgf

group

1.98

Pka catalytic subunit

group

1.954

IFN alpha/beta

group

1.947

SRC (family)

group

1.941

STAT5a/b

group

1.804

ADRB

group

-1.878

DNA-methyltransferase

group

-1.973

Sod

group

-2

Pde4

group

-2.186

estrogen receptor

group

-2.266

Calmodulin

group

-2.333

Rb

group

-2.728

EGLN

group

-3.461

N-cor

group

-3.486

EGF

growth factor

4.298

VEGFA

growth factor

4.09

IGF1

growth factor

4.07

ANGPT2

growth factor

3.59

TGFB1

growth factor

3.473

AREG

growth factor

3.267

AGT

growth factor

3.21

FGF2

growth factor

3.162

NRG1

growth factor

3.034

FGF7

growth factor

2.923

PGF

growth factor

2.382

NGF

growth factor

2.371

FGF10

growth factor

2.333

TGFA

growth factor

2.27
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GHRL

growth factor

2.138

FGF21

growth factor

1.871

HGF

growth factor

1.771

NRG4

growth factor

-2.207

CCN5

growth factor

-2.53

TRPV4

ion channel

2.227

KCNJ11

ion channel

1.982

CLCN5

ion channel

-1.944

INSR

kinase

5.205

CHUK

kinase

4.501

STK11

kinase

3.693

PIK3R1

kinase

3.587

IKBKB

kinase

3.523

CAB39L

kinase

3.308

IKBKG

kinase

3.281

MTOR

kinase

3.25

JAK1

kinase

3.228

RAF1

kinase

3.228

AKT1

kinase

3.086

EIF2AK2

kinase

2.961

ERBB2

kinase

2.948

JAK2

kinase

2.943

PRKCD

kinase

2.916

MAPK14

kinase

2.785

SRC

kinase

2.653

EGFR

kinase

2.642

MAP3K7

kinase

2.578

EIF2AK4

kinase

2.575

NTRK2

kinase

2.517

IKBKE

kinase

2.507

MAPKAPK2

kinase

2.465

FGFR1

kinase

2.457

PIM1

kinase

2.393

CHEK2

kinase

2.392

MAP2K3

kinase

2.366

MAPK9

kinase

2.298

MET

kinase

2.289

RIPK2

kinase

2.265

TNK1

kinase

2.219

MAP3K1

kinase

2.191

162

CSF1R

kinase

2.173

MAPK8

kinase

2.132

Brd4

kinase

2.121

PRKD1

kinase

2.08

BRD4

kinase

2.038

PRKCA

kinase

2.025

PRKAR2B

kinase

2

RIPK1

kinase

1.982

ILK

kinase

1.976

ROCK2

kinase

1.964

MAP3K14

kinase

1.964

DDR1

kinase

1.953

IRAK4

kinase

1.939

PIK3CA

kinase

1.904

ROR1

kinase

1.89

EFNA2

kinase

1.89

PLK1

kinase

-1.953

Sik1

kinase

-1.969

SIK1/SIK1B

kinase

-1.98

ERBB4

kinase

-1.997

GNE

kinase

-2

PCK1

kinase

-2.414

CDK19

kinase

-2.706

TRIB3

kinase

-2.778

MAP4K4

kinase

-5.009

PPARG

ligand-dependent nuclear receptor

5.312

PPARA

ligand-dependent nuclear receptor

4.129

ESRRA

ligand-dependent nuclear receptor

3.94

PPARD

ligand-dependent nuclear receptor

3.469

NR1I3

ligand-dependent nuclear receptor

2.734

ESR1

ligand-dependent nuclear receptor

2.56

RORA

ligand-dependent nuclear receptor

2.514

NR1I2

ligand-dependent nuclear receptor

1.918

NR3C2

ligand-dependent nuclear receptor

1.907

THRA

ligand-dependent nuclear receptor

-2.102

NR0B2

ligand-dependent nuclear receptor

-2.277

NR4A1

ligand-dependent nuclear receptor

-2.6

miR-124-3p (and other miRNAs w/seed AAGGCAC)

mature microRNA

miR-217-5p (and other miRNAs w/seed ACUGCAU)

mature microRNA

-2

miR-27a-3p (and other miRNAs w/seed UCACAGU)

mature microRNA

-2.005
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-1.777

miR-155-5p (miRNAs w/seed UAAUGCU)

mature microRNA

-2.079

miR-199a-3p (and other miRNAs w/seed CAGUAGU)

mature microRNA

-2.213

miR-24-3p (and other miRNAs w/seed GGCUCAG)

mature microRNA

-2.408

mir-145

microRNA

-1.799

mir-33

microRNA

-2.414

let-7

microRNA

-2.925

mir-21

microRNA

-3.595

ELAVL1

other

4.795

MYD88

other

4.55

TICAM1

other

4.027

TMEM173

other

3.32

RETNLB

other

3.297

CCNC

other

3.267

RETN

other

3.123

PCGEM1

other

3.105

SCAP

other

3.089

Hbb-b2

other

3

CD44

other

2.938

HRG

other

2.828

SELPLG

other

2.828

Firre

other

2.828

RABL6

other

2.668

BID

other

2.646

C2CD5

other

2.619

C1QA

other

2.58

THBS4

other

2.578

APP

other

2.564

Ins1

other

2.521

TRAF3IP2

other

2.457

NKX2-2-AS1

other

2.449

TRADD

other

2.449

EWSR1

other

2.449

FST

other

2.446

TP53COR1

other

2.425

METRNL

other

2.401

THBS1

other

2.401

TAC1

other

2.361

PEBP1

other

2.335

CAMP

other

2.329

SAMSN1

other

2.309
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S100A9

other

2.245

ACTB

other

2.236

HNF1A-AS1

other

2.219

ADM2

other

2.216

Trp53cor1

other

2.207

ERFE

other

2.2

LINC00963

other

2.176

GAST

other

2.173

MYOC

other

2.157

LLGL2

other

2.121

MEDAG

other

2

SH3TC2

other

2

PAF1

other

2

ORMDL3

other

1.994

PNN

other

1.982

TG

other

1.981

LGALS3

other

1.975

LAMA5

other

1.964

TERF2IP

other

1.964

ASXL2

other

1.89

EFNA1

other

1.89

LIN9

other

1.834

RPTOR

other

1.795

MAVS

other

1.795

NOD2

other

1.767

SFTPD

other

-1.824

TSC2

other

-1.838

HOTAIR

other

-1.872

TOPBP1

other

-1.924

RBL2

other

-1.937

NREP

other

-1.954

SPINT2

other

-1.964

SLPI

other

-1.964

RBM5

other

-1.964

MGP

other

-1.982

BCL2L12

other

-2

SCGB3A2

other

-2

UBD

other

-2

FANCC

other

-2

CORT

other

-2
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PLIN5

other

-2.109

TNIP1

other

-2.195

PECAM1

other

-2.2

SELENOS

other

-2.2

TUG1

other

-2.224

ZNF106

other

-2.333

CIDEC

other

-2.36

INSIG2

other

-2.391

ANXA2

other

-2.425

1810019D21Rik

other

-2.5

GAS2L3

other

-2.63

Bvht

other

-2.668

FLCN

other

-2.711

Irgm1

other

-3.487

VCAN

other

-3.789

SOCS1

other

-4.111

RICTOR

other

-4.741

INSIG1

other

-4.746

USP22

peptidase

3.742

CFB

peptidase

2.789

F2

peptidase

2.766

SENP1

peptidase

2.607

PLG

peptidase

2.185

MBTPS1

peptidase

2

MMP1

peptidase

1.97

MMP2

peptidase

1.782

ADAM17

peptidase

1.762

PSEN1

peptidase

-1.818

USP18

peptidase

-1.982

ZMPSTE24

peptidase

-2.377

PSMB11

peptidase

-2.858

NCSTN

peptidase

-3.45

CLPP

peptidase

-5.648

PPP2CA

phosphatase

PDCD1

phosphatase

-1.89

PPP1R15B

phosphatase

-1.964

NT5E

phosphatase

-2

PON1

phosphatase

-2

PTPN6

phosphatase

-2.534

PTPN11

phosphatase

-2.559

166

2.236

Ptprd

phosphatase

PPARGC1A

transcription regulator

5.108

ATF4

transcription regulator

4.757

SREBF1

transcription regulator

4.571

CEBPA

transcription regulator

4.327

STAT1

transcription regulator

4.302

PPARGC1B

transcription regulator

4.052

CEBPB

transcription regulator

3.967

HIF1A

transcription regulator

3.892

MITF

transcription regulator

3.889

IRF3

transcription regulator

3.888

IFI16

transcription regulator

3.73

MED1

transcription regulator

3.723

IRF7

transcription regulator

3.65

JUN

transcription regulator

3.618

SREBF2

transcription regulator

3.545

NFKBIA

transcription regulator

3.531

FOXM1

transcription regulator

3.46

NFKB1

transcription regulator

3.412

MYC

transcription regulator

3.4

FOXO1

transcription regulator

3.362

RELA

transcription regulator

3.34

EGR1

transcription regulator

3.337

NFE2L2

transcription regulator

3.302

KLF15

transcription regulator

3.217

REL

transcription regulator

3.177

SPIB

transcription regulator

3.13

MTPN

transcription regulator

3.096

Esrra

transcription regulator

3.049

STAT3

transcription regulator

3.029

CREB1

transcription regulator

3.025

MLXIPL

transcription regulator

2.949

NCOA2

transcription regulator

2.91

GATA4

transcription regulator

2.899

CTNNB1

transcription regulator

2.811

STAT4

transcription regulator

2.75

ATF6

transcription regulator

2.687

SP3

transcription regulator

2.678

TP63

transcription regulator

2.624

YBX1

transcription regulator

2.621
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-2.646

NFYA

transcription regulator

2.598

SMYD1

transcription regulator

2.588

MLX

transcription regulator

2.577

IRF5

transcription regulator

2.558

EBF1

transcription regulator

2.554

E2F3

transcription regulator

2.534

TFAM

transcription regulator

2.53

CCND1

transcription regulator

2.497

DDIT3

transcription regulator

2.487

FOXF2

transcription regulator

2.434

IRF1

transcription regulator

2.389

STAT2

transcription regulator

2.386

ETS1

transcription regulator

2.375

ECSIT

transcription regulator

2.372

TFE3

transcription regulator

2.35

SP1

transcription regulator

2.281

XBP1

transcription regulator

2.273

IRF8

transcription regulator

2.258

HIRA

transcription regulator

2.236

FOS

transcription regulator

2.23

PLAGL1

transcription regulator

2.216

NRF1

transcription regulator

2.212

SPI1

transcription regulator

2.211

CARM1

transcription regulator

2.204

SRA1

transcription regulator

2.2

NCOA3

transcription regulator

2.197

TWIST2

transcription regulator

2.19

USF2

transcription regulator

2.18

ELK1

transcription regulator

2.16

HDAC5

transcription regulator

2.157

SMAD2

transcription regulator

2.149

ARNT2

transcription regulator

2.121

MEN1

transcription regulator

2.057

MYBL2

transcription regulator

1.998

PITX2

transcription regulator

1.997

FOXL2

transcription regulator

1.988

MED14

transcription regulator

1.987

CEBPE

transcription regulator

1.982

SIM1

transcription regulator

1.976

CRTC1

transcription regulator

1.969
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HUWE1

transcription regulator

PHF1

transcription regulator

1.96

VDR

transcription regulator

1.958

MAF

transcription regulator

1.951

WDR5

transcription regulator

1.944

HEY1

transcription regulator

1.941

HEY2

transcription regulator

1.94

ASCL1

transcription regulator

1.912

ELL2

transcription regulator

1.89

LHX1

transcription regulator

1.89

MAFB

transcription regulator

1.841

HNF4A

transcription regulator

1.837

HDAC4

transcription regulator

1.83

H2AX

transcription regulator

1.802

FOSL1

transcription regulator

1.786

KLF11

transcription regulator

1.777

HAND2

transcription regulator

1.765

MYCN

transcription regulator

1.763

NFAT5

transcription regulator

1.755

MDM4

transcription regulator

-1.763

CTCF

transcription regulator

-1.803

ID1

transcription regulator

-1.837

ASXL1

transcription regulator

-1.89

HOXA3

transcription regulator

-1.912

ZNF281

transcription regulator

-1.914

DNAJB6

transcription regulator

-1.945

ZBTB16

transcription regulator

-1.948

NOTCH4

transcription regulator

-1.951

MXI1

transcription regulator

-1.969

FHL2

transcription regulator

-1.976

MAML1

transcription regulator

-1.98

HOXA11

transcription regulator

-1.982

HAND1

transcription regulator

-1.982

MRTFB

transcription regulator

-1.985

PIAS1

transcription regulator

-1.986

Cux1

transcription regulator

-2

IKZF2

transcription regulator

-2

HES3

transcription regulator

-2

ONECUT1

transcription regulator

-2

HNF1B

transcription regulator

-2.034
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1.963

CBL

transcription regulator

-2.056

KDM5B

transcription regulator

-2.144

FOXA1

transcription regulator

-2.165

SERTAD2

transcription regulator

-2.177

FOXA3

transcription regulator

-2.202

CREBZF

transcription regulator

-2.207

SP110

transcription regulator

-2.309

TFAP2C

transcription regulator

-2.414

SRSF2

transcription regulator

-2.433

GLIS2

transcription regulator

-2.449

MED13

transcription regulator

-2.496

SMAD7

transcription regulator

-2.517

TAF4

transcription regulator

-2.6

MRTFA

transcription regulator

-2.689

SIRT1

transcription regulator

-2.728

NRIP1

transcription regulator

-2.853

TRPS1

transcription regulator

-2.874

RBL1

transcription regulator

-3.12

ZFP36

transcription regulator

-3.617

SRF

transcription regulator

-3.887

KDM5A

transcription regulator

-4.134

EIF2S1

translation regulator

3.302

EIF4E

translation regulator

2.89

RPL22

translation regulator

-2.425

CD28

transmembrane receptor

4.805

TLR7

transmembrane receptor

4.58

TLR3

transmembrane receptor

4.231

IFNAR1

transmembrane receptor

3.906

TLR4

transmembrane receptor

3.697

TLR9

transmembrane receptor

3.575

CD36

transmembrane receptor

2.575

CD40

transmembrane receptor

2.491

CD2

transmembrane receptor

2.449

PLA2R1

transmembrane receptor

2.415

OLR1

transmembrane receptor

2.396

TLR8

transmembrane receptor

2.191

SEMA7A

transmembrane receptor

2.121

LTBR

transmembrane receptor

2.121

EDNRA

transmembrane receptor

2

Klra7 (includes others)

transmembrane receptor

1.982
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IFNGR1

transmembrane receptor

1.982

ITGA5

transmembrane receptor

1.98

NCR2

transmembrane receptor

1.98

IL6R

transmembrane receptor

1.978

IL17RA

transmembrane receptor

1.964

ICOS

transmembrane receptor

1.944

LGR5

transmembrane receptor

1.937

CD14

transmembrane receptor

1.931

ITGA6

transmembrane receptor

1.925

TNFRSF9

transmembrane receptor

1.912

F3

transmembrane receptor

1.908

IGF1R

transmembrane receptor

1.892

IL11RA

transmembrane receptor

1.876

TYROBP

transmembrane receptor

1.782

NGFR

transmembrane receptor

-1.972

IL27RA

transmembrane receptor

-1.982

SFRP1

transmembrane receptor

-3

IL10RA

transmembrane receptor

-3.156

UCP1

transporter

4.317

Hbb-b1

transporter

3.881

HBA1/HBA2

transporter

3.207

SYVN1

transporter

3

ALB

transporter

2.621

SLC29A1

transporter

2.433

SLC5A5

transporter

2

BAX

transporter

1.961

FABP1

transporter

-1.89

SCARB1

transporter

-1.949

SLC30A7

transporter

-1.982

STAR

transporter

-2

HBB

transporter

-2

APOA1

transporter

-2.183

SFTPA1

transporter

-2.221

ABCC8

transporter

-2.224

ABCB4

transporter

-2.228

COMMD1

transporter

-2.449

TFRC

transporter

-2.478

APOE

transporter

-5.113
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Table 6. Candidate transcription regulators of LOX gene expression in HGPS. The
eight transcription regulators identified by IPA that are upstream of LOX and either
activated or inhibited in HGPS. The table also shows the basis for their exclusion using
the filters identified in Fig. 2.22B and the corresponding citations in the IPA database.

Transcription
Regulator
DDIT3

negative regulator of LOX (Engström et
al. 2006) but activated in HGPS

Fos

positive regulator of LOX (Johnston et
al. 2000) but inhibited in HGPS

Myc

negative regulator of LOX (O’Connell et
al. 2003) but activated in HGPS

TFAP2C

transcriptional activator of LOXL2 as
well as LOX (Bogachek et al. 2014)

FOXM1

transcriptional activator of LOXL2 as
well as LOX (Park et al. 2011)

HIF1A

transcriptional activator of LOXL2 as
well as LOX (Schietke et al. 2010; Elvidge
et al. 2006; Wang et al. 2005)

STAT3

effect on LOX is in coordination with
HIF-1A (Pawlus et al. 2014)

KLF11

inconsistent effects of KLF11 on LOX
gene expression (Mathison et al. 2013)
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3.1 Abstract
Children with Hutchinson-Gilford Progeria Syndrome (HGPS) suffer from multiple
cardiovascular pathologies due to the expression of progerin, a mutant form of the
nuclear envelope protein Lamin A. Progerin expression has a dramatic effect on arterial
smooth muscle cells (SMCs) and results in decreased viability and increased arterial
stiffness. However, very little is known about how progerin affects SMC contractility.
Here, we studied the LaminAG609G/G609G mouse model of HGPS and found reduced
arterial contractility at an early age that correlates with a decrease in smooth muscle
myosin heavy chain (SM-MHC) mRNA and protein expression. Traction force
microscopy on isolated SMCs from these mice revealed reduced force generation
compared to wild-type controls; this effect was phenocopied by depletion of SM-MHC in
WT SMCs and overcome by ectopic expression of SM-MHC in HGPS SMCs. Arterial
SM-MHC levels are also reduced with age in wild-type mice and humans, suggesting a
common defect in arterial contractility in HGPS and normal aging.
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3.2 Introduction
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare premature aging
disease. The “classical” form of HGPS is caused by a point mutation (c. 1824C>T;
pG608G) in the LMNA gene (Lamin A)(Gonzalo et al. 2016). This mutation causes the
expression of progerin, a mutant form of the nuclear envelope protein Lamin A that has a
50 amino acid deletion and retains a farnesylated C-terminus (Gonzalo et al. 2016;
Capell et al. 2007). Others have shown that progerin can alter nuclear lamina structure
to cause nuclear blebbing, altered nuclear import and export, and dynamic epigenetic
changes (Gonzalo et al. 2016; Kelley et al. 2011; Arancio et al. 2014; Dahl et al. 2006).
Children with HGPS begin to display clinical symptoms about two years after birth,
including loss of hair, thin and aged skin, and growth retardation – characteristics of
normally aged individuals (Gonzalo et al. 2016; Merideth et al. 2008). Cardiovascular
complications, including arterial fibrosis, generation of severe atherosclerotic lesions,
and the death of arterial smooth muscle cells (SMCs), are hallmarks of the disease, and
HGPS children typically die from heart attacks or strokes (Gerhard-Herman et al. 2011;
Olive et al. 2010; Stehbens et al. 2001; Brassard et al. 2016; Varga et al. 2006).
Vascular SMCs normally populate the medial layer of arteries, but at autopsy, HGPS
patients display very few medial SMCs, and their arteries are instead filled with a
collagen-dense matrix (Varga et al. 2006; Stehbens et al. 2001).
One of the main functions of vascular SMCs is to regulate blood flow to target
organs by modulating arterial tone and peripheral resistance. Vascular tone is regulated
by periodic contraction and dilation of the arteries (Brozovich et al. 2016). Similar to
186

other muscle cells, the major contractile components in SMCs consists of actin and
myosin (Webb 2003; Hathaway et al. 1991). However, a smooth muscle-specific myosin
heavy chain (SM-MHC, encoded by the Myh11 gene) and smooth muscle alpha-actin
(SMA, encoded by the Acta2 gene) exist in SMCs, and these play important roles in
SMC contractility (Martin et al. 2007; Lehman & Morgan 2012; Webb 2003; Hathaway et
al. 1991).
The Myh11 gene is alternatively spliced into four SM-MHC isoforms, and these
allow for the prolonged tonic contraction of SMCs (Babu et al. 2000). Additionally, SMCs
contain other cell-specific contractile proteins such as transgelin (gene Tagln), an actin
cross-linking protein, and calponin (gene Cnn1) that can regulate ATPase activity of
myosin in smooth muscle (Carmichael et al. 1994; Shanahan et al. 1993; Zhang et al.
2001). The inability to properly regulate vascular tone through contraction and dilation
may lead to impaired blood flow to target tissues (Brozovich et al. 2016; Reho et al.
2014).
As HGPS is a rare disease, animal models are used to understand the pathology
caused by progerin expression, especially when looking for early events that are not
amenable to analysis at autopsy. The LmnaG609G/G609G mouse model (hereafter referred
to as HGPS mice) has been commonly used since it contains the equivalent point
mutation seen in the classical HGPS human syndrome at the mouse Lmna locus (Osorio
et al. 2011). This mouse model recapitulates many of the cardiovascular complications
seen in the human syndrome including arterial fibrosis and stiffening as well as the
progressive loss of aortic SMCs as these mice approach the end of their lifespan (Osorio
et al. 2011; Murtada et al. 2020; del Campo et al. 2019). Studies in HGPS mice have
also observed decreased arterial vasoconstriction, although these studies were
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performed on arteries isolated from older HGPS mice (approx.100 and 140 days) that
had the expected loss of SMCs at 140 days (Murtada et al. 2020; del Campo et al.
2020). Thus, whether reduced arterial contractility is an early event in HGPS remains
unclear.
In this work, we analyzed arterial gene expression and contractility in young (2month) HPGS mice, before SMC loss is detectable (von Kleeck et al. 2021), with the
goal of identifying potentially causal events in HPGS pathogenesis. We found a reduced
abundance of SM-MHC mRNA and protein that was associated with impaired arterial
contraction in isolated HGPS carotid arteries and reduced force generation in isolated
HGPS SMCs. Moreover, RNAi-mediated downregulation of SM-MHC reduced traction
forces in WT SMCs while enforced expression of SM-MHC increased traction force in
HGPS SMCs. Interestingly, reduced SM-MHC abundance is also a characteristic of
normal arterial aging, both in WT mice and in humans. Impaired arterial SMC
contractility may be a common feature of premature and normal aging.
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3.3 Results
Reduced smooth muscle myosin heavy chain and contractility early in HGPS. To better
understand the effects of progerin expression on SMC function, I interrogated our recent
genome-wide transcriptome analysis of isolated descending aortas from 2-month-old WT
and HGPS mice (von Kleeck et al. 2021). I chose to focus on mice at 2-months of age
as, aside from stunted growth, these young mice do not show overt features of the
syndrome. In particular, the arteries of 2-month HGPS mice have yet to show SMC loss
or apoptosis (von Kleeck et al. 2021). KEGG pathway analysis (Kanehisa 2019) of the
differentially expressed genes in these HGPS vs. WT aortas indicated that several
pathways associated with contractility were altered early in HGPS including vascular
smooth muscle contraction, focal adhesions, and ECM-receptor interactions (Fig. 3.01a,
Fig. 3.02a-b).
To extend the results of the KEGG analysis, I performed RT-qPCR on 2-month
WT and HGPS aortas and evaluated the expression of several SMC contractile genes
(Fig. 3.01b). The mRNA level of Myh11, the gene encoding SM-MHC, was significantly
decreased while levels of other contractility-regulating genes (Acta2, Tagln, and Cnn1)
mRNA were not significantly altered (Fig. 3.01B). SM-MHC has multiple isoforms (Babu
et al. 2000; Martin et al. 2007), and I found that all the Myh11 mRNA isoforms present in
the aorta were decreased in HGPS (Fig. 3.01c). Additionally, immunoblotting (Fig. 3.01de) and immunostaining (Fig. 3.01f-g) of 2-month WT and HGPS aortas showed
decreased abundance of SM-MHC protein while SMA protein was minimally affected.
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I then expanded our analysis to the carotid artery and found similar results to
what we observed in the aorta: HGPS carotid arteries showed a preferential decrease in
the level of SM-MHC protein as determined by immunostaining (Fig. 3.03a-b) and a
decrease in Myh11 mRNA as determined by RT-qPCR (Fig. 3.03c). The reduced
expression of SM-MHC led us to reason that arterial contractility might be defective in
HGPS arteries, even at early ages when the number of arterial SMCs is still similar to
WT (von Kleeck et al. 2021). To test this hypothesis, we measured how 2-month WT and
HGPS carotid arteries respond to KCl, a canonical vasoconstrictor dependent on SMMHC for its effect (Hathaway et al. 1991). Contractility was measured on a pressure
myograph so that results could be obtained at physiological arterial pressure and
stretch(Ferruzzi et al. 2013; Amin et al. 2012). Indeed, carotid artery vasoconstriction to
KCl was reduced in HGPS (Fig. 3.03d), supporting the idea that decreased
vasoconstriction is an early event in HGPS and even precedes the loss of SMCs from
large arteries. As I have previously reported increased arterial stiffness at this timepoint,
I treated WT and HGPS mice with lysyl oxidase inhibitor β-aminopropionitrile at a dosing
regimen shown to reduce arterial stiffness (von Kleeck et al. 2021) and evaluated if
decreasing vessel stiffness restored contractility to HGPS carotids. The results showed
that reducing arterial stiffness had no significant effect on vessel contractility of HGPS
mice (Fig. 3.03e).
To get a general idea of when arterial SM-MHC is downregulated in HGPS, I
assessed Myh11 transcript levels in isolated aortas of 1-, 2-, and 3-month HGPS mice
(Fig. 3.04a). In comparison to 1-month HGPS aortas, Myh11 mRNA was significantly
downregulated in 2-month HGPS aortas and remained downregulated through 3months. Surprisingly, Acta2 transcript levels did not significantly change throughout the 1
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to 3-month period (Fig. 3.04a). I also evaluated Myh11 transcript levels in other SMCcontaining tissues and found that the downregulation of SM-MHC was specific to the
vascular smooth muscle cells of the aorta (Fig. 3.04b), as bladder and intestine did not
display a reduction in transcript levels.

Reduced SM-MHC is causal for traction force defects in HGPS SMCs. To determine if
the reduced arterial contractility observed in HGPS carotids was associated with
defective vascular SMC force generation, I isolated primary aortic SMCs from 2-month
WT and HGPS mice. First, we evaluated SM-MHC and SMA abundance in isolated
SMCs and observed a preferential reduction in SM-MHC levels in HGPS, consistent with
our observations in vivo (Fig. 3.05a-b). Although smooth muscle myosins are thought to
be the major force generating myosin in SMCs, non-muscle myosins IIA and IIB (NMII2A
and NMIIB) are also present and are believed to perform a house-keeping function
(Eddinger & Meer 2007). The abundance of these non-muscle myosins trended lower in
HGPS SMCs although not to the same extent as SM-MHC (Fig. 3.05a-b).
We next performed traction force microscopy on primary WT and HGPS SMCs.
HGPS SMCs presented with decreased cell area (Fig. 3.05c) and force generation
compared to WT (Fig. 3.05d-e; column 1 vs 2), suggesting an important role for SMMHC in contractility. We then assessed the contribution of non-muscle myosins to HGPS
cell force generation by treating WT and HGPS SMCs with blebbistatin, a myosinATPase inhibitor (Fig. 3.05d-e). We used a low concentration of blebbistatin expected to
inhibit non-muscle myosins but not SM-MHC (Limouze et al. 2004). This low dose
treatment decreased cell area and decreased traction force in HGPS SMCs to very low
levels (Fig. 3.05c-d; column 2 vs 4). Low dose blebbistatin treatment also reduced cell
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area and traction force in WT SMCs (Fig. 3.05c-d; columns 1 vs 3), but the remaining
traction force in WT SMCs remained much higher than in the blebbistatin-treated HGPS
cells, (Fig. 3.05d; columns 3 vs 4) as would be expected given the higher level of SMMHC in WT SMCs. Note that the magnitude of the blebbistatin effect on decreasing
mean traction force was similar in WT and HGPS SMCs (~70 and 75%, respectively)
despite their difference in SM-MHC abundance. This finding supports the notion that our
low dose blebbistatin treatment was preferentially targeting the non-muscle myosins and
not smooth muscle myosin as reported (Limouze et al. 2004) (also see Discussion). The
data in Fig. 3.05 therefore indicate that defective expression of SM-MHC in HGPS SMCs
correlates with reduced cell traction force and that HGPS SMCs maintain a basal level of
force generation through the action of non-muscle myosins.
As decreased cellular contractility is associated with changes to the actin
cytoskeleton, I evaluated stress fibers in WT and HGPS SMCs (Fig. 3.06a). However, I
found that average actin intensity across the cell as visualized by phalloidin stain was
not reduced and even slightly higher in HGPS SMCs (Fig. 3.06b). As progerin
expression is shown to disrupt nucleoskeletal connections (Chang et al. 2019; Booth et
al. 2015), I also evaluated actin intensity over the nucleus but saw no change in
comparison to WT SMCs (Fig. 3.06c). Thus, the basal amount of force generated by the
non-muscle myosins (see above), working together with the low amounts of SM-MHC,
appears sufficient to support the stress fiber formation seen in these cultured HGPS
SMCs, at least when the cells are cultured on a rigid substratum.
I then treated WT SMCs with two distinct siRNAs targeting Myh11 (Fig. 3.07a-b)
and found that each siRNA resulted in a significant reduction in cell area (Fig. 3.07c) and
a ~70% reduction in mean traction force (Fig. 3.07d-e), which was similar to the ~80%
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reduction we observed in HGPS SMCs as compared to WT (Fig. 3.05d; columns 1 vs.
2). Thus, deliberate reduction of SM-MHC in WT SMCs phenocopied the reduced
traction force seen in HGPS SMCs. Conversely, adenoviral enforced expression of SMMHC (Fig. 3.08a-b) increased cell area (Fig. 3.08c) and traction force in HGPS SMCs
(Fig. 3.08d-e). I do note that traction forces in the HPGS SMCs infected with adenoMyh11 were not quite increased to the levels seen in WT SMCs (see Discussion).
Interestingly, knockdown of Lmna did not reproduce the decreased Myh11 or Acta2
mRNA seen in HGPS (Fig. 3.09), indicating that the effect is likely due to progerin
expression rather than reduced Lmna levels. Nevertheless, the results collectively
indicate that defective SM-MHC expression in HGPS SMCs is causally related to the
defect in SMC force generation.

Reduced SM-MHC in aging aortas of WT mice and humans. Many parallels have been
drawn between HGPS and natural aging, especially in regard to age-associated
cardiovascular pathology (Brassard et al. 2016; Gonzalo et al. 2016; Olive et al. 2010).
As reduced arterial contractility has also been observed with age (Wheeler et al. 2015;
Seawright et al. 2018), I asked if this reduction in contractility was associated with a
preferential decrease in SM-MHC. Indeed, immunofluorescence staining of carotid artery
cross sections from 2- and 24-month WT mice revealed a decrease in SM-MHC staining
in the aged WT mice and a smaller difference in the levels of SMA (Fig. 3.10a-b), which
was associated in a decrease in carotid contractility in 24-month WT mice in response to
KCl (Fig. 3.10c). Moreover, I found a similar reduction in SM-MHC levels in ascending
aorta and aortic root sections from relatively young (age = 35-49 years) versus older
(age = 77-81 years) humans whereas SMA abundance was minimally changed (Fig.
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3.10d-e). Thus, reduced SM-MHC expression, and a consequent effect on arterial
contraction, may be a common event in both HGPS and the natural aging process.

3.4 Discussion
Medial SMCs play a major role in arterial vasoconstriction, which is essential for
regulation of vascular tone and blood flow to target tissues (Brozovich et al. 2016; Reho
et al. 2014). As SMC death is a hallmark of HGPS, it is not surprising that reduced
arterial contractility has been observed in late HGPS, when arteries are deficient in their
number of SMCs (Stehbens et al. 2001; Murtada et al. 2020; Osorio et al. 2011).
However, we show here that reduced contractility in HGPS begins before the onset of
many clinical phenotypes of the syndrome and prior to the loss of SMCs. Thus, reduced
vasoconstriction is one of the earliest cardiovascular defects in HGPS, at least in mice,
and not merely a secondary consequence of SMC death or increased arterial stiffness.
We also show that these young HGPS arteries are defective for expression of SM-MHC
and that arteries of aged WT mice and humans also display reduced SM-MHC
abundance. Additionally, this decrease in SM-MHC was specific to the vascular SMC
population as SMCs in bladder and intestinal tissue did not display the defect. Thus, the
defective expression of SM-MHC in the arteries of young HGPS mice foreshadows the
pathophysiology of normal arterial aging.
By using primary SMCs in culture, I was able to link the decreased abundance of
SM-MHC to decreased cell area and defective force generation. My initial experiments
used pharmacologic inhibition of myosin II with blebbistatin and were based on Limouze
et al. (Limouze et al. 2004), which demonstrated that the blebbistatin IC50 for smooth
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muscle myosins is >10-fold greater than that of the non-muscle myosins (80 versus 2-5
M). Thus, we reasoned that use of 15 M blebbistatin should be selective for the nonmuscle myosins, which are expressed at similar levels in both WT and HGPS SMCs.
Though the IC50 difference was smaller, a similar result has also been reported Zhang
et al. (Zhang et al. 2017). We acknowledge that both of these studies examined
blebbistatin effects on purified proteins and that the blebbistatin IC50's for different
myosins may differ in cells. Nevertheless, if 15 M blebbistatin were also inhibiting
smooth muscle myosin, one would not expect to see the similar effect of blebbistatin on
mean traction force that we observed in WT versus HGPS SMCs (given their large
difference in the amount of SM-MHC). The fact that treating HGPS SMCs with
blebbistatin further decreased traction force suggests that non-muscle myosins provide
basal force generation for HGPS SMCs. I postulate that the action of non-muscle
myosins is why cultured HGPS SMCs display no overt defects in stress fiber formation.
Further analysis used RNAi and ectopic expression to assess the effect of SMMHC on traction force. Reducing SM-MHC levels in WT SMCs with RNAi produced a
similar percent reduction in traction force as observed in HGPS SMCs. Additionally,
restoration of SM-MHC levels in HGPS through adenoviral overexpression partially
rescued SMC force generation. This incomplete effect could be due to a multifaceted
regulation of SMC contractility that relies on regulatory proteins and signaling pathways
aside from smooth muscle myosin and actin (Hathaway et al. 1991; Webb 2003).
Indeed, KEGG pathway (Kanehisa 2019) evaluation of our genome-wide transcriptome
analysis (GEO ascension number GSE165409) revealed slight decreases in genes such
as Myl9, the smooth muscle myosin regulatory light chain, and Mlck1, smooth muscle
myosin light chain kinase (Fig. 3.02b). Although not reduced to the extent of SM-MHC
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(Myh11), the combined contributions of other gene products such as these may be
required to restore WT levels of contractility to HGPS SMCs.
Even though we have reported decreased force generation in isolated SMCs,
arterial contractility at a tissue level can depend on multiple factors from the external
environment (Hathaway et al. 1991; Webb 2003). For example, the composition and
stiffness of the extracellular matrix can dictate the ability of smooth muscle to contract
(Ahmed & Warren 2018; Sazonova et al. 2015), and the arteries of HGPS mice are
much stiffer than WT (del Campo et al. 2019; Murtada et al. 2020; von Kleeck et al.
2021). However, reducing arterial stiffness through administration of BAPN did not
restore arterial contractility to HGPS arteries. Additionally, work done by del Campo et
al. (del Campo et al. 2020), albeit in older (14 weeks) HGPS mice, found that collagen
disruption by collagenase in aorta did not restore the contractile response of arteries in
response to KCl. Collectively, these findings suggest that although the ECM is stiffer in
HGPS arteries, it may not play as much of a role in regulating vasoconstriction as altered
SMC force generation. Additionally, arterial contractility in vivo relies on complex
signaling of agonist-receptor interactions (Webb 2003; Hathaway et al. 1991). It is
possible that in addition to reduced contractile machinery, cells in HGPS arteries are
producing altered amounts of circulating factors essential for regulating vasoconstriction
and vasodilation.
How progerin affects SM-MHC mRNA levels remains to be clearly defined.
Research suggests that incorporation of progerin into the nuclear lamina can change the
nuclear architecture, making nuclei stiffer and blebbed (Booth et al. 2015; Verstraeten et
al. 2008). This effect could potentially interfere with the nuclear translocation of
transcription factors essential for contractile gene transcription. Additionally, cell
196

contractility is tightly tied to mechanotransduction, or the sensing of the mechanical
properties of the microenvironment (Martino et al. 2018). As transmission of mechanical
stimuli from the microenvironment to the nucleus depends on the nuclear lamina and
LINC (linker of nucleoskeleton and cytoskeleton) complex (Martino et al. 2018), the
altered nuclear lamina in HGPS may impair mechanotransduction (Chang et al. 2019;
Booth et al. 2015).
Many phenotypic similarities exist between HGPS and normal aging, and it has
been reported that some aged tissues show low levels of progerin expression (Scaffidi &
Misteli 2006; Olive et al. 2010; McClintock et al. 2007; Rodriguez et al. 2009). We show
that SM-MHC levels are also decreased in aging mouse and human arteries. It remains
to be determined if the molecular mechanisms underlying reduced SM-MHC abundance
in HGPS and normal arterial aging are common or distinct. Nevertheless, if reduced
levels of SM-MHC leads to diminished arterial contraction and blood flow, then this
phenotype of defective SM-MHC mRNA and protein abundance in early HGPS may
provide important insight into complications arising from reduced blood flow in normal
aging (Dinenno et al. 1999; Dinenno et al. 2001).

3.5 Methods
Mice and artery isolations. For aging experiments, WT C57BL/6 mice were purchased
from Jackson Labs and aged up to 24-months. LMNAG609G/+ mice on the C57/BL6
background were generously provided Dr. Carlos Lopez-Otin (Universidad de Oviedo,
Oviedo, Spain)(Osorio et al. 2011). Mice were genotyped using the following primers:
Forward:

AAGGGGCTGGGAGGACAGAG;
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and

Reverse:

AGCATGCCATAGGGTGGAAGGA. Mice were fed a chow diet ad libitum. For
experiments including HGPS arteries or cells, WT littermate controls were obtained from
LMNAG609G/+ matings.
Unless noted otherwise, arteries were perfused with PBS in situ through the left
ventricle, the left and right carotids were isolated, and the descending aorta was isolated
from the end of the aortic arch to the diaphragm. The isolated arteries were cleaned of
excess fat and stored in RNAlater for RT-qPCR or genome-wide analysis, flash frozen
and stored at -80oC for protein analysis, or fixed in Prefer (Anatech #414) for embedding
and sectioning. Animal protocols were approved by the University of Pennsylvania
Institutional Animal Care and Use Committee, and animal experiments followed the
recommended ARRIVE guidelines. Experiments were performed on male mice unless
otherwise specified in the legends.

Human artery sections. Human aortic root or ascending aorta sections from both men
and women were obtained from patients undergoing aortic valve/root replacement
and/or ascending aortic repair/replacement at Columbia University Irving Medical Center
under IRB Protocol # AAAR6796 with informed consent from all subjects. Specimens
were fixed in 10% formalin for 24 h and embedded in paraffin. Cross sections (5-m)
were prepared. Two cohorts of samples (young and old) were generated based on age
(35-49 years and 77-81 years, respectively). Results from aortic root and ascending
aorta were combined for data analysis.

Genome-wide transcript analysis. Our previously described genome-wide analysis of
differentially expressed genes in 2-month WT versus HGPS mice(von Kleeck et al.
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2021) (GEO ascension number GSE165409) was subjected to KEGG pathway
analysis(Kanehisa 2019) using gprofiler (https://biit.cs.ut.ee/gprofiler/gost). The cutoffs
used were >0.5 log2 or <-0.5 log2 fold change and an adjusted p-value of < 0.0001.
Carotid artery contractility analysis. Carotid artery contractility was measured using a
DMT 114P pressure myograph. Dissected left carotid arteries were cleaned of excess
fat, secured at both ends to 380-µm diameter steel cannulas in the myograph chamber
using four silk sutures (Teleflex Medical, 104-S), and maintained in 5 ml of Hanks
Balanced Salt Solution with calcium. The closed system was checked for leaks by
pressurizing the vessel at 30 mm Hg using HBSS. The system was then returned to 0
mm Hg, and un-stretched vessel length (UVL) was determined as the minimum distance
between the cannulas where the artery was no longer bent.
Mounted vessels were preconditioned by stretching them axially to 1.15 times
their UVL at 40 mm Hg for 15 min and then 1.3 times their UVL at 60 mm Hg for 15
min. The preconditioned vessels were brought to their in-vivo stretch (IVS) based on the
values we recently reported(von Kleeck et al. 2021) and pressurized to 100 mm Hg.
Increasing concentrations of KCl (10-4 M to 10-1 M in Hanks Balanced Salt Solution with
calcium; 5 ml) were added to the vessel chamber sequentially at 10-min intervals or
once the constriction plateau had been reached. Each new KCl solution was added after
removing the prior KCl solution. Outer diameters were recorded in real time at each drug
concentration using an inline tracking camera (Imaging Source) and MYOVIEW
software.

Cell culture, viral infection, and RNAi. Primary mouse SMCs were isolated from the
descending aortas of 2-month WT and HGPS male mice and prepared by explant
culture as described(Cuff et al. 2001). SMCs were cultured in growth medium [1:1
Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F-12 supplemented with 2 mM L199

glutamine and 20 mM HEPES, pH7.4] with 20% FBS. Cells were passaged at near
confluence with trypsin/EDTA and used between passages 4-6. Near confluent,
asynchronous SMCs were infected with adenoviruses encoding LacZ (control) and
Myh11 (Vigene Biosciences VH802236). Adenoviruses were amplified using standard
procedures, added to WT or HGPS SMCs in growth medium at a MOI of 800, and
incubated overnight. The infected cells were washed and incubated for 72 h in fresh
growth medium before subsequent analysis.
siRNA-mediated knock down of SM-MHC in near-confluent WT SMCs was
performed

using

Lipofectamine

RNAiMAX

Transfection

Reagent

(Thermofisher

#13778100) in OPTI-MEM with two distinct siRNAs (Ambion s70252 and s70253) at a
final siRNA concentration of 150 nM. A non-specific siRNA (Ambion 4390843) was used
as control. After 4 h of siRNA transfection, cells were switched to fresh growth medium.
Protein or traction force analysis was performed 72 h after transfection.

Traction Force Microscopy (TFM). Polyacrylamide hydrogels with a Young’s modulus of
20-25 kPa were prepared as described(Shutova et al. 2017) with 0.2 µm diameter
fluorescent microspheres (F8810; Invitrogen, 1% vol/vol) added to the polyacrylamide
solution before polymerization. Hydrogels were coated with 10 µg/ml bovine fibronectin
(EMD-341631) as described(Klein et al. 2007). After three 10-min PBS washes,
hydrogels were incubated with cell growth medium for 30 min. Cells were sparsely
plated on the hydrogels (~1000 cells/cm2) and incubated for 24 h before imaging.
Fluorescence images of cells and embedded beads were captured at 20X magnification
using a Zeiss Axio Observer 7 inverted microscope with Zeiss Axiocam 503 color CCD
camera in an environmental chamber at 37oC and 5% CO2. The cells were visualized
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with Lysosensor Green DND-189 (Invitrogen L7535, 1:1000), added immediately before
imaging. Image sequences were taken for live cells and beads. A solution of 10% SDS
(Invitrogen; 5% of media volume) was then added to the culture medium and incubated
for 10 min before image sequences were taken a second time. Data analysis was
performed largely as described(Shutova et al. 2017) using freely available plug-ins for
ImageJ (Tseng et al.(Tseng et al. 2012); adapted from Dembo and Wang(Dembo &
Wang 1999)). For Fourier transform traction cytometry, the Poisson’s ratio of the
polyacrylamide gel was assumed to be 0.45 and a regularization parameter of 10−9 was
used. Traction force vector maps were analyzed using a custom script in MATLAB
(Mathworks) to determine mean traction stress generated by each cell and total force
exerted per cell. Cell area was determined from the corresponding images of green
fluorescence in ImageJ. For cells genetically modified with siRNA or adenoviral infection,
cells were transfected or infected as described above, incubated in fresh media for 48 h,
and plated on hydrogels for an additional 24 h before being imaged for TFM. For
blebbistatin treated cells, SMCs were incubated with 15 M blebbistatin or vehicle (an
equivalent dilution of DMSO) in growth media for 30 min prior to traction force
microscopy analysis. Results shown for the TFM experiments were accrued from 2-3
independent experiments. As variability in traction forces between experiments may
arise from batch-to-batch differences in hydrogels or primary SMCs, relevant controls
were included as reference in each experiment. Similarly, comparisons between
experiments were based on percent changes in mean traction force per cell rather than
changes in Newtons.
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RT-qPCR. Descending aortas or carotid arteries were isolated and cleaned from 2month WT and HGPS mice. Cleaned tissues were stored in RNAlater (Qiagen) at -80oC
for subsequent analysis. Total RNA was isolated with the RNeasy Fibrous Tissue Mini
Kit (Qiagen) according to manufacturer's instructions. For carotid analyses, left and right
carotids were combined for each mouse. For RT-qPCR of cultured SMCs, RNA was
extracted using TriZol reagent (Thermofisher 15596026) according to manufacturer’s
instructions. Reverse transcription reactions contained 200-500 ng of total RNA. Ten to
fifteen percent of the cDNA was subjected to RT-qPCR. Samples were run in technical
duplicates on an ABI Prism 7000 sequence detection system or ABI Quantstudio 3 with
the following primer-probe sets from ThermoFisher:. Tagln: Mm00441661_g1, Myh11:
Mm00443013_m1, Acta2: Mm00725412_s1, Cnn1: Mm00487032_m1. For the RTqPCR of Myh11 isoforms, custom primer-probe (FAM-labeled) sets were from
ThermoFisher: SM-A isoform: Forward CCACAAGGGCAAGAAAGACA, Reverse
TTCTTGACGGTTTTCGCATT, Probe CAGCATCACGGGGGAGCTG. SM-B isoform:
Forward GTGGCATCCTCCCACAAG, Reverse GGATTGGGTTTGCCTGTAGA, Probe
CGCAAGGTCCATCTTTTGCCTAC.

SM1

CTTCGCCCAAGTGACTTTTT,

AAGTGACCATGGGTGCAAAT,

Reverse

isoform:

Forward
Probe

AACACTGCTCCCAGAGCGAGC. SM2 isoform: Forward ACGCCCTCAAGAGCAAACT,
Reverse

GCCCTTCTGGAAGGAACAA,

Probe

CCCCACAGGAAACTTCGCAGT.

Samples from each mouse were accrued, and the final RT-qPCR reactions were
performed at one time. Results from each experiment were analyzed using the ddCt
method and normalized to the mean of the respective control.
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Immunoblotting. For tissue immunoblotting, isolated aortas were thawed, chopped into
small pieces and sonicated in lysis buffer (50 mM Tris-HCl pH 8, 250 mM NaCl, 2 mM
EDTA, 1% NP-40) containing protease inhibitors (Cell Signaling Technologies 5872S).
Lysates were centrifuged for 5 min (4oC, 15,000 x g). The supernatants were collected
and quantified with the Bio-Rad Protein Assay (Catalog #5000006) with a BSA standard.
Similar amounts (~25g) of each sample were diluted into SDS sample buffer (final
concentration of 50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 0.01% Bromophenol blue,
and 1% β-mercaptoethanol), fractionated on 7.5% SDS polyacrylamide gels, and
electrophoretically transferred to nitrocellulose.

For immunoblotting of cell lysates,

isolated WT and HGPS SMCs were plated at confluence in 60-mm culture dishes for 24
h. Cytoplasmic fractions were collected using NE-PER nuclear cytoplasmic extraction kit
(Thermo 79933). For cell experiments using siRNA transfection or adenoviral infection,
cells were lysed directly in SDS sample buffer after a 72-h incubation with the siRNA or
adenovirus.
Incubations with primary antibodies were performed overnight at 4oC with rocking
in TBST (Tris-buffered saline with 0.1% Tween 20) with 5% milk or 2% BSA. Incubation
with secondary antibodies were performed for 2 h at room temperature in the same
TBST buffer as the primary antibody. The antibodies used were non-muscle myosin 2A:
Abcam Ab55456 (1:2000), non-muscle myosin 2B: Cell Signaling 3404 (1:2000), smooth
muscle actin: Sigma F3777 (1:1000), smooth muscle myosin heavy chain: Protein Tech
21404-1-AP (1:300), glyceraldehyde-3-phosphate dehydrogenase (GAPDH): Invitrogen
MA5-15738 (1:500), focal adhesion kinase: BD Transduction labs 610088 (1:300), and
-tubulin: Santa Cruz SC-8035 (1:300). Bound antibodies were visualized by enhanced
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chemiluminescence. Blots were stripped and re-probed using Restore Western Blot
Stripping Buffer (Thermo 21059).
Immunoblots were quantified in ImageJ relative to one of three loading controls
(FAK, -tubulin, or GAPDH) depending upon the molecular masses of additional probed
proteins to minimize stripping and reprobing of blots; see Fig. 3.11 for validation of
loading controls. Immunoblot quantification normalized HGPS or Myh11 siRNA signal
intensities to the mean signal intensity of the respective WT control, which was set to 1.0
for each blot in order to combine data from multiple experiments. A Grubbs’ test was
used to justify exclusion of an outlier.

Tissue Immunostaining. For mouse tissue immunostaining, 2- or 24-month WT and 2month HGPS male mouse right carotid arteries or descending aortas were perfused with
PBS, excised, cleaned to remove excess fat, and fixed in Prefer (Anatech #414).
Carotids and aortas were embedded in paraffin, and 5-m cross sections were prepared.
Paraffin sections from mouse and human arteries were deparaffinized and hydrated
before antigen unmasking (Vector Labs, H3300) for 25 min at ~100oC). Carotid or aortic
cross sections were washed in PBS three times before blocking with 2% BSA in PBS for
15 min, incubated overnight at 4oC with antibodies directed to smooth muscle myosin
heavy chain (Protein Tech 21404-1-AP, diluted 1:200 in PBS) or smooth muscle actin
(FITC-conjugated; Sigma F3777, diluted 1:300 in PBS). Replicate sections were
incubated in parallel with isotype-matched control antibodies. All samples were washed
three time with PBS before incubation with a 1:100 dilution of Alexa 594-conjugated
isotype-matched secondary antibody (Invitrogen goat anti-rabbit A11012) for two h at
room temperature. Sections were then washed three times in PBS followed by addition
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of Dapi (1:500 dilution in PBS). Slides were briefly washed in PBS and then water before
mounting with SlowFade Gold (Thermo, S36936). Results were visualized with a Nikon
Eclipse 80i microscope with a QI-Click Qimaging camera. Carotid arteries were imaged
at 20x magnification and pseudo-colored green (SM-MHC) or red (SMA). Samples from
each mouse were accrued, and the final immunostainings were performed at one time.
Images were quantified using ImageJ. The media of each section was traced
using the polygon drawing tool, and its raw integrated density was divided by the area of
the outlined media to obtain relative fluorescence intensity. Background intensity, as
determined from the isotype-matched control antibodies, was negligible. Relative
fluorescence intensity values were plotted relative to the mean fluorescence intensity
value of the corresponding control for each experiment. A Grubbs’ test was used to
justify exclusion of an outlier.

Cell immunostaining. For cell immunostaining, SMCs were plated on 12mm coverslips
and incubated overnight before fixation with 3.7 % formaldehyde+ 1% Triton-X for
Paxillin and Phalloidin staining for 20 min. Following fixation, cells were incubated in
permeabilization buffer (0.4% Triton-X-100, 2% BSA, and 50 mM NH4Cl in PBS) for 2 h
at room temperature. Three quick PBS washes were performed followed before addition
of primary antibody to paxillin (BD Transduction Labs 610052, 1:50) diluted in blocking
buffer (0.3% Triton-X-100, 2% BSA in PBS) overnight at 4oC. Three 10 min PBS washes
were performed followed by the addition of secondary antibody (Invitrogen A21202) and
phalloidin stain (Invitrogen A12381, 1:100) for 2 h at room temperature. Coverslips were
washed three times in PBS and dipped in water before mounting with SlowFade Gold
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(Thermo, S36936). Results were visualized with a Nikon Eclipse 80i microscope with a
QI-Click Qimaging camera. Pictures were taken at 40x magnification.
Average phalloidin intensity in the cell and over the nucleus was calculated using
detailed methods published by Zonderland et al. (2019). Cell area measurement were
determined during traction force microscopy experiments as described below.

Statistical Analysis. Statistical analysis was conducted using Prism software (GraphPad)
with tests based on the method of data collection and quantification (see Supplemental
Methods). Statistical significance for immunostaining, TFM, AFM, and RT-qPCR was
determined using 2-tailed Mann-Whitney tests unless testing for significance in a
particular direction. Significance in immunoblot results was determined by Wilcoxon
signed rank test. Significance of the myography vasoconstriction experiments was
determined by two-way ANOVA, and statistical differences due to genotype are shown in
the figure.
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3.7 Figures

Figure 3.01. Reduced smooth muscle myosin heavy chain abundance in HGPS
aortas. (a) KEGG pathway analysis was performed on the differentially expressed
genes from 2-month WT versus HGPS descending aortas (n=6 per genotype). KEGG
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pathways with p-adjusted values < 0.05 are shown. (b) Descending aortas were isolated
from 2-month WT and HGPS mice (n=5-7 per genotype). SMC contractility gene
transcript levels were assessed by RT-qPCR and plotted relative to the WT control. (c)
Smooth muscle myosin heavy chain isoform transcript expression was assessed by RTqPCR in 2-month WT and HGPS descending aortas (n=7 per genotype) and plotted
relative to the WT control. (d) Representative images of SM-MHC and SMA protein
levels determined from 2-month WT and HGPS descending aortas by immunoblotting.
Focal Adhesion Kinase (FAK) is shown as the loading control. Black boxes around the
immunoblots indicate cropping for removal of extraneous space. (e) Quantification of
immunoblotting results normalized for loading and plotted relative to the WT control.
Results show mean ± SE (n=7 per genotype). (f) Representative images of 2-month WT
(n=7) and HGPS (n=9) descending aorta cross sections immunostained for SM-MHC
and SMA; scale bar=50 m. (g) Quantification of aortic immunostaining with results
plotted relative to the WT controls. Results in b, c and g are shown as box plots with
Tukey whiskers. Significance in panels b, c and g was determined by Mann-Whitney
tests. Significance in panel e was determined by Wilcoxon signed rank test.
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Figure 3.02. Additional analysis of genome-wide transcriptome profiling. (a)
Volcano plot displaying differentially expressed genes from genome wide transcriptome
analysis of 2-month WT and HGPS aortas (n=6 per genotype). Red dots display genes
that met the cutoffs of >0.5 log2 or <-0.5 log2 fold change and an adjusted p-value of <
0.0001. (b) Genes within the cutoffs were subjected to KEGG pathway analysis (see Fig.
3.01a), and log2 fold change values for genes within the vascular smooth muscle
(VSMC) contractility pathway are shown.

210

Figure 3.03. Reduced smooth muscle myosin heavy chain and decreased
contractility in HGPS carotid arteries. (a) Representative images of 2-month WT
(n=10) and HGPS (n=7) carotid artery cross sections immunostained for SM-MHC and
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SMA; scale bar=50 m. (b) Quantification of carotid artery immunostaining with results
plotted relative to the WT controls. (c) Carotid arteries from 2-month WT and HGPS
mice (n=6 per genotype) were isolated, and Myh11 and Acta2 mRNA transcript levels
were determined by RT-qPCR. Results are plotted relative to the WT controls. Results in
b and c are plotted as box plots with Tukey whiskers, and significance was determined
by Mann-Whitney tests. (d) Mixed sex 2-month WT (n=7) and HGPS (n=5) carotid
arteries were mounted on a pressure myograph and pressurized to 90 mm Hg. Percent
vasoconstriction was measured in response to increasing concentrations of KCl.
Significance in panel d was determined by two-way ANOVA, and results show mean ±
SD. (e) WT and HGPS mice were subjected to daily PBS (WT n=6; HGPS n=7) or BAPN
(WT n=4; HGPS n=6) injections starting at ~1-month of age (see Ch. 2 methods).
Injections were continued until ~2-months of age and carotid arteries were isolated and
subjected to vasoconstriction analysis as described in panel d. Plot shows mean ± SE,
and significant was determined by 2-way ANOVA evaluating changes between treatment
groups. Significance between WT PBS and HGPS BAPN mice are reported in the figure.
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Figure 3.04. Myh11 transcript decreases over time in HGPS Aorta. (a) Descending
aortas were isolated from 1-month, 2-month, and 3-month WT and HGPS mice and
Myh11 and Acta2 transcript levels were evaluated by RT-qPCR (n=4 per genotype).
HGPS transcript levels were normalized to respective age-matched WT levels (WT
represented by dashed white line). Plots show mean fold change ± SE. Significance
determined by ANOVA with Dunnett post-tests comparing each point to its respective
levels in the 1-month HGPS aorta. (b) Myh11 transcript levels were evaluated in
intestine (n=5 per genotype) and bladder (n=3 per genotype) by RT-qPCR in 2-month
WT and HGPS mice. HGPS transcript levels were normalized to WT. Results show
mean ± SE. Statistical significance determined by Mann-Whitney.
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Figure 3.05. Decreased myosin abundance and traction force in isolated HGPS
aortic vascular smooth muscle cells. (a) Representative images of cytosolic lysates
from cultured SMCs immunoblotted for SM-MHC, non-muscle myosin II A and B (NMIIA
and NMIIB, respectively), and SMA. GAPDH is shown as the loading control. Black
boxes around the immunoblots indicate cropping for removal of extraneous space. Blots
were stripped and re-probed when evaluating the abundance of multiple myosins and
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SMA. (b) Quantification of immunoblotting results normalized for loading and plotted
relative to the WT control. Results show mean ± SE (n=5-7). Significance was
determined by Wilcoxon signed rank test. (c-e) Cultured SMCs were incubated on
polyacrylamide hydrogels for 24 h. Cells were treated with vehicle (DMSO) or 15 M
blebbistatin (BBI) for 30 min prior to traction force analysis. (c) Cell area and (d) total
traction force plots (n=37-57 cells) are shown, and each dot represents the total traction
force of a single cell. Significance was determined by Mann-Whitney tests, and results
are displayed as scatter plots. (e) Representative traction force images of cells analyzed
in panel d. Cell areas are outlined in white, and traction force scale bars (in
nanonewtons) are displayed to the right of each respective image. Optical scale bar=50
m.
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Figure 3.06. WT and HGPS SMCs display similar F-Actin. (a) WT and HGPS primary
SMCs cultured on glass coverslips were stained with phalloidin to visualize F-actin.
Scale bar 50 μm. (b) Average actin intensity across the cell and (c) Actin intensity over
the nucleus was quantified. Data in panels B-C are accrued from 2 individual
experiments quantifying 10-12 cells per genotype per experiment. Statistical testing was
done by Mann-Whitney test.

216

Figure 3.07. Knock down of SM-MHC reduces force generation in WT SMCs. Aortic
SMCS isolated from 2-month WT mice were incubated with a control siRNA (siCtrl) or
two distinct siRNAs targeting Myh11. (a) Representative images of lysates from the
transfected cells immunoblotted for SM-MHC and GAPDH (loading control). Black boxes
around the immunoblots indicate cropping for the removal of extraneous space. (b)
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Quantification of immunoblotting results normalized for loading and plotted relative to the
siCtrl control. Results show mean ± SE (n=4-5). Significance was determined by
Wilcoxon signed rank test. (c) Cell area and (d) total traction force plots of siCtrl- or
siMyh11-treated SMCs (n=63-69 cells). Each dot represents the total traction force of a
single cell. Significance was determined by Mann-Whitney tests. (e) Representative
traction force images of cells analyzed in panel d. Cell areas are outlined in white, and
traction force scale bars (in nanonewtons) is displayed to the right of each respective
image. Optical scale bar=50 m.
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Figure 3.08. Smooth muscle myosin heavy chain overexpression restores
contractility in isolated HGPS smooth muscle cells. Aortic SMCs isolated from 2month WT and HGPS mice were incubated with adenovirus encoding LacZ (control) or
Myh11 for 72 h. (a) Representative images of lysates from the infected cells
immunoblotted for SM-MHC and GAPDH (loading control). Black boxes around the
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immunoblots indicate cropping for the removal of extraneous space. (b) Quantification of
immunoblotting results normalized for loading and plotted relative to the WT LacZ
control. Results show mean ± SE (n=6). Significance was determined by Wilcoxon
signed rank test. (c) Cell area and (d) total traction force plots of primary WT and HGPS
aortic SMCs incubated with an adenovirus encoding LacZ or Myh11 (n=47-65 cells).
Each dot represents the total traction force of a single cell. Significance was determined
by Mann-Whitney tests. (e) Representative traction force images of cells analyzed in
panel d. Cell areas are outlined in white, and traction force scale bars (in nanonewtons)
are displayed to the right of each respective image. Optical scale bar=50 m.
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Figure 3.09. Acute LMNA knockdown does not reduce smooth muscle myosin
heavy chain or smooth muscle actin mRNA. LMNA mRNA was knocked-down in WT
SMCs using two distinct siRNAs as previously described in Figure 2.24, and transcript
levels of Lmna, Myh11, and Acta2 were analyzed by RT-qPCR and normalized to the
Ctrl siRNA treatment (n=3). Statistical significance was determined by two-way ANOVA
with Holm-Sidak post-tests.
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Figure 3.10. Decreased smooth muscle myosin heavy chain in aged mouse and
human arteries. (a) Representative images of 2-month (n=7) and 24-month (n=9-10)
WT mice carotid artery cross sections immunostained for SM-MHC and SMA; scale
bar=50 m. (b) Quantification of carotid artery immunostaining with results plotted
relative to the WT controls. (c) Mixed sex 2-month WT (n=7, reproduced from Fig. 3.03d)
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and 24-month WT (n=6) carotid arteries were mounted on a pressure myograph and
pressurized to 90 mm Hg. Percent vasoconstriction was measured in response to
increasing concentrations of KCl. Significance in panel c was determined by two-way
ANOVA, and results show mean ± SD. (d) Representative images of human ascending
aorta and aortic root cross sections of young (35-49 years, n=6-7) and old (77-81 years,
n=7) immunostained for SM-MHC and SMA; scale bar=200 m. (e) Quantification of
immunostaining of ascending aorta and aortic root sections with results plotted relative
to the young cohort. Results in b and e show box plots with Tukey whiskers. Significance
was determined by 1-tail Mann-Whitney tests.
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Figure 3.11. Validation of loading controls. WT and HGPS SMC lysates were
immunoblotted for SM-MHC and three loading controls; Focal Adhesion Kinase (FAK),
−Tubulin, and GAPDH. Results are representative of several independent experiments
probing for multiple loading controls.
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Chapter 4: Direct effects of progerin
on smooth muscle cell contractility
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4.1 Introduction
Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare premature aging
disease that affects around 1 in 4-8 million births (Sinha et al. 2014). At around a year
after birth, HGPS children present with progressive clinical signs of aging such as loss of
hair, thinning of the skin, stiff joints, and severely stunted growth (Saxena & Kumar
2020). HGPS is also characterized by arterial dysfunction including a dramatic loss of
smooth muscle cells (SMCs) from the large arteries, a severely fibrotic arterial
environment, and prominent atherosclerotic lesions (Merideth et al. 2008; Saxena &
Kumar 2020). Ultimately, HGPS children die in their early teen years due to heart attack
and stroke.
The classical form of HGPS is a result of a single nucleotide point mutation to the
Lamin A gene, leading to altered splicing and production of a mutant form of Lamin A
termed progerin (De Sandre-Giovannoli et al. 2003; Eriksson et al. 2003; Goldman et al.
2004). Compared to normal Lamin A, progerin lacks 50 amino acids near the C-terminus
and remains permanently farnesylated, which leads to improper incorporation into the
inner nuclear membrane and formation of an altered nuclear lamina network (Hamczyk
et al. 2018; Saxena & Kumar 2020).
Lamin A, one of the major elements of the nuclear lamina, is a critical component
for mechanotransduction signaling. Mechanical feedback such as

actomyosin

contraction from the cytoskeleton is transmitted to the nucleus through the Linker of
Nucleoskeleton and Cytoskeleton (LINC) complex. The LINC complex connects to the
actin cytoskeleton and intermediate filaments through Nesprin proteins which cross the
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outer nuclear membrane. Nesprins connect to SUN proteins in the nuclear envelope,
and SUN proteins connect to the nuclear lamina meshwork on the inner nuclear
membrane (Dahl et al. 2008; Dahl & Kalinowski 2011; Crisp et al. 2006; Martino et al.
2018). The disrupted nuclear lamina due to the presence of progerin has been
associated with altered mechanotransduction (Dahl et al. 2006; Verstraeten et al. 2008;
Chen et al. 2014). The SMC population is constantly responding to mechanical stimuli,
whether it be feedback from the stiffness of the extracellular matrix (ECM), or the cyclic
stretching of the arteries due to blood flow from the heart. In particular, Kim et al. (2018)
showed that progerin-expressing SMCs showed increased cell death in response to
repetitive biaxial stretching, and forced disruption of the LINC complex reduced SMC
death in vivo (Kim et al. 2018).
SMCs comprise the media layer of the large elastic arteries where they regulate
blood flow by tonic vasoconstriction or dilation (Webb 2003; Hathaway et al. 1991).
SMCs can undergo phenotypic modulation, existing along a spectrum from a
differentiated “contractile state” to a more dedifferentiated “synthetic state” (Owens et al.
2004; Davis-Dusenbery et al. 2011). Contractile SMCs have high expression of smooth
muscle contractile machinery, such as smooth muscle myosins, smooth muscle actin,
calponin, and transgelin. Upon stimuli such as arterial injury, SMCs can dedifferentiate to
a more synthetic state where they downregulate expression of key contractile genes and
become migratory, proliferative, and remodel the ECM to promote wound healing (Hao
et al. 2003; Owens et al. 2004; Rensen et al. 2007a). However, in some diseases such
as atherosclerosis, phenotypic switching can lead to an aberrant population of synthetic
SMCs, leading to arterial stenosis (Hao et al. 2003; Grootaert & Bennett 2021).
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Phenotypic switching is regulated in part by mechanotransduction in SMCs.
Mechanical strain increased accumulation of ECM proteins and produced a proliferative
response in SMCs (Lee et al. 2001; Wang et al. 2018). In other work, hypertensive
pressure stimulated phenotypic switching to a more synthetic state, altering actin
organization and cell structure (Onoue et al. 2008; Sit et al. 2020). Our lab has recently
reported that ECM stiffness promotes emergence of both contractile and synthetic SMCs
from a "null" precursor population that possesses neither contractile nor synthetic
characteristics; this emergence is regulated by stiffness-stimulated activation of Rac and
Rho GTPases (Talwar et al. 2021). Taken together, these studies suggest that disrupted
mechanotransduction, as observed in HGPS SMCs, may lead to altered SMC gene
expression and disrupted modulation of phenotypic state. Interestingly, I previously
reported that HGPS SMCs display defective force generation and present with downregulation of SMC contractility markers, in particular SM-MHC (see Chapter 3).

As

reduced contractility is a key hallmark of a more synthetic SMC, my results raise the
possibility that HGPS SMCs exist in an altered phenotypic state.
The phenotypic state of SMCs is largely regulated by cis-acting elements in DNA
termed CArG boxes (CC(AT)6GG) in the promoters of contractile genes, which allow
binding of Serum Response Factor (SRF) and myocardin-related transcription factors
(MRTFs) to promote contractile gene expression (Kim et al. 1997; Li et al. 1996; Mack &
Owens 1999). Transcriptional repressors, such as Kruppel like factor 4 (KLF4), or
activators, such as MRTF-A, also known as MKL1/MAL, are critical for balancing
phenotypic state. Indeed, studies show that MRTF-A can induce contractile gene
expression and promote SMC differentiation as a transcriptional activator of SRF (Jeon
et al. 2008; Du et al. 2004). Interestingly, MRTF-A localization is mechanosensitive. In
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unstimulated cells, MRTF-A is sequestered in the cytoplasm through binding to G-Actin
through its RPEL motifs which flank a nuclear localization signal (Guettler et al. 2008).
Upon actin polymerization, the G-actin pool is depleted, and the exposed nuclear
localization signal allows MRTF-A to enter the nucleus and modulate gene expression.
Ho et al. (2013) showed that Lamin A-deficient fibroblasts had decreased actin
polymerization and consequently reduced nuclear import of MRTF-A (Ho et al. 2013).
Surprisingly, they corelated defective MRTF-A signaling with altered localization of
emerin, an inner-nuclear membrane protein that caps the pointed end of actin filaments
and promotes actin polymerization in vitro. Interestingly, Osmanagic-Myers et al. (2018)
have shown that progerin expression in endothelial cells also mislocalizes emerin
protein, and MRTF-A is sequestered at the nuclear periphery (Osmanagic-Myers et al.
2018). Oddly, this sequestration was associated with increased MRTF-A gene
transcription.
In this chapter, I show that acute progerin expression in WT SMCs recapitulates
the decreased SM-MHC but not the increased LOX or decreased miR-145 abundance
observed in HGPS. I provide preliminary evidence indicating HGPS SMCs from the
widely used LMNAG609G/G609G HGPS mouse model (Osorio et al. 2011) present with
decreased MRTF-A nuclear localization and that this defect can be recapitulated by
ectopic expression of progerin in WT SMCs. Furthermore, I show that knockdown of
MRTF-A decreases contractile gene expression in WT SMCs and discuss the similarities
and differences between the MRTF-A-dependent contractile gene profile and that of
HGPS SMCs. These findings suggest that altered nuclear localization of MRTF-A in
HGPS SMCs could contribute to the decline in contractile function observed in isolated
HGPS cells and arteries and that progerin may be promoting a more synthetic-like state
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in HGPS SMCs. However, additional complimentary and follow-up experiments are
needed to support this hypothesis and are expanded upon in the Discussion section.

4.2 Results
Acute Progerin expression reduces SMMHC and traction force in WT SMCs. As
previous experiments displaying reduced SM-MHC, reduced force generation, and
increased LOX abundance (reported in Chapters 2 and 3) were conducted in HGPS
SMCs which have chronic progerin expression, I wanted to determine whether acute
progerin expression in WT SMCs would recapitulate our observations. Overexpression
of GFP-tagged progerin in WT SMCs did not recapitulate the decreased miR-145 and
increased LOX abundance observed in HGPS SMCs (Fig. 4.01a-b). However, acute
progerin expression did selectively reduce SM-MHC protein and Myh11 mRNA levels in
comparison to SMA protein and Acta2 mRNA (Fig. 4.01c-e). This reduction in SM-MHC
was accompanied by a reduction in cell area and decreased traction force in progerin
overexpressing cells (Fig. 4.01f-h).

HGPS aorta display a reduced MRTF-A target-gene signature. I postulated that the
reduced force generation and contractile gene expression of HGPS SMCs may be due
to HGPS SMCs existing in a more synthetic state. I interrogated our transcriptome-wide
analysis of WT and HGPS aortas for significantly altered contractile and synthetic
markers (Rensen et al. 2007b; Owens et al. 2004; Beamish et al. 2010; Long et al. 2008;
Miano 2003; Rzucidlo et al. 2007) and found that key contractile SMC markers were
downregulated (Fig. 4.02a, green) while synthetic SMC markers tended to be
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upregulated (Fig. 4.02a, red). Canonical regulation of contractile gene expression in
SMCs relies on the delicate balance of transcriptional activators, such as MRTF-A, or
repressors, such as KLF4, to modulate SRF activity (Fig. 4.02b). I used Ingenuity
Pathway Analysis (IPA) on our previously reported genome-wide sequencing of 2-month
WT and HGPS aorta (von Kleeck et al. 2021) to predict activation or inhibition of
upstream regulators of genes associated with SMC differentiation.

This analysis

identified MRTF-A and KLF4 based upon enriched target gene sets from nearly 4,000
differentially expressed genes. IPA predicted a slightly reduced target gene signature for
KLF4, which would not explain the decreased contractile gene expression I observed in
HGPS aortas (Fig. 4.02c, also see Chapter 3). In contrast, the MRTF-A target-gene
signature, and consequently SRF signature, was highly reduced (Fig. 4.02c). As many
SMC contractile genes are regulated by MRTF-A (see Introduction), this finding was
consistent with the idea that reduced MRTF-A signaling could account for the decreased
force generation observed in HGPS SMCs (Chapter 3).

Reduced nuclear-cytoplasmic ratios of MRTF-A in HGPS SMCs. MRTF-A protein levels
were similar in lysates of 2-month WT and HGPS aorta (Fig. 4.03a-b), consistent with
many studies showing that MRTF-A activity is regulated by cytoplasmic-nuclear
translocation (see Introduction). Indeed, I observed that isolated HGPS SMCs had a
significantly reduced nuclear-cytoplasmic ratio of MRTF-A as compared to WT controls
(Fig. 4.03c-d).

To determine if reduced nuclear MRTF-A in HGPS was a direct

consequence of progerin, I expressed GFP-tagged progerin in WT SMCs and observed
MRTF-A distribution. I saw that progerin-expressing cells (Fig. 4.03e, white arrows),
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displayed more diffuse MRTF-A in comparison to cells lacking progerin or WT SMCs
cells expressing GFP.

MRTF-A knockdown reduces contractile gene expression. MRTF-A is a positive
regulator of many contractile genes expressed in SMCs and one report indicates that it
also regulates LOX levels in mammary epithelial cells (Gurbuz et al. 2014). I used
siRNA-mediated knockdown of MRTF-A in primary WT SMCs to determine if reduced
MRTF-A would recapitulate the increased Lox and preferential reduction in Myh11
transcript levels seen in HGPS SMCs. As opposed to Gurbuz et al. (2014), I found that
knockdown of MRTF-A did not change Lox or miR-145 transcript levels (Fig. 4.04a) to a
similar extent of what was observed in HGPS SMCs (Fig. 4.04b). Intriguingly, I have
noted that HGPS aorta display a more selective reduction in smooth muscle myosin
heavy chain (SM-MHC, gene Myh11) as opposed to other contractile genes such as
alpha-smooth muscle actin (SMA, gene Acta2), calponin (gene Cnn1), or transgelin
(gene Tagln). I found that knockdown of MRTF-A by three separate siRNAs did produce
a more pronounced reduction in Myh11 transcript than Acta2 (although both transcripts
were significantly reduced, Fig. 4.04c), similar to what was observed in HGPS SMCs
(Fig. 4.04d). However, MRTF-A knockdown also produced a pronounced decrease in
Cnn1 which was not observed in HGPS aorta (Fig. 4.04e).

4.3 Discussion
In this work in progress, I show that the acute progerin expression recapitulates
the decrease in SM-MHC observed in HGPS but progerin does not have a direct effect
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on the miR-145-LOX pathway. Furthermore, a bioinformatically-predicted decrease in
MRTF-A signaling in vivo correlates with a decrease in nuclear-cytoplasmic abundance
of MRTF-A in isolated HGPS SMCs. Acute progerin expression in WT SMCs
recapitulates the altered nuclear localization of MRTF-A seen in HGPS SMCs.
Additionally, knockdown of MRTF-A decreased contractile gene expression in WT
SMCs, albeit MRTF-A knockdown appears to reduce many contractile genes in addition
to Myh11. More studies will be needed to compare the contractile gene profile in MRTFA knockdown cells and HGPS SMCs. Moreover, direct DNA-binding studies through
chromatin immunoprecipitation will be needed to confirm that this decreased nuclear
abundance correlates with reduced MRTF-A association with SRF promoter elements of
these contractility genes.
Intriguingly, acute expression of progerin revealed that the altered miR-145-LOX
signaling in HGPS is not a direct effect of progerin. This suggests that cell-extrinsic
factors contribute to the high LOX expression observed in HGPS arteries. As
composition of the extracellular matrix can have direct effects on gene expression and
cell signaling, it may be that altered matrix deposition by HGPS SMCs is driving the
decreased miR-145 and consequent increase in LOX expression. Alternatively, it may be
that increased LOX abundance is a consequence of long-term rather than acute progerin
expression, and a time course to understand how gene expression changes with
extended progerin expression in WT SMCs will aid our understanding. However, acute
progerin expression did have a direct effect on reducing SM-MHC abundance and
decreasing traction force in HGPS SMCs. Follow-up studies to understand how progerin
may be altering the epigenetic landscape of SMCs will help to determine why progerin
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has a more selective effect on decreasing SM-MHC as opposed to other contractile
genes.
Future experiments will determine how progerin is causing altered nuclear
MRTF-A localization. HGPS cells expressing a MRTF-A construct lacking RPEL actinbinding motifs could be used to determine if the altered nuclear localization of MRTF-A is
due to altered actin dynamics or due to defective nuclear import independent of actin.
Intriguingly, both altered actin dynamics such as altered nuclear F-actin formation
(Takahashi et al. 2020; Mu et al. 2020) and deregulated nuclear import (Kelley et al.
2011) have been reported in HGPS fibroblasts. I have previously reported that HGPS
SMCs show no overt changes in stress fiber abundance or organization as visualized
with phalloidin stain (see Chapter 3). However, fluorescence recovery after
photobleaching (FRAP) experiments to study actin polymerization dynamics in HGPS
SMCs could be useful in determining if HGPS SMCs have lowered actin polymerization
rates, which may explain the reduced nuclear MRTF-A. Further experimentation to
examine emerin localization could be used to determine if HGPS SMCs also present
with altered emerin distribution as previously reported in HGPS endothelial cells and
Lamin A knockout fibroblasts (Ho et al. 2013; Osmanagic-Myers et al. 2018). Better
understanding MRTF-A localization could highlight the similarities between how progerin
alters signaling in multiple cell types.
Increased ECM production and decreased contractility are observed in HGPS
mouse arteries and cells (del Campo et al. 2019; del Campo et al. 2020; Chapter 2-3).
Thus, I hypothesize that HGPS SMCs exist in a more dedifferentiated, synthetic state.
This idea is further supported by a more synthetic like gene profile from unbiased
transcriptome-wide analysis of HGPS aortas and my observation of reduced size of
241

HGPS SMCs, as dedifferentiated SMCs are smaller than differentiated ones (Talwar et
al. 2021, Chapter 3). My observations support the idea that progerin expression may be
promoting a more synthetic-like gene program in HGPS SMCs in part through altering
MRTF-A nuclear localization. Intriguingly, knockdown of MRTF-A produced a significant
reduction in all contractile genes analyzed (Myh11, Acta2, Cnn1, Tagln), albeit to
different extents. However, in HGPS arteries I observed a much more striking decrease
in Myh11 than other contractile genes (see chapter 3). It would be worthwhile to survey a
larger array of contractile genes in both HGPS SMCs and in MRTF-A knockdown SMCs
to get a better understanding of potential overlaps in the contractile gene signatures. It
could be that additional altered signaling pathways complement the effect of reduced
MRTF-A translocation to generate the selective profile of contractile gene expression
seen in HGPS.
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4.4 Methods
Mice and artery isolation. LMNAG609G/+ mice on the C57/BL6 background were
generously provided Dr. Carlos Lopez-Otin (Universidad de Oviedo, Oviedo, Spain).
Mice

were

genotyped

using

the

following

primers:

Forward:

AAGGGGCTGGGAGGACAGAG; and Reverse: AGCATGCCATAGGGTGGAAGGA,
with band sizes of 100bp for WT and 240bp for LMNAG609G. Mice were fed a chow diet
ad libitum. For HGPS mouse experiments, WT littermate controls were obtained from
LMNAG609G/+ matings. Arteries were perfused with PBS in situ through the left ventricle,
and the descending aorta was isolated from the end of the aortic arch to the diaphragm.
The isolated aorta was cleaned of excess fat and flash frozen and stored at -80C for
protein analysis. Animal protocols were approved by the University of Pennsylvania
Institutional Animal Care and Use Committee.

Genome-wide transcript analysis. I used our previously described genome-wide analysis
of differentially expressed genes in 2-month WT versus HGPS mouse aortas to
interrogate pathway activation or inhibition (von Kleeck et al. 2021) (GEO ascension
number GSE165409). Differentially expressed genes having a 1.5x fold change and
adjusted p-values of <0.001 were subjected to a core analysis with Ingenuity Pathway
Analysis (IPA). Default settings were used for all other core analysis parameters. The
core analysis included the prioritization of upstream regulators based on enrichment of a
regulator’s target gene set in the set of differentially expressed genes. For each
regulator, IPA tested the directionality of each of the genes in the overlap to infer an
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activation or inactivation of the regulator (Z-score). We defined putative upstream
regulators of DEGs as those having Z-scores >1.75 (activated) or <-1.75 (inhibited).

Cell culture and RNAi. Primary mouse SMCs were isolated from the descending aortas
of 2-month WT and HGPS male mice and prepared by explant culture as described (Cuff
et al. 2001). SMCs were cultured in growth medium [1:1] Dulbecco’s modified Eagle’s
medium (DMEM)/Ham’s F-12 supplemented with 2 mM L-glutamine and 20 mM HEPES,
pH7.4] with 20% FBS. Cells were passaged at near confluence with trypsin/EDTA and
used between passages 4-6.
siRNA-mediated knock-down of MRTF-A in near-confluent WT SMCs was
performed

using

Lipofectamine

RNAiMAX

Transfection

Reagent

(Thermofisher

#13778100) in OPTI-MEM with a final siRNA concentration of 300 nM (Origene 223701).
A non-specific siRNA was used as control (included from Origene). After 4-hours of
siRNA transfection, cells were switched to fresh growth medium. RT-qPCR analysis was
performed 72-hours after transfection.

GFP-Progerin Adenovirus.

pBABE-GFP-Progerin (Addgene 17663) was cloned into

pENTR/D-TOPO by PCR (Invitrogen K2400-20). The resultant GFP-progerin entry
vector was gel-purified (Qiagen 28104) then cloned into the pAd/CMV/V5-DEST
Gateway vector (Invitrogen V493-20). Protocols were followed in accordance with
manufacturer’s instructions. The Gateway vector was then transfected into 293A cells,
which were collected ~10 days after transfection when lytic plaques were visible. Crude
lysate from transfected 293A cells were used to transduce additional 293A cells and titer
the virus. For SMC experiments, GFP-Progerin adenovirus was used at 300-500 moi.
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Virus was incubated in fresh media on SMCs for 16 hours, after which the media was
replaced with fresh growth media and incubated for an additional 56 hours (a total of 72
hours).

Immunostaining and nuclear-cytoplasmic quantification. WT and HGPS primary aortic
SMCs were plated on glass coverslips in fresh growth medium for 24 hours at ~60%
confluency before fixation in 3.7% formaldehyde in PBS for 1hr at room temperature.
Coverslips were blocked and permeabilized for 2 hours in PBS containing 0.4% Triton X100, 2% BSA and 50 mM NH4Cl at room temperature. Coverslips were rinsed with PBS
and primary antibody (MRTF-A: Protein Tech #21166-1-AP, 1:50 dilution) diluted in
blocking buffer (PBS containing 0.4% Triton X-100, 2% BSA) was added to the
coverslips and incubated at 4oC overnight. Coverslips were washed in blocking buffer
three times for 10 minutes each before addition of secondary antibody (Alexafluor-488
chicken anti-Rabbit Santa Cruz #A21441, 1:100; in addition to DAPI stain, 1:300) in
blocking buffer for 2 hours at room temperature. Coverslips were washed three times for
10 minutes each in blocking buffer, rinsed in PBS, then dipped in water, and mounted
using SlowFade Gold anti-fade agent (Thermofisher #P36930). Fluorescent images
were acquired on a Nikon Eclipse inverted phase contrast microscope and captured on
the QI Click Qimaging camera using QCapture Suite Plus software.
Nuclear-cytoplasmic ratios of MRTF-A were calculated using ImageJ. The
nuclear boundary was traced using DAPI stain, and the tracing was added to the region
of interest (ROI) manager. This nuclear tracing was then overlayed on the MRTF-A stain
images, and mean pixel intensity of MRTF-A in the nucleus was recorded (mean pixel
intensity = raw integrated density/area). Then, using long-exposures of MRTF-A staining
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to mark cell boundary, the entire cell area was traced, and total MRTF-A raw integrated
density was recorded for the entire cell. The nuclear raw integrated density of MRTF-A
was then subtracted from the total cell raw integrated density to get the cytoplasmic raw
integrated density of MRTF-A. The cytoplasmic raw integrated density was then divided
by the cytoplasmic area (total cell area – nuclear area) to get the mean pixel intensity of
MRTF-A in the cytoplasm. Nuclear-cytoplasmic ratios are the mean pixel intensity of
MRTF-A in the nucleus divided by the mean pixel intensity of MRTF-A in the cytoplasm.

RT-qPCR of mRNAs. RNA was extracted from cultures of primary SMCs with TRIzol
reagent (Thermofisher 15596026) according to manufacturer’s instruction. Ten to fifteen
percent of the cDNA was subjected to qPCR with the following primer-probe sets from
Applied Biosystems: MRTF-A: Mm00461840_m1, Myh11: Mm00443013_m1, Acta2:
Mm00725412_s1,

Tagln:

Mm00441661_g1,

Cnn1:

Mm00487032_m1,

Lox

(Mm00495386_m1), has-miR-145 (TM: 002278), SnoRNA202 (TM:001232). The primerprobe set for 18S rRNA has been described (Klein et al. 2007). qPCR samples were
analyzed in duplicates. Levels of each tested transcript were normalized to 18S rRNA,
and changes in RNA abundance were calculated using the ddCT method.

Immunoblotting. For tissue immunoblotting, isolated aortas were thawed, chopped into
small pieces and sonicated (using a Virtis Virsonic 475 cell disruptor) in ~150 μl lysis
buffer (50 mM Tris-HCl pH 8, 250 mM NaCl, 2 mM EDTA, 1% NP-40) containing
protease inhibitors (Cell Signaling Technologies 5872S). Lysates were centrifuged for 5
minutes (4oC, 15,000 x g), and the supernatants were diluted into SDS sample buffer
(final concentration of 50mM Tris pH 6.8, 2% SDS, 10% glycerol, 0.01% Bromophenol
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blue) with 1% β-mercaptoethanol. The samples (20-30 μg) were fractionated on 7.5%
SDS

polyacrylamide

gels

and

electrophoretically

transferred

to

nitrocellulose.

Incubations with primary antibodies were performed overnight at 4oC with rocking in
TBST (Tris-buffered saline with 0.1% Tween 20) with 5% milk or 2% BSA. Incubation
with secondary antibodies were performed for 2-hours at room temperature in the same
TBST-buffer as the primary antibody. The antibodies used were: MRTF-A: Protein Tech
#21166-1-AP, 1:50 dilution; GAPDH: thermofisher MA5-15738, 1:400 dilution; ECL antimouse IgG HRP: GE healthcare 3143, 1:500. Bound antibodies were visualized by
enhanced chemiluminescence and quantified on a GE ImageQuant LAS4000.

Statistical Analysis. Statistical analysis was performed using Prism software (GraphPad),
and statistical tests are defined in respective figure legends. Mann-Whitney tests or Onesample t-tests were used for comparison between two groups and two-way ANOVA was
used for testing of significance throughout multiple groups.
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4.6 Figures

Figure 4.01. Progerin expression in WT SMCs reduces SM-MHC and force
generation. Vascular SMCs isolated from 2-month WT mouse aorta were incubated
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with adenovirus encoding GFP (control) or GFP-Progerin (Progerin) for 72-hours. (A)
LOX abundance was evaluated by immunoblot from lysates of primary WT aortic SMCs
incubated with adenovirus encoding GFP or GFP-Progerin. Black boxes around the
immunoblots indicate cropping for removal of extraneous space (n=2). (B) Lox and miR145 transcript levels were evaluated by RT-qPCR in primary WT aortic SMCs incubated
with adenovirus encoding GFP or GFP-Progerin (n=6-8). Results displayed as box plots
with Tukey bars. (C-D) SM-MHC (n=6) and SMA (n=4) protein abundance was
evaluated by immunoblot from lysates of primary WT aortic SMCs incubated with
adenovirus encoding GFP or GFP-Progerin. Results are quantified in panel D and
results show mean ± SE. (E) Myh11 and Acta2 mRNA levels were evaluated by RTqPCR in primary WT aortic SMCs incubated with adenovirus encoding GFP or GFPProgerin (n=7-8). Results displayed as box plots with Tukey bars. (F) Cell area and (G)
Total traction force plots of primary WT aortic SMCs incubated with adenovirus encoding
GFP or GFP-Progerin (n=60-70 cells). (H) Representative traction force images of cells
treated as described in panels F-G. Cell areas are outlined in white and traction force
scale bars (in nanonewtons) are displayed to the right of each respective image. Optical
scale bar = 50 mm. Significance in panel B, E, F, and G was determined by MannWhitney tests. Significance in panel D was determined by Wilcoxon signed rank test.
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Figure 4.02. Reduced MRTF-A signature in HGPS aorta. (A) Significantly altered
contractile (green) and synthetic (red) SMC markers as determined by genome-wide
transcriptome analysis of WT and HGPS aortas (n=6 per genotype). (B) Schematic
depicting serum response factor (SRF) binding to CArG elements in DNA which are
responsible for the regulation of SMC contractile genes. Myocardin binding further
enhances SRF transcriptional activity. SRF can be directly positively modulated by
myocardin-related transcription factor A (MRTF-A) or indirectly inhibited by Kruppel like
factor 4 (KLF4).

(C) Ingenuity pathway analysis (IPA) performed on genome-wide

transcriptome analysis of 2-month WT and HGPS aorta (n=6 per genotype). Negative Zscores suggest an inhibited signature as determined from enrichment of SRF, MRTF-A,
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and KLF4 target genes. Asterisk denotes a significantly inhibited pathway as determined
by IPA.

Figure 4.03. Reduced nuclear MRTF-A in HGPS smooth muscle cells (SMCs). (A-B)
2-month WT (n=3) and HGPS (n=4) aorta lysates were immunoblotted for MRTF-A and
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GAPDH (loading control) and MRTF-A protein levels were quantified in panel B. Bar
graph displays means ± SD (C) Primary aortic SMCs were isolated from 2-month WT
and HGPS mice and immunostained for MRTF-A. (D) Quantification of nuclearcytoplasmic MRTF-A ratio from immunostaining of WT and HGPS SMCs (n=~120-150
cells accrued over 4 independent experiments). Statistical significance determined by
Mann-Whitney. (E) WT SMCs were incubated with adenovirus encoding GFP or GFPProgerin for 72-hours. SMCs were immunostained for MRTF-A. White arrows point to
progerin-containing nuclei to highlight the reduced nuclear MRTF-A present in progerinexpressing cells. Scale bars display 50μm. Images are representative of 2 independent
experiments.
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Figure 4.04. MRTF-A knockdown reduces SMC contractile gene mRNA levels. (A)
WT SMCs were incubated with a scrambled (SCR, control) siRNA or three unique
siRNAs toward MRTF-A for 72-hours (n=5). LOX mRNA and miR-145 expression levels
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were quantified by RT-qPCR after MRTF-A knockdown and normalized to scrambled
control. Statistical significance between SCR and siRNA-treated cells was determined by
Two-way ANOVA with Sidak post-tests comparing each siRNA treatment to SCR
control. (B) In an independent experiment, transcript levels of Lox and miR-145 in HGPS
SMCs were quantified by RT-qPCR ad normalized to WT SMC transcript levels (n=6-8).
Statistical significance determined by Mann Whitney. (C) MRTF-A was knocked down in
WT SMCs as described in panel A and mRNA levels for contractile genes were analyzed
by qPCR and normalized to scrambled control. Statistical significance between SCR and
siRNA-treated cells was determined by Two-way ANOVA with Sidak post-tests
comparing each siRNA treatment to SCR control. (D) In an independent experiment,
mRNA levels of Myh11 and Acta2 in HGPS SMCs were quantified by RT-qPCR ad
normalized to WT SMC transcript levels (n=6-8). Statistical significance determined by
one-sample t-test comparing to a theoretical mean of 1. (E) Contractile gene transcript
levels in 2-month WT and HGPS aorta (reproduced from chapter 3). Statistical
significance determined by Mann-Whitney.
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Chapter 5: Discussion and future
directions
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5.1 Overview
Although the genetic basis of the mutation causing Hutchinson-Gilford Progeria
Syndrome (HGPS) has been well studied, how this mutation severely affects the
vasculature, and in particular the vascular smooth muscle cell (SMC) population, has
remained elusive. The HGPS vasculature has been characterized as a collagen-dense,
fibrotic environment with a significant loss of SMCs from the medial layer of large
arteries (Gerhard-Herman et al. 2011; Merideth et al. 2008; Olive et al. 2010). HGPS
children are highly susceptible to accumulation of atherosclerotic plaques in which
vessel occlusion or plaque rupture leads to heart attack or stroke (Gerhard-Herman et al.
2011; Merideth et al. 2008; Olive et al. 2010). So far, the link between the progressive
cardiovascular disease in HGPS and progerin, the mutated Lamin A protein, has not
been functionally characterized.
In Chapter 2 of this thesis, I evaluated the progressive arterial stiffening that
takes place in HGPS by using a mouse model to study the disease. I found that arterial
stiffening takes place much earlier than others have reported - before the onset of
severe HGPS phenotypes such as SMC depletion (del Campo et al. 2019; Murtada et al.
2020). Instead of arterial stiffness originating from high abundance of collagens like has
been reported in aged HGPS mice (del Campo et al. 2019; Murtada et al. 2020), I found
that arterial stiffening at an early timepoint correlates with an upregulation of the collagen
cross-linking enzyme lysyl oxidase (LOX). Furthermore, I found that HGPS arteries and
SMCs present with decreased miR-145, a known regulator of LOX transcript levels, and
restoration of miR-145 reduced LOX expression in HGPS SMCs to WT levels.
Intriguingly, in addition to regulating LOX expression, miR-145 is also a marker of the
264

contractile phenotype of SMCs. Decreased miR-145 led me to hypothesize that HGPS
SMCs may exist in a less contractile, or synthetic, state in HGPS arteries.
Thus, in Chapter 3, I characterized arterial contractility at the same timepoint I
reported increased arterial stiffening in HGPS. Interestingly, HGPS arteries present with
decreased contractile ability at an early age of 2-months, and the decreased contraction
of HGPS arteries is likely not due to increased arterial stiffness, as reducing arterial
stiffness did not restore vessel contractility. Rather, transcriptome profiling of HGPS
aortas revealed a decrease in expression of the SMC contractile machinery – especially
that of smooth muscle myosin heavy chain (SM-MHC), which was one of the most downregulated contractile genes in the analysis. Isolated primary HGPS SMCs showed
reduced force generation, and restoration of SM-MHC corrected traction force to near
WT levels.
In preliminary findings in Chapter 4, I show that reduced traction force and
decreased SM-MHC, but not miR145 or LOX regulation, are direct effects of progerin.
This finding prompted me to explore the MRTF-A signaling pathway as a potential
explanation for how progerin may be altering contractile gene expression. My
bioinformatic analysis of transcriptome-wide profiling in HGPS aortas showed a
decreased MRTF-A target-gene signature, and this correlated with a decreased nuclearcytoplasmic ratio of MRTF-A in isolated HGPS SMCs. Knockdown of MRTF-A in WT
SMCs resulted in decreased expression of many SMC contractile genes but did not
perfectly recapitulate the selective decrease in SM-MHC seen in HGPS SMCs. These
results suggest that other signaling pathways in addition to MRTF-A must also be at play
to downregulate SM-MHC. Furthermore, reduced MRTF-A does not alter LOX mRNA or
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miR-145 expression, so there must be additional pathways independently promoting
arterial stiffening and decreased contractility in HGPS (Fig. 5.01).
The following sections of the discussion will focus on the topics of arterial
stiffening and contractility in HGPS to discuss potential future directions for this work as
well as outstanding questions that still remain to be addressed in the field of HGPS
cardiovascular biology. Lastly, I will touch on the similarities and differences I have found
between premature aging and natural aging, and what our understanding of HGPS may
mean for insights into arterial stiffening in the aging population.

5.2 Arterial stiffening in HGPS
Arterial stiffening is a major cholesterol-independent risk factor for cardiovascular
disease that increases naturally with age (Mitchell et al. 2010). Increased arterial
stiffness is associated with impaired lung function, slower gait speed, and diminishing
physical functioning in day-to-day life (Laurent et al. 2019). Although genetic factors
certainly dictate arterial stiffening (Laurent et al. 2005; Lacolley et al. 2009; Logan et al.
2015), environmental factors such as aerobic fitness condition, low body fat, low
cholesterol, and low salt are associated with decreased arterial stiffening in populations
around the world (Laurent et al. 2019). However, understanding genetic predisposition to
arterial stiffening will help to develop targeted therapeutics to reduce arterial stiffening in
both HGPS as well as natural and ultimately reduce the burden of cardiovascular
disease.
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In the case of HGPS, progerin expression specifically in the vascular SMC
population has been connected to the elevated arterial stiffness (del Campo et al. 2019).
Intriguingly, mice expressing progerin under an endothelial-specific promotor did not
develop arterial stiffening (del Campo et al. 2019), suggesting a specific role for the SMC
population. Furthermore, collagenase degradation of the arterial matrix ex vivo resulted
in a reduction in arterial stiffening in HGPS mice, indicating a role for collagens in the
stiffening of HGPS vessels (del Campo et al. 2019). In collaboration with del Campo et
al. (2019), I observed an increase in collagens-III, IV, V, and XII in 14-week HGPS mice.
However, the increased collagens in HGPS mouse arteries were reported in vessels
near the end of the HGPS mouse lifespan, but work reported in this thesis is the first to
analyze mice at a very early timepoint before the onset of serious HGPS pathology.
Interestingly, I found arterial stiffening in HGPS begins with increased expression of LOX
rather than the canonically expected increase in fibrillar collagens. LOX has not been
previously implicated in HGPS pathology. Collectively, my results and those of del
Campo et al. (2019) indicate that, while collagen abundance may increase during the
HGPS mouse lifespan, initial arterial stiffening is due to increased collagen cross-linking.
Although I have demonstrated that LOX is a key protein in promoting the initial
arterial stiffening of HGPS, LOX inhibition with BAPN did not fully reduce circumferential
stiffness of HGPS arteries to WT levels, suggesting that additional ECM remodeling
events are contributing to the stiffening process. Future work to characterize changes in
ECM composition, advanced glycosylation end products, proteoglycans, and other
cross-linking enzymes such as transglutaminases, all of which have been associated
with increased tissue stiffening (Steppan et al. 2017; Oh et al. 2017; Goldin et al. 2006;
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Barkovskaya et al. 2020; Chen et al. 2020), will help to provide a more thorough picture
of arterial stiffening in HGPS. Additional work elucidating the initiation of arterial
stiffening would benefit from unbiased proteomics methods to understand how the ECM
composition changes over time and correlate changes in ECM protein abundance with
myographic analysis of HGPS arteries in a time-course manner. Pairing a time course of
bi-weekly myography with proteomic analyses of the ECM of HGPS arteries would allow
for correlation of proteins that are associated with arterial stiffening. Although we used
genome-wide transcriptome profiling to infer altered ECM proteins, future studies should
focus on using proteomic approaches to understand ECM composition as transcript
levels do not always correlate with ECM deposition, as I observed in aged WT aorta
which displayed low LOX transcript but high LOX protein abundance.
In addition to aberrant ECM, HGPS SMCs could also be contributing to a stiffer
microenvironment through increased cellular stiffness. Indeed, it has been shown that
arterial stiffness in aged monkeys is correlated with increased stiffness of isolated SMCs
from aged monkeys (Sehgel et al. 2015; Qiu et al. 2007; Qiu et al. 2010). However, as
cells are delicately entwined in their microenvironment, the contribution of cells versus
ECM may be hard to tease out. Work not shown in this thesis attempting to pressurize
decellularized carotids using pressure myography was unsuccessful, as vessels either
ruptured or developed large leaks upon pressurization.
Although I have identified the deregulated miR-145-LOX expression as causal for
arterial stiffening in HGPS mice, an essential question that remains is how progerin
expression is causing deregulation of this pathway and increased LOX abundance. As
reported in Chapter 4, I surprisingly saw that acute progerin expression in WT SMCs did
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not alter miR-145 levels or change LOX protein abundance. This likely suggests that the
altered miR-145-LOX signaling is either due to cell extrinsic mechanisms or the longterm presence of progerin during development. Additionally, the altered miR-145-LOX
abundance in HGPS is likely not due to the signaling or communication from other
arterial cell types, such as endothelial cells, as primary cultured SMCs also displayed
increased LOX mRNA in the absence of other cell types normally present in arteries.
A potential hypothesis for the deregulated miR145-LOX pathway in HGPS is that
the ECM deposited by HGPS SMCs may influence the high LOX expression. Growing
HGPS SMCs on ECM derived from WT SMCs or vice versa would help to evaluate
whether the ECM influences LOX abundance. In addition, circulating factors in HGPS
mice and patients may impact LOX levels. Bloodwork from HGPS mice evaluating
transforming growth factor-β (TFG-β), platelet derived growth factor (PDGF), or glucose
levels may provide insight as all have been shown to regulate LOX (Fang et al. 2016;
Green et al. 1995; Chronopoulos et al. 2010).

However, whether these signaling

pathways are miR-145 dependent or independent have yet to be evaluated.
An additional overarching question that remains is why are HGPS SMCs
stiffening their environment, and is this possibly a beneficial adaptation? The nuclei of
HGPS cells are brittle and fragile, as has been previously reported in HGPS skin
fibroblasts (Verstraeten et al. 2008). Kim et al. (2018) have shown that HGPS SMCs are
more susceptible to DNA damage and death due to biaxial strain. I hypothesize that in
order to protect the fragile nucleus from the constant strain of pulsatile blood flow on the
arterial network, HGPS SMCs may be secreting and remodeling the ECM to stiffen the
environment and reduce the amount of strain. Thus, this arterial stiffening seen in HGPS
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might be a protective mechanism to preserve the fragile HGPS SMCs for an extended
period of time. To test this hypothesis, it would be of interest to reduce arterial stiffening,
either with BAPN or new generation LOX-inhibitors (see below), and evaluate the
progressive loss of SMCs with arterial softening. If increased matrix stiffness is a
protective mechanism for HGPS SMCs to survive longer, decreasing arterial stiffness
would place the HGPS SMCs under increased strain as the artery circumferentially
distends more due to pulsatile blood flow, causing SMC loss at an earlier timepoint.
Although the cardiovascular community generally regards arterial stiffening as a comorbidity during normal aging, it is worth considering that arterial stiffening may be
playing a protective role in pathological genetic conditions such as HGPS. As such, it is
critical to consider the negative impacts of arterial softening just as much as the
beneficial effects.
Interestingly, I did not observe that reducing arterial stiffness through chronic
BAPN administration extends lifespan in HGPS mice. Aside from the simple explanation
that arterial stiffness has little influence on lifespan in HGPS, alternative explanations
and potential future directions merit further exploration. The toxic side effects of BAPN,
as discussed in Chapter 2, may offset the beneficial effects of reducing arterial stiffness.
A new pan-LOX inhibitor, PXS-5505, has recently passed Phase 1 clinical trials with an
excellent safety profile (How et al. 2020). Using a daily dosing regimen of PXS-5505 in
place of BAPN would eliminate the uncertainties caused by the toxicity of BAPN.
An additional complication when studying HGPS mouse survival after arterial
softening is that mice are highly resistant to develop and die of cardiovascular disease.
For example, to study atherosclerosis in mice, the field has used Apolipoprotein E
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(Apoe) null or Low-density lipoprotein receptor (LDLR) deletion to generate non-HDL
hyperlipidemia in mice (Getz & Reardon 2012). Indeed, HGPS mice on the Apoe-null
background and HGPS mice expressing progerin driven under a SMC-specific promotor
on the Apoe-null background developed more severe atherosclerosis and died earlier
than control Apoe-null mice (Hamczyk, Villa-Bellosta, et al. 2018). Interestingly, our lab
has shown that treating Apoe-null mice with BAPN and reducing arterial stiffness
significantly reduced monocyte recruitment and lesion area in aortas (Kothapalli et al.
2012; Liu et al. 2019). It may be of interest to understand if reducing arterial stiffness can
prolong the lifespan of HGPS mice on the Apoe-null background. However, as LDLcholesterol is not altered in human HGPS patients (Szamosi et al. 1984; Gordon et al.
2005), studying mice on an Apoe-null background may not provide a certain explanation
for what is happening in the human syndrome. Newer animal models such as minipigs
and monkeys, which have more human-like lipoprotein profiles (Getz & Reardon 2012),
have now been developed to study HGPS (Dorado et al. 2019; Wang et al. 2020).
Although arterial stiffening and cardiovascular disease have not been fully characterized
in these models yet, they may provide a more similar phenotype to the human
syndrome.
Lastly, I may have not observed BAPN-induced increases in HGPS mouse
lifespan because HGPS mice may not be dying from cardiovascular consequences. In
fact, the cause of death in LMNAG609/G609G HGPS mice is not well understood. Recently,
Kreienkamp (2019) showed that HGPS mice succumb to starvation and cachexia, and
placing HGPS mice on a high-fat diet increased lifespan and further exacerbated
cardiovascular pathology as HGPS mice lived longer (Kreienkamp et al. 2019).
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Reducing arterial stiffness may have not improved lifespan because HGPS mice were
dying from starvation and cachexia before the onset of severe cardiovascular
complications. Placing HGPS mice on a high-fat diet and performing chronic BAPN or
PXS-5505 administration may provide a better way to understand how reducing arterial
stiffness can benefit the cardiovascular system as HGPS mice display more overt
cardiovascular phenotypes the longer they survive (Kreienkamp et al. 2019). However,
as in all pharmacology, drug administration will be a delicate balance about finding the
proper therapeutic window. The LOX inhibitor dose and regimen must be sufficient to
reduce arterial stiffness but not induce aorta rupture or aortic aneurysm (consequences
of long-term BAPN administration (Ren et al. 2016)) or have other systemic effects.

5.3 Arterial contractility in HGPS
My studies show that the decreased arterial contractility of HGPS arteries is a
very early event which precedes the loss of SMCs from the large arteries. Although
others have demonstrated decreased arterial contractility, they have done so at a late
stage in the lifespan of HGPS mice where decreased SMC number and additional HGPS
pathologies complicate the cause of reduced contractility (del Campo et al. 2020;
Murtada et al. 2020). Because HGPS arteries presented with severe arterial stiffening at
the early timepoint in which we evaluated contractility, I hypothesized that increased
arterial stiffness may prevent HGPS arteries from properly contracting. However,
reducing arterial stiffness by BAPN treatment did not restore arterial contractility in
response to KCl. Thus, the reduction in contractility observed in HGPS mice is likely not
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due to increased arterial stiffness. An alternative hypothesis is that reduced contractility
in HGPS arteries is instead due to altered SMC force generation. Supporting this
hypothesis, I found that primary HGPS SMCs are defective for expression of SMC
contractility genes (particularly Myh11), that they show decreased force generation by
traction force microscopy, and that overexpression of SM-MHC increased traction force.
As a further study, it would be of interest to mate HGPS mice with SM-MHC transgenic
mice to understand if restoration of SM-MHC can restore arterial contractility in vivo, and
if rescuing the reduced contractility observed in HGPS corrects any pathologies that are
typically found in the disease.
However, it is worth noting that forced expression of SM-MHC did not completely
restore traction force of HGPS SMCs to WT levels, suggesting that defective expression
of contractile proteins other than SM-MHC may also contribute to the phenotype. In
Chapter 3, I mention that genes such as MYL9, the smooth muscle myosin light chain,
and MYLK, the smooth muscle myosin light chain kinase, are also reduced in HGPS
arteries, although not to the same extent as SM-MHC. Indeed, the majority of genes that
appeared in the SMC contractility category from KEGG analysis of transcriptome-wide
profiling of aortas were downregulated in HGPS aortas. Intriguingly those profiling
results also indicated that the mRNA levels of ADRA1D, the alpha-1D adrenergic
receptor, was downregulated to a similar extent as SM-MHC in HGPS arteries. Although
I used a vasoconstrictor that acts through membrane depolarization (KCl) and not Gprotein signaling to evaluate arterial contractility in HGPS, it may be of interest to study if
HGPS mice and children have a reduced response to adrenergic signaling due to
decreased abundance of ADRA1D.
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One major additional question that remains is why the reduction in SM-MHC is
restricted to the vascular SMC population, as intestine and bladder tissue (which also
contain SMCs) did not show a reduction in SM-MHC, nor do HGPS children show any
serious issues with either organ. I had originally hypothesized that this was likely due to
the high mechanical stress that vascular SMCs are under in comparison to other SMC
types in the body. As strain propagates mechanical information to vascular SMCs
through mechanotransduction (Goldschmidt et al. 2001), including information about the
expression of contractile genes (Reusch et al. 1997; Reusch et al. 1996), it could be that
progerin’s role in interrupting mechanotransduction signaling (Dahl et al. 2006;
Verstraeten et al. 2008) has a bigger effect in tissues that are undergoing the highest
amounts of mechanical stress. However, an issue complicating this interpretation is that
acute progerin expression in primary cultured SMCs, which are not subjected to cyclic
strain, also expressed decreased levels of SM-MHC (Chapter 4). It is possible that
vascular SMCs may be inherently different and more susceptible to progerin expression
than other SMC types.
Intriguingly, HGPS mice expressing a dominant negative KASH domain under a
SMC-specific promoter, thus disrupting the LINC complex in SMCs in vivo, do not
display the typical arterial fibrosis and SMC loss, suggesting that progerin’s role in
altering nuclear mechanotransduction is critical to the HGPS phenotype (Kim et al.
2018). It would be of interest to see if these HGPS mice expressing the dominant
negative KASH have restored arterial expression of Myh11 mRNA and contractility. This
would link the decreased SM-MHC to disrupted mechanosensing in HGPS vascular
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SMCs as well as provide insight into a possible mechanism of how progerin is causing
altered contractility.
HGPS pathology may be associated with abundance of progerin, as disease
progression in homozygous progerin mice is much faster than that of heterozygous
progerin mice. Lamin A expression scales with tissue stiffness, and tissues subjected to
high levels of mechanical stress tend to have higher levels of Lamin A (Swift et al. 2013).
It would be of interest to compare Lamin A, and thus progerin, expression levels
between different subtypes of SMCs to understand if the vascular SMC population
inherently produces more Lamin A, or progerin, than other subtypes, potentially
explaining why they are more susceptible. Indeed, Kim et al. (2018) found that the aorta
had one of the highest levels of Lamin A expression in comparison to other tissue types
(Kim et al. 2018).
Although it may be that HGPS pathology is associated with progerin abundance,
it is also possible that presence of WT Lamin A can protect against progerin’s effects,
which could explain why heterozygous progerin mice develop pathology more slowly.
Interestingly, de la Rosa (2013) et al. found that mosaic mice in which approximately
50% of the cells were deficient for ZMPSTE24, the enzyme critical for pre-Lamin A
processing (see Introduction), develop normally and do not possess a progeria
phenotype (whereas full ZMPSTE24 knockout mice develop a severe progeria
phenotype). ZMPSTE24 knockout fibroblasts, which normally have a slower proliferation
rate, thrived when co-cultured with WT fibroblasts. Mosaic mice did not display changes
in tissue health or plasma concentrations of IGF1 or blood glucose, which were
significantly lowered in ZMPSTE24 knockout mice (De La Rosa et al. 2013). These
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results suggest that extrinsic factors from healthy Lamin A-expressing cells may protect
against the detrimental effects of prelamin-A-expressing cells. This idea provides
exciting opportunities for gene-editing techniques, in which a long-term disadvantage
has been their inability to incorporate into a large number of cells in the body (Koblan et
al. 2021; Santiago-Fernández et al. 2019; Beyret et al. 2019). De la Rosa et al. (2013)
demonstrated that it may be possible to alleviate the progeria phenotype by correcting
the mutation in just half of the body’s cells.
In Chapter 4, I show that decreased nuclear MRTF-A may be responsible for
reducing many contractility genes in HGPS SMCs, but why SM-MHC is downregulated
more than others remains a question to be answered. Epigenetic silencing of specific
contractile genes may provide an explanation for the selective decrease. It may be of
value to understand the methylation status of the Myh11 promoter or enhancer regions
at upstream CpG islands. Additionally, it is possible that the Myh11 promoter or
enhancers, which have been shown to be critical for transcription of the gene (Manabe &
Owens 2001; Madsen et al. 1997),

may have altered histone modifications .

Furthermore, genes associated with the nuclear lamina are highly heterochromatic and
generally silenced (van Steensel & Belmont 2017; Bank & Gruenbaum 2011; Shevelyov
& Ulianov 2019). It would be of interest to see if the region of chromatin containing the
Myh11 gene has an altered association with the nuclear lamina in HGPS, as chromatin
association studies with progerin have revealed highly altered binding in HGPS dermal
fibroblasts (Köhler et al. 2020).
It would also be beneficial to evaluate arterial contractility and SM-MHC
abundance in mice treated with the only FDA-approved therapy for HGPS – Lonafarnib
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(Voelker 2021). Lonafarnib is a farnesyltransferase inhibitor that restores genome
organization and corrects nuclear blebbing in HGPS fibroblasts (Bikkul et al. 2018;
Gabriel et al. 2017). In clinical trials, lonafarnib reduced pulse-wave velocity
measurements of arterial stiffness, and decreased carotid artery wall echo density
(Gordon et al. 2018). Lonafarnib is predicted to work by preventing farnesylation of
progerin, causing the unfarnesylated progerin protein to be degraded (Columbaro et al.
2005). As lonafarnib reduces the abundance of progerin, I would expect the drug to
restore vessel contractility as I have shown progerin expression is directly associated
with decreased force generation. Treating HGPS primary SMCs with lonafarnib and
evaluating traction force would be one way to test this idea and understand the drug’s
effect.

5.4 Smooth muscle differentiation in HGPS
SMCs can undergo phenotypic switching from contractile to synthetic, ECM
producing cells (see Introduction). Intriguingly, the observations I have reported in HGPS
SMCS and arteries, such as decreased contractile proteins and increased ECM/arterial
stiffening, are very consistent with what the literature has reported from “synthetic”, or
dedifferentiated, SMCs. I hypothesize that progerin expression is promoting the
transition of SMCs to a more synthetic state, whether it be through direct modification of
gene expression or through alterations in the microenvironment and signaling pathways
(Fig. 5.01).
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As a first example, miR-145 is a marker of the contractile cell type, and I have
reported reduced miR-145 in HGPS SMCs (Davis-Dusenbery et al. 2011; Cheng et al.
2009; Hutcheson et al. 2013). Secondly, Osteopontin (gene Spp1), a key marker of the
synthetic SMC population (Shanahan et al. 1993; Wang et al. 2012), is one of the most
significantly elevated genes in HGPS arteries as determined by our transcriptome-wide
profiling. Lastly, I have observed reduced MRTF-A signaling, a key regulator of the
contractile SMC phenotype (Jeon et al. 2008; Du et al. 2004), in HGPS aorta and SMCs.
However, it is likely that altered MRTF-A signaling alone is not sufficient to explain all of
these observations: although I observed that MRTF-A knockdown produced a decrease
in SMC contractile gene expression, knockdown did not affect LOX or miR-145 transcript
levels. This suggests other deregulated events in HGPS must also be playing a role in
modulating the synthetic gene profile. Aside from intracellular signaling pathways,
feedback from the ECM can also promote phenotypic switching of SMCs (Hedin &
Thyberg 1987; Yamamoto et al. 1993), so the altered ECM of HGPS arteries may
contribute to the increased dedifferentiation phenotype of HGPS SMCs. A careful
proteomics study evaluating the composition of the arterial ECM in comparison to the
decrease in contractile proteins as the HGPS mouse ages may help to identify ECM
proteins responsible for altering SMC phenotypic state. Conversely, the phenotypic state
of SMCs can influence secretion of ECM. Thus, the decreased contractility and
increased arterial stiffness observed in HGPS may not be entirely independent.
However, because of the tight connection between these two phenomena, it may be
very hard to tease apart whether dedifferentiation of HGPS SMCs drives ECM
remodeling or whether ECM remodeling drives dedifferentiation of HGPS SMCs.
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5.5 Similarities and differences between HGPS
and normal aging
As there are many described similarities between the cardiovascular pathologies
of HGPS and normal aging including increased arterial stiffness, calcification, and
atherosclerosis (see introduction; Hamczyk, del Campo, et al. 2018), I postulated that
studying the rapid cardiovascular complications in HGPS may provide insight into the
mechanism of arterial aging in healthy individuals. Indeed, I observed highly elevated
circumferential arterial stiffening in both young HGPS and 24-month WT mouse carotid
arteries. However, young HGPS mice did not display significant axial stiffening while 24month WT mice displayed severe axial stiffening, suggesting that the mechanisms are
not the same. However, it is important to note that in late-stage HGPS mice, severe axial
stiffening has been reported (Murtada et al. 2020). This implies that in the HGPS model,
circumferential stiffness occurs first, followed by axial stiffening at a later timepoint. In
contrast, work by Brankovic et al. (2019), which studied mechanics of WT carotid
arteries at 2, 6, 12, and 24-months, showed that onset of arterial stiffening occurred
simultaneously in both the axial and circumferential directions starting as early as 12months (Brankovic et al. 2019). They also showed that knockout of matrix
metalloproteinase 12 (MMP12), a potent elastase, decreased axial stiffening due to age
but had little effect on circumferential mechanics (Brankovic et al. 2019). As collagen
deposition and arterial fibrosis are common to both HGPS (Olive et al. 2010; GerhardHerman et al. 2011; Merideth et al. 2008) and normally aged arteries (Kohn et al. 2015;
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Tsamis et al. 2013), altered elastin degradation dynamics may underlie the differential
axial stiffening seen in normal aging and HGPS.
Further evidence that differential mechanisms are driving arterial stiffening and
fibrosis in HGPS versus normal aging comes from my work with miR-145, which showed
decreased expression in the medial layer of HGPS aortas but not in 24-month WT
aortas. Additionally, in normally aged arteries LOX protein was upregulated in both the
media and adventitial layers, whereas elevated LOX expression was restricted to the
medial layer in HGPS. Nevertheless, the similarity of increased LOX abundance in both
premature and normal aging suggests that LOX inhibition may be a potential therapeutic
approach to target arterial stiffening in both cases.
Additionally, I reported that decreased contractility in both HGPS and normal
mouse aging was associated with less SM-MHC and postulated that the reduced
contractility may be due to a more synthetic population of SMCs. Intriguingly, miR-145
has been identified as a marker of the contractile state of SMCs. Although I observed
decreased contractility in 24-month WT carotids, I did not observe decreased miR-145
levels. This further supports the hypothesis that although the end readout of decreased
arterial contractility may be similar in HGPS and normal aging, the contractile gene
profile of the arteries is likely different and the mechanisms underlying the decreased
contractility may be diverse.
As a limitation of this dissertation, it is important to note that many arterial
comparisons were performed between young (1- or 2-month) HGPS mice and old WT
mice (24-month, a timepoint at the end of the WT mouse lifespan). The young HGPS
timepoint was chosen so that I could observe the initial driving factors of cardiovascular
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pathology. However, when making comparisons between young HGPS arteries and
naturally aged arteries, the selected timepoints may not be analogous. For example, the
cardiovascular pathology of young 2-month HGPS mice may more so resemble that of
12-month WT mice, while 3-month HGPS mice (a time point more toward the end of
HGPS mouse lifespan) may better resemble the 24-month WT mouse. An in-depth study
evaluating a progression of arterial aging in both HGPS and WT mice would further shed
light on potential comparable timepoints to understand similarities and differences in
cardiovascular pathologies.
Overall, although the end read-outs of increased arterial stiffness and decreased
contractility may be the same, I believe the mechanisms underlying these processes are
inherently different in HGPS and normal aging. In HGPS, arterial aging happens rapidly,
and I believe genetic factors are much more prominent in promoting cardiovascular
pathologies. In WT aging, cardiovascular pathologies develop over a much more
extended period of time, and although genetics certainly have an effect, the extended
period of time allows for environmental factors such as diet, physical activity, hormone
levels, stress, and inflammation to also play a very powerful role in vascular pathologies.
Nevertheless, work presented in this thesis gives new insights into the increased arterial
stiffening and decreased arterial contractility in premature and natural aging and sheds
light on potential therapeutic approaches to reduce the burden of cardiovascular
disease.
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5.6 Figures

Figure 5.01. Proposed model of progerin’s mechanism of action in promoting
increased arterial stiffness and decreased arterial contractility in HGPS. In healthy
SMCs, progerin inhibits nuclear localization of MRTF-A to reduce contractile gene
expression through a direct effect. Additional pathways critical for expression of SMMHC are also directly inhibited by progerin, contributing to the reduced arterial
contractility observed in HGPS arteries. Progerin also indirectly decreases miR-145
levels to cause elevated LOX and promote arterial stiffening.
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